0001662252-18-000094.txt : 20181003 0001662252-18-000094.hdr.sgml : 20181003 20181003172632 ACCESSION NUMBER: 0001662252-18-000094 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20180531 FILED AS OF DATE: 20181003 DATE AS OF CHANGE: 20181003 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HypGen Inc CENTRAL INDEX KEY: 0001653629 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 371780402 STATE OF INCORPORATION: NV FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55860 FILM NUMBER: 181106086 BUSINESS ADDRESS: STREET 1: 1999 AVENUE OF THE STARS STREET 2: SUITE 1100 CITY: CENTURY CITY STATE: CA ZIP: 90067 BUSINESS PHONE: 000-000-0000 MAIL ADDRESS: STREET 1: 1999 AVENUE OF THE STARS STREET 2: SUITE 1100 CITY: CENTURY CITY STATE: CA ZIP: 90067 FORMER COMPANY: FORMER CONFORMED NAME: HypGen Inc. DATE OF NAME CHANGE: 20170731 FORMER COMPANY: FORMER CONFORMED NAME: MEGA BRIDGE INC. DATE OF NAME CHANGE: 20170410 FORMER COMPANY: FORMER CONFORMED NAME: Asset Solutions Inc DATE OF NAME CHANGE: 20150921 10-K 1 hpgn10k.htm 10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended May 31, 2018

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________

Commission file number 333-207383

HYPGEN INC.

(Exact name of registrant as specified in its charter)

Nevada		37-1780402
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1999 Avenue of the Stars Suite 1100

Century City, California 90067

(Address of principal executive offices, including zip code)

424-253-1210

Registrant’s telephone number, including area code

n/a

Address of Previous Executive Office

Securities registered under Section 12(b) of the Act:

None		N/A
Title of each class		Name of each exchange on which registered

Securities registered under Section 12(g) of the Act:

None

(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No x

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or, an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company”, in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	x
(Do not check if smaller reporting company)		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x

On November 30, 2017, the last business day of the registrant’s most recently completed second quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was undeterminable due to the lack on an active trading market of the Common Stock of the registrant on the OTC Bulletin Board system.

As of October 1, 2018, the registrant had 50,000,502 shares of common stock issued and outstanding. No market value has been computed based upon the fact that no active trading market had been established as of October 1, 2018.

PART I

Forward Looking Statements.

This report contains forward-looking statements which relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled "Risk Factors," that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are stated in United States dollars ($USD) and are prepared in accordance with United States Generally Accepted Accounting Principles.

In this annual report, unless otherwise specified, all references to "common stock" refer to the common shares in our capital stock.

As used in this annual report, the terms "we", "us", "our", "Hypgen" and "Asset Solutions" mean Asset Solutions Inc, unless the context clearly requires otherwise.

ITEM 1. BUSINESS

General

The Company originally incorporated in the State of Nevada on March 26, 2015 as Asset Solutions Inc. and established a fiscal year end of May 31.

The Company’s original line of business, as reflected in discontinued operations had initial revenues, hard assets (office in Poland) and has incurred net losses since inception. We are a development-stage company in the business of developing and bringing to market a drug demonstrating a potential to reduce the destruction of neurons that have been associated with Parkinson's disease. Our business office is office is located at 1999 Avenue of the Stars Suite 1100 Century City, California 90067. The Company’s main phone number is (424) 253-1210.

On January 18th, 2017, Olaf Robak, the Company's President and CEO, executed a stock purchase agreement with First Legacy Management LLC, which acquired 4,000,000 shares of common stock, representing 80% ownership of the Company. First Legacy Management LLC paid $350,000.00 in cash. Simultaneous with this transaction, Mr. Olaf Robak resigned from his official positions as Director, CEO, CFO, President, Treasurer and Secretary of the Company, and on the same day the shareholders of the Corporation voted Mr. Antonio Treminio as Director & CEO.

On March 9, 2017 FINRA notified the Company that request for symbol change was approved. Effective March 13, 2017 the Company’s common stock began trading under the symbol MGBR.

On June 28, 2017, the Company executed an Asset Assignment Agreement (“Asset Assignment Agreement”) with Richard L. Chang Holding’s LLC (“Holdings LLC”), pursuant to which Holdings was issued be 60,000,000 shares of the Company’s common stock and 2,000,000 restricted, non-convertible, non-dividend paying shares of the Company’s preferred stock with 1000 to 1 voting rights over shares of the Company’s common stock. In consideration of these share issuances, Holdings LLC has assigned to the Company all of its rights, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016, titled “COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. Additionally, pursuant to the terms of the Asset Assignment Agreement, upon the Company receiving a minimum of $1,000,000 in equity financing, Holdings shall assign to the Company all of its rights, title and interest to United States Utility Patent Application No USPTO Application No. 15/385,862 filed on December 20, 2016, titled ”COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. The Asset Assignment Agreement grants to Holdings LCC the right to require the Company to assign back to Holdings LLC the Patent Application and all related intellectual property in the even the Company does not raise a minimum of $1,000,000 in equity financing by June 28, 2018. In the event that Holdings LLC exercises this right of reversion, the 2,000,000 shares of Preferred Stock issued to Holdings LLC shall be assigned to Apica Investments Limited or its assigns. As of May 31, 2018, the Company has not raised any capital towards the $1,000,000 requirement. As of the filing of this report Holdings LLC has not exercised its right of reversion under the Asset Assignment Agreement.

On July 18, 2017, we filed Articles of Merger with the Secretary of State of Nevada in order to effectuate a merger with our wholly-owned subsidiary, HypGen Inc. Shareholder approval was not required under Section 92A.180 of the Nevada Revised Statutes. As part of the merger, our board of directors authorized a change in our name to “HypGen Inc” and our Articles of Incorporation have been amended to reflect this name change.

On August 1, 2017, the Company changed its name to Hypgen Inc. to more accurately reflect the Company’s new strategic direction as it focuses its efforts on developing therapeutic treatment options for Parkinson's disease. Effective with the name change the Company’s trading symbol was changed to HPGN with OTC Markets.

SUBSEQUENT EVENTS

On June 1, 2018, the Company entered into a two-year consulting agreement with Richard L. Chang, Holdings LLC, a related party, an entity controlled by director, Richard L. Chang. Under the terms of the agreement the Company will compensate the consultant at the rate of $20,000 per monthly for services provided assisting in the area clinical operations, managing their patents and other intellectual property as well as assisting the Company in scientific and technical matters concerning manufacturing the drug, research and development.

On June 25, 2018, the Company issued a promissory note in the amount of $4,000 to Imagic, a related party. The note matures on June 25, 2019 and bears 5% interest.

On July 5, 2018, the Company entered into a Termination and Share Cancellation Agreement with Rafferty Finances, S.A. (“Rafferty”) pursuant to which the Company and Rafferty agreed to (i) the rescission and termination of the Consulting Agreement and Common Stock Purchase Warrant dated June 28, 2017 between the Company and Rafferty; (ii) the cancellation of 5,000,000 shares of Company common stock previously issued to Rafferty; (iii) Rafferty’s assistance to the Company to complete the cancellation of an additional 469,500 shares of Company common stock; and (iv) the issuance of 500,000 shares of Company common stock to Rafferty. The foregoing is only a brief description of the material terms of the Termination and Share Cancellation Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreement which is filed as an exhibit to this Current Report. The issuance of the shares of common stock was made in reliance on the exemption provided by Section 4(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company’s reliance upon Section 4(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the securities was an accredited investor.

On July 5, 2018, the Company entered into a Termination and Share Cancellation Agreement with Brighton Capital Ltd. (“Brighton”) pursuant to which the Company and Brighton agreed to (i) the rescission and termination of the Consulting Agreement and Common Stock Purchase Warrant dated June 28, 2017 between the Company and Brighton; and (ii) the cancellation of 5,500,000 shares of Company common stock from the 6,000,000 shares of Company common stock previously issued to Brighton. The foregoing is only a brief description of the material terms of the Termination and Share Cancellation Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder.

On July 9, 2018, the Company entered into a Cancellation Agreement with certain shareholders of the Company pursuant to which the Company and the shareholders agreed to the cancellation of a total of 74,999,998 shares. In consideration of the share cancellations and provided that the Company raises a minimum of $1,000,000 in equity financing on or before June 28, 2019, Richard L. Chang Holding’s, LLC agreed to waive its right of reversion of the patent assets contributed to the Company pursuant to the Asset Assignment Agreement dated June 28, 2017. The foregoing is only a brief description of the material terms of the Cancellation Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder.

On July 9, 2018, the Company entered into a Warrant Amendment Agreement with certain warrant holders of the Company pursuant to which the Company and the warrant holders agreed to amend warrants previously issued to them to reduce the number of warrants in the total amount of 10,000,000. In consideration of the amendment and provided that the Company raises a minimum of $1,000,000 in equity financing on or before June 28, 2019, Richard L. Chang Holding’s, LLC agreed to waive its right of reversion of the patent assets contributed to the Company pursuant to the Asset Assignment Agreement dated June 28, 2017. The foregoing is only a brief description of the material terms of the Warrant Amendment Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder.

On October 1, 2018, Imagic, LLC granted the Company a two-year extension to a 5%, one-year, promissory note dated September 14, 2017, having a principal amount of $6,000. Imagic, LLC, is wholly owned by Ben Chang, son of Director Richard L. Chang and Chief Executive Officer of Rich Pharmaceuticals, Inc.

On October 1, 2018, Richard L. Chang Holdings granted a two-year extension to a 5%, one-year, promissory note dated November 3, 2017, having a principal amount of $5,000. Richard L. Chang Holdings is controlled by director Richard L. Chang. The note matures on November 3, 2018 and bears 5% interest.

Product

For the fiscal year ended May 31, 2018 the comparative financials are presented with the former line of business of the sale and distribution of office chair products such as office chairs as well as office chairs accessories to wholesalers. The office chair products segment was officially discontinued as of August 8, 2017. The office chair products segment is reflected in discontinued operations for the periods presented.

As of this report date, the Company has shifted its focus to reflect its new strategic direction to focus its efforts on developing therapeutic treatment options for Parkinson's disease.

Our Suppliers

The Company has not identified a supplier for its Parkinson’s diseases related drug currently in phase II trials.

Sales and Marketing Strategy

As of this report date, the Company has shifted its focus to reflect its new strategic direction to focus its efforts on developing therapeutic treatment options for Parkinson's disease.

Parkinson's disease is a chronic and progressive movement disorder. Symptoms continue and worsen over time. Nearly one million people in the U.S. suffer with Parkinson's disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms. Parkinson's disease involves the malfunction and death of vital nerve cells in the brain, called neurons. Parkinson's primarily affects neurons in an area of the brain called the substantia nigra. Some of these dying neurons produce dopamine, a chemical that sends messages to the part of the brain that controls movement and coordination. As Parkinson's disease progresses, the amount of dopamine produced in the brain decreases, leaving a person unable to control movement normally. The specific group of symptoms that some individuals experience varies from person to person. For more information, please see: Parkinson's Disease Foundation http://www.pdf.org About HypGen, Inc., formerly Mega Bridge, Inc. HypGen intends to focus its efforts on developing therapeutics treatment for Parkinson's disease. HypGen has been assigned all of the right, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016 (the "Patent Application"), titled "COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON'S DISEASE" and all related intellectual property, inventions and trade secrets, data, and clinical study results.

We have recently acquired seminal intellectual property that has demonstrated a potential to reduce the destruction of neurons that have been associated with Parkinson's disease. The Company will update investors as we progress with our plans to conduct clinical studies to assess potential treatment options for Parkinson's disease based upon this intellectual property platform.

As reflected in discontinued operations, the Company sold and distributed of office chair products such as office chairs as well as office chairs accessories to wholesalers.

Competition

The level of competition in the medical treatment field is extremely high and dependent on government approval through the Food and Drug Administration. Trials may take a long time and be very expensive. Many of our established competitors have developed a brand or brands which are very established and familiar to customers. Brand recognition is often translated in the consumer’s mind as trust. Potential customers may prefer similar products of more recognized competitors’ products over ours. Our competitors may have the ability to shift profits from other brands to a completive product whereby aggressive being able to control pricing, research and development as well as the ability to allocate greater resources to drug trials. Economies of scale, established business processes and established distribution networks would make it easier for our larger established competitors to effectively bring products to market, negotiate price discounts with their suppliers which would leave us at a disadvantage. We will be in a market where we compete with many domestic and international companies offering similar products. We will be in direct competition with them. Many of these companies may have a greater, more established customer base than us. We may be unable to continue to compete effectively with these existing or new competitors, which could have a material adverse effect on our financial condition and results of operations.

Marketing and Sales Distribution Agreement with our supplier

In our current line of business, the Company is not party to any marketing or sales distribution agreements.

Reports to Security Holders

We intend to furnish our shareholders annual reports containing financial statements audited by our independent registered public accounting firm and to make available quarterly reports containing unaudited financial statements for each of the first three quarters of each year. We file Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K with the Securities and Exchange Commission in order to meet our timely and continuous disclosure requirements. We may also file additional documents with the Commission if they become necessary in the course of our company’s operations.

The public may read and copy any materials that we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is www.sec.gov.

Environmental Regulations

We do not believe that we are or will become subject to any environmental laws or regulations of the United States. While our products and business activities do not currently violate any laws, any regulatory changes that impose additional restrictions or requirements on us or on our products or potential customers could adversely affect us by increasing our operating costs or decreasing demand for our products or services, which could have a material adverse effect on our results of operations.

Government Regulation

Pharmaceutical companies are subject to extensive regulation by government authorities in the countries in which they do business. Certain laws and regulations that govern our business are discussed below.

General. Our business has been and will continue to be subject to numerous laws and regulations. Failure to comply with these laws and regulations, including those governing the manufacture and marketing of our products, could subject us to administrative and legal proceedings and actions by various governmental bodies. Criminal charges, substantial fines and/or civil penalties, warning letters and product recalls or seizures, delays in product approvals, as well as limitations on our ability to conduct business in applicable jurisdictions, could result from such proceedings and actions.

In the United States

Drug Regulation. In the U.S., biopharmaceutical products are subject to extensive pre- and post-market regulations by the Food and Drug Administration (“FDA”), including regulations that govern the testing, manufacturing, safety, efficacy, labeling and storage of our products, record keeping, advertising and promotion. Our products are also subject to post-market surveillance under the United States Federal Food, Drug, and Cosmetic Act (“FFDCA”) and its implementing regulations with respect to drugs, as well as the Public Health Service Act and its implementing regulations with respect to biologics. The FDA also regulates our Consumer Healthcare products.

Other U.S. federal agencies, including the Drug Enforcement Administration (“DEA”), also regulate certain of our products. The U.S. Federal Trade Commission has the authority to regulate the advertising of consumer healthcare products, including OTC drugs and dietary supplements. Many of our activities also are subject to the jurisdiction of the SEC.

Before a new biopharmaceutical product may be marketed in the U.S., the FDA must approve a New Drug Application “ NDA” for a new drug or a Biologic License Application (“BLA”) for a biologic. The steps required before the FDA will approve an NDA or BLA generally include preclinical studies followed by multiple stages of clinical trials conducted by the study sponsor; sponsor submission of the application to the FDA for review; the FDA’s review of the data to assess the drug’s safety and effectiveness; and the FDA’s inspection of the facilities where the product will be manufactured.

Before a generic drug may be marketed in the U.S., the FDA must approve an abbreviated new drug application (“ANDA”). The ANDA review process typically does not require new preclinical and clinical studies, because it relies on the studies establishing safety and efficacy conducted for the referenced drug previously approved through the NDA process. The ANDA process, however, does require the sponsor to conduct one or more bioequivalence studies to show that the ANDA drug is bioequivalent to the previously approved referenced brand drug, submission of an application to the FDA for review, and the FDA’s inspection of the facilities where the product will be manufactured.

As a condition of product approval, the FDA may require a sponsor to conduct post-marketing clinical studies, known as Phase 4 studies, and surveillance programs to monitor the effect of the approved product. The FDA may limit further marketing of a product based on the results of these post-market studies and programs. Any modifications to a drug or biologic, including new indications or changes to labeling or manufacturing processes or facilities, may require the submission and approval of a new or supplemental NDA or BLA before the modification can be implemented, which may require that we develop additional data or conduct additional preclinical studies and clinical trials. Our ongoing manufacture and distribution of drugs and biologics is subject to continuing regulation by the FDA, including recordkeeping requirements, reporting of adverse experiences associated with the product, and adherence to Current Good Manufacturing Practices (“cGMPs”), which regulate all aspects of the manufacturing process. We are also subject to numerous regulatory requirements relating to the advertising and promotion of drugs and biologics, including, but not limited to, standards and regulations for direct-to-consumer advertising. Failure to comply with the applicable regulatory requirements governing the manufacture and marketing of our products may subject us to administrative or judicial sanctions, including warning letters, product recalls or seizures, delays in product approvals, injunctions, fines, civil penalties and/or criminal prosecution.

Sales and Marketing. The marketing practices of U.S. biopharmaceutical companies are generally subject to various federal and state healthcare laws that are intended to prevent fraud and abuse in the healthcare industry and protect the integrity of government healthcare programs. These laws include anti-kickback laws and false claims laws. Anti-kickback laws generally prohibit a biopharmaceutical company from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular product. False claims laws generally prohibit anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for goods (including drugs) or services to third-party payers (including Medicare and Medicaid) that are false or fraudulent and generally treat claims generated through kickbacks as false or fraudulent. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions and/or exclusion from federal healthcare programs (including Medicare and Medicaid). The federal government and various states also have enacted laws to regulate the sales and marketing practices of pharmaceutical companies. The laws and regulations generally limit financial interactions between manufacturers and healthcare providers; require disclosure to the federal or state government and public of such interactions; and/or require the adoption of compliance standards or programs. Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. Individual states, acting through their attorneys general, have become active as well, seeking to regulate the marketing of prescription drugs under state consumer protection and false advertising laws. Given the lack of clarity in laws and their implementation, our activities could be subject to the penalties under the pertinent laws and regulations.

Pricing and Reimbursement. Pricing for our pharmaceutical products depends in part on government regulation. Government and private third-party payers routinely seek to manage utilization and control the costs of our products. Given certain states’ current and potential ongoing fiscal crises, a growing number of states are considering a variety of cost-control strategies, including capitated managed care plans that typically contain cost by restricting access to certain treatments. In addition, we expect that consolidation and integration of pharmacy chains and wholesalers, who are the primary purchasers of our pharmaceutical products in the U.S., will increase competitive and pricing pressures on pharmaceutical manufacturers, including us.

Anti-Corruption. The FCPA prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations.

Outside the United States

We may encounter similar regulatory and legislative issues in most other countries.

Available Information

All reports of the Company filed with the SEC are available free of charge through the SEC’s web site at www.sec.gov. In addition, the public may read and copy materials filed by the Company at the SEC’s Public Reference Room located at 100 F Street, N.E., Washington, D.C. 20549. The public may also obtain additional information on the operation of the Public Reference Room by calling the Commission at 1-800-SEC-0330.

Employees

At May 31, 2018 the Company had three employees and a consultant, dedicating substantially all of his time to the affairs of the Company. Formerly, Antonio Treminio, acted as Chief Executive Officer and sole director who devoted substantially all of his time to the affairs of the Company until his resigned as a director of the Company and Chief Executive Officer effective June 28, 2017. As of the August 29, 2017 the Company has entered into several agreements with consultants to support the Company’s new strategic direction as it focuses its efforts on developing therapeutic treatment options for Parkinson's disease.

Offices

The Company’s main office is located at 1999 Avenue of the Stars Suite 1100 Century City, California 90067. The Company’s main phone number is (424) 253-1210.

The former business office and head of our discontinued operations is located at 5 Garbary, Gdansk, Poland 80327. On May 29, 2015 the Company purchased a 500 sq. feet of office in a stand along the building for $13,653, reflected in assets from discontinued operations.

ITEM 1A. RISK FACTORS

Our common shares are considered speculative. Prospective investors should consider carefully the risk factors set out below.

An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below and the other information in this prospectus before investing in our common stock. If any of the following risks occur, our business, operating results and financial condition could be seriously harmed. The trading price of our common stock, when and if we trade at a later date, could decline due to any of these risks, and you may lose all or part of your investment.

RISKS ASSOCIATED TO OUR BUSINESS

We have sustained recurring losses since inception and expect to incur additional losses in the foreseeable future.

We were formed on March 26, 2015 and have reported annual net losses since inception. For our years ended May 31, 2018 and 2017, we experienced net losses of $892,248 and $205,287, respectively. We used cash in operating activities of $356,334 and $192,050 in 2018 and 2017, respectively. As of May 31, 2018, we had an accumulated deficit of $1,129,153.

In addition, we expect to incur additional losses in the foreseeable future, and there can be no assurance that we will ever achieve profitability. Our future viability, profitability and growth depend upon our ability to successfully operate, expand our operations and obtain additional capital. There can be no assurance that any of our efforts will prove successful or that we will not continue to incur operating losses in the future. Our management is devoting substantially all of its efforts to developing its product and there can be no assurance that our efforts will be successful. There is no assurance that can be given that management’s actions will result in our profitable operations or the resolution of our liquidity problems.

We are a development stage company and have commenced limited operations in our business. We expect to incur operating losses for the foreseeable future.

We were incorporated on March 26, 2015 and to date have been involved primarily in organizational activities, getting initial sales, reflected in discontinued operations. We have commenced limited business operations and are pursuing a new line of business. Accordingly, we have no way to evaluate the likelihood that our business will be successful. Potential investors should be aware of the difficulties normally encountered by new companies and the high rate of failure of such enterprises. The likelihood of success must be considered in light of the problems, expenses, difficulties, complications and delays encountered in connection with the operations that we plan to undertake. These potential problems include, but are not limited to, unanticipated problems relating to the ability to generate sufficient cash flow to operate our business, and additional costs and expenses that may exceed current estimates. We anticipate that we will incur increased operating expenses without realizing increase in revenues. We expect to incur losses into the foreseeable future. We recognize that if the effectiveness of our business plan is not forthcoming and if we fail to secure additional capital we may lose the right to use the patent and thus, we will not be able to continue business operations. There is no history upon which to base any assumption as to the likelihood that we will prove successful, and it is doubtful that we will generate any operating revenues or ever achieve profitable operations. If we are unsuccessful in addressing these risks, our business will most likely fail.

Regulations are constantly changing, and in the future our business may be subject to additional regulations that increase our compliance costs.

We believe that we understand the current laws and regulations to which our products will be subject in the future. However, federal, state and foreign laws and regulations relating to the sale of our products are subject to future changes, as are administrative interpretations of regulatory agencies. If we fail to comply with such federal, state or foreign laws or regulations, we may fail to obtain regulatory approval for our products and, if we have already obtained regulatory approval, we could be subject to enforcement actions, including injunctions preventing us from conducting our business, withdrawal of clearances or approvals and civil and criminal penalties. In the event that federal, state, and foreign laws and regulations change, we may need to incur additional costs to seek government approvals, in addition to the clearance we intend to seek from the U.S. Food and Drug Administration in order to sell or market our products. If we are slow or unable to adapt to changes in existing regulatory requirements or the promulgation of new regulatory requirements or policies, we or our licensees may lose marketing approval for our products which will impact our ability to conduct business in the future.

We face strong competition from larger and well-established drug companies, which could harm our business and ability to operate profitably.

Our industry is competitive. There are many different drug companies that are far better funded products distributors. Even though the industry is highly fragmented, it has a number of large and well-established companies, which are profitable and have developed a brand name. Aggressive marketing tactics and established distribution markets implemented by our competitors could impact our limited financial resources and adversely affect our ability to compete in our market.

If we do not attract customers, we will not make a profit, which ultimately will result in a cessation of operations.

We do not currently have a product approved to bring to market. We may not obtain approval from the Food and Drug Administration. Even if we obtain approval for our product and develop a market for our product, there is no guarantee that we will generate a profit. If we cannot generate a profit, we will have to suspend or cease operations. You are likely to lose your entire investment if we cannot obtain approval for our products at prices which generate a profit.

Because we are small and do not have much capital, our marketing campaign may not be enough to attract sufficient clients to operate profitably. If we do not make a profit, we will suspend or cease operations.

Due to the fact we are small and do not have much capital, we must limit our marketing activities and may not be able to make our products known to potential customers. Because we will be limiting our marketing activities, we may not be able to establish a market and operate profitably. If we cannot operate profitably, we may have to suspend or cease operations.

We rely on key officers, consultants and scientific and medical advisors, and their knowledge of our business and technical expertise would be difficult to replace.

We are highly dependent on our officers, consultants and scientific and medical advisors because of their expertise and experience in medical device development. We do have a “key man” life insurance policy for our Chief Executive Officer. If we are unable to obtain additional funding, we will be unable to meet our current and future compensation obligations to such employees and consultants. In light of the foregoing, we are at risk that one or more of our consultants or employees may leave our company for other opportunities where there is no concern about such employers fulfilling their compensation obligations, or for other reasons. The loss of the technical knowledge and management and industry expertise of any of our key personnel could result in delays in product development, loss of customers and sales and diversion of management resources, which could adversely affect our results of operations.

Any additional funding, we arrange through the sale of our common stock will result in dilution to existing shareholders.

We must raise additional capital in order for our business plan to succeed. Our most likely source of additional capital will be through the sale of additional shares of common stock. Such stock issuances will cause stockholders' interests in our company to be diluted. Such dilution will negatively affect the value of an investor's shares.

As an "emerging growth company" under the jobs act, we are permitted to rely on exemptions from certain disclosure requirements.

We qualify as an "emerging growth company" under the JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to:

•	have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;

•	provide an auditor attestation with respect to management's report on the effectiveness of our internal controls over financial reporting;

•	comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);

•	submit certain executive compensation matters to shareholder advisory votes, such as "say-on-pay" and "say-on-frequency;" and

•	disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive's compensation to median employee compensation.

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

We will remain an "emerging growth company" for up to five years, or until the earliest of (i) the last day of the first fiscal year in which our total annual gross revenues exceed $1 billion, (ii) the date that we become a "large accelerated filer" as defined in Rule 12b-2 under the Securities Exchange Act of 1934, which would occur if the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three year period. Even if we no longer qualify for the exemptions for an emerging growth company, we may still be, in certain circumstances, subject to scaled disclosure requirements as a smaller reporting company. For example, smaller reporting companies, like emerging growth companies, are not required to provide a compensation discussion and analysis under Item 402(b) of Regulation S-K or auditor attestation of internal controls over financial reporting.

Until such time, however, we cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

The trading in our shares will be regulated by the securities and exchange commission rule 15g-9 which established the definition of a "penny stock."

Our shares are defined as a penny stock under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), and rules of the Commission. The Exchange Act and such penny stock rules generally impose additional sales practice and disclosure requirements on broker-dealers who sell our securities to persons other than certain accredited investors who are, generally, institutions with assets in excess of $2,000,000 or individuals with net worth in excess of $1,000,000 or annual income exceeding $200,000 ($300,000 jointly with spouse), or in transactions not recommended by the broker-dealer. For transactions covered by the penny stock rules, a broker dealer must make certain mandated disclosures in penny stock transactions, including the actual sale or purchase price and actual bid and offer quotations, the compensation to be received by the broker-dealer and certain associated persons, and deliver certain disclosures required by the Commission. Consequently, the penny stock rules may make it difficult for you to resell any shares you may purchase, if at all.

Due to the lack of a trading market for our securities, you may have difficulty selling any shares you purchase in this offering.

We are not currently registered on any market or public stock exchange. There is presently no demand for our common stock and no public market exists for the shares being offered in this prospectus. We have contacted a market maker to apply to have the shares quoted on the Over-the-Counter Bulletin Board ("OTCBB"). The OTCBB is a regulated quotation service that displays real-time quotes, last sale prices and volume information in over-the-counter securities. The OTCBB is not an issuer listing service, market or exchange. Although the OTCBB does not have any listing requirements, to be eligible for quotation on the OTCBB, issuers must remain current in their filings with the SEC or applicable regulatory authority. If we are not able to pay the expenses associated with our reporting obligations we will not be able to apply for quotation on the OTC Bulletin Board. Market makers are not permitted to begin quotation of a security whose issuer does not meet this filing requirement. Securities already quoted on the OTCBB that become delinquent in their required filings will be removed following a 30 to 60 day grace period if they do not make their required filing during that time. We cannot guarantee that our application will be accepted or approved and our stock listed and quoted for sale. If no market is ever developed for our common stock, it will be difficult for you to sell any shares you purchase in this offering. In such a case, you may find that you are unable to achieve any benefit from your investment or liquidate your shares without considerable delay, if at all. In addition, if we fail to have our common stock quoted on a public trading market, your common stock will not have a quantifiable value and it may be difficult, if not impossible, to ever resell your shares, resulting in an inability to realize any value from your investment.

We will incur ongoing costs and expenses for sec reporting and compliance. Without revenue we may not be able to remain in compliance, making it difficult for investors to sell their shares, if at all.

We are required to file annual, quarterly and current reports, or other information with the SEC as provided by the Securities Exchange Act. We have contacted a market maker to apply to have the shares quoted on the OTC Electronic Bulletin Board. To be eligible for quotation, issuers must remain current in their filings with the SEC. In order for us to remain in compliance we will require future revenues to cover the cost of these filings, which could comprise a substantial portion of our available cash resources. If we are unable to generate sufficient revenues to remain in compliance it may be difficult for you to resell any shares you may purchase, if at all. Also, if we are not able to pay the expenses associated with our reporting obligations we will not be able to apply for quotation on the OTC Bulletin Board.

We may be exposed to potential risks and significant expenses resulting from the requirements under section 404 of the Sarbanes-Oxley act of 2002.

We are required, pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, to include in our annual report our assessment of the effectiveness of our internal control over financial reporting. We expect to incur significant continuing costs, including accounting fees and staffing costs, in order to maintain compliance with the internal control requirements of the Sarbanes-Oxley Act of 2002. Development of our business will necessitate ongoing changes to our internal control systems, processes and information systems. If our business develops and grows, our current design for internal control over financial reporting will not be sufficient to enable management to determine that our internal controls are effective for any period, or on an ongoing basis. Accordingly, as we develop our business, such development and growth will necessitate changes to our internal control systems, processes and information systems, all of which will require additional costs and expenses.

In the future, if we fail to complete the annual Section 404 evaluation in a timely manner, we could be subject to regulatory scrutiny and a loss of public confidence in our internal controls. In addition, any failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm our operating results or cause us to fail to meet our reporting obligations. However, as an "emerging growth company," as defined in the JOBS Act, our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 until the later of the year following our first annual report required to be filed with the SEC, or the date we are no longer an emerging growth company. At such time, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level at which our controls are documented, designed or operating.

Risks Relating to Our Organization and Our Common Stock

We are a publicly registered company that is subject to the reporting requirements of federal securities laws, which can be expensive and may divert resources from other projects, thus impairing our ability to grow.

We are a public reporting company and, accordingly, subject to the information and reporting requirements of the Exchange Act and other federal securities laws, including compliance with the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”). The costs of preparing and filing annual and quarterly reports, proxy statements and other information with the SEC and furnishing audited reports to stockholders will cause our expenses to be higher than they would have been if we remained private.

We will be required to incur significant costs and require significant management resources to evaluate our internal control over financial reporting as required under Section 404 of the Sarbanes-Oxley Act, and any failure to comply or any adverse result from such evaluation may have an adverse effect on our stock price.

As a smaller reporting company as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, we are required to evaluate our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act of 2002 (“Section 404”). Section 404 requires us to include an internal control report with the Annual Report on Form 10-K. This report must include management’s assessment of the effectiveness of our internal control over financial reporting as of the end of the fiscal year. This report must also include disclosure of any material weaknesses in internal control over financial reporting that we have identified. Failure to comply, or any adverse results from such evaluation, could result in a loss of investor confidence in our financial reports and have an adverse effect on the trading price of our equity securities. Management believes that our internal controls and procedures are currently not effective to detect the inappropriate application of U.S. GAAP rules. Management realizes there are deficiencies in the design or operation of our internal control that adversely affect our internal controls which management considers to be material weaknesses including those described below:

•	We have insufficient quantity of dedicated resources and experienced personnel involved in reviewing and designing internal controls. As a result, a material misstatement of the interim and annual financial statements could occur and not be prevented or detected on a timely basis.

•	We do not have an audit committee. While not being legally obligated to have an audit committee, it is our view that to have an audit committee, comprised of independent board members, is an important entity-level control over our financial statements.

•	We did not perform an entity level risk assessment to evaluate the implication of relevant risks on financial reporting, including the impact of potential fraud-related risks and the risks related to non-routine transactions, if any, on our internal control over financial reporting. Lack of an entity-level risk assessment constituted an internal control design deficiency which resulted in more than a remote likelihood that a material error would not have been prevented or detected and constituted a material weakness.

•	We lack personnel with formal training to properly analyze and record complex transactions in accordance with U.S. GAAP.

•	We have not achieved the optimal level of segregation of duties relative to key financial reporting functions.

Achieving continued compliance with Section 404 may require us to incur significant costs and expend significant time and management resources. We cannot assure you that we will be able to fully comply with Section 404 or that we and our independent registered public accounting firm would be able to conclude that our internal control over financial reporting is effective at fiscal year-end. As a result, investors could lose confidence in our reported financial information, which could have an adverse effect on the trading price of our securities, as well as subject us to civil or criminal investigations and penalties. In addition, our independent registered public accounting firm may not agree with our management’s assessment or conclude that our internal control over financial reporting is operating effectively.

FINRA sales practice requirements may also limit a stockholder’s ability to buy and sell our stock.

In addition to the “penny stock” rules described above, FINRA has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. The FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares.

Public company compliance may make it more difficult for us to attract and retain officers and directors.

The Sarbanes-Oxley Act and new rules subsequently implemented by the SEC have required changes in corporate governance practices of public companies. As a public company, we expect these new rules and regulations to increase our compliance costs and to make certain activities more time consuming and costly. As a public company, we also expect that these new rules and regulations may make it more difficult and expensive for us to obtain director and officer liability insurance in the future and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our board of directors or as executive officers.

The market price and trading volume of shares of our common stock may be volatile.

The market price of our common stock could fluctuate significantly for many reasons, including reasons unrelated to our specific performance, such as limited liquidity for our stock, reports by industry analysts, investor perceptions, or announcements by our competitors regarding their own performance, as well as general economic and industry conditions. For example, to the extent that other large companies within our industry experience declines in their share price, our share price may decline as well. Fluctuations in operating results or the failure of operating results to meet the expectations of public market analysts and investors may negatively impact the price of our securities. Quarterly operating results may fluctuate in the future due to a variety of factors that could negatively affect revenues or expenses in any particular quarter, including vulnerability of our business to a general economic downturn, changes in the laws that affect our products or operations, competition, compensation related expenses, application of accounting standards and our ability to obtain and maintain all necessary government certifications and/or licenses to conduct our business. In addition, when the market price of a company’s shares drops significantly, stockholders could institute securities class action lawsuits against the company. A lawsuit against us could cause us to incur substantial costs and could divert the time and attention of our management and other resources.

We may not pay dividends in the future. Any return on investment may be limited to the value of our common stock.

We do not anticipate paying cash dividends in the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our stock price appreciates.

Our common stock is currently considered a “penny stock,” which may make it more difficult for our investors to sell their shares.

Our stock is categorized as a penny stock. The SEC has adopted Rule 15g-9 which generally defines “penny stock” to be any equity security that has a market price (as defined) less than US$ 5.00 per share or an exercise price of less than US$ 5.00 per share, subject to certain exceptions. Our securities are covered by the penny stock rules, which impose additional sales practice requirements on broker-dealers who sell to persons other than established customers and accredited investors. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared by the SEC which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction and monthly account statements showing the market value of each penny stock held in the customer’s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer’s confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the stock that is subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to trade our securities. We believe that the penny stock rules discourage investor interest in and limit the marketability of our common stock.

Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.

If our stockholders sell substantial amounts of our common stock in the public market, or upon the expiration of any statutory holding period under Rule 144, or issued upon the exercise of outstanding options or warrants, it could create a circumstance commonly referred to as an “overhang” and in anticipation of which the market price of our common stock could fall. The existence of an overhang, whether or not sales have occurred or are occurring, also could make more difficult our ability to raise additional financing through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.

Market for Securities

There has been no market for our securities and a public market may never develop, or, if any market does develop, it may not be sustained. Our common stock is not traded on any exchange or on the over-the-counter market. We have a market maker who has filed an application with the Financial Industry Regulatory Authority ("FINRA") for our common stock to be eligible for trading on the Over-the-Counter Bulletin Board. To be eligible for quotation, issuers must remain current in their quarterly and annual filings with the SEC. If we are not able to pay the expenses associated with our reporting obligations we will not be able to continue the quotation on the OTC Bulletin Board. There can be no assurance that our common stock will ever be quoted on a stock exchange or a quotation service or that any market for our stock will develop.

Risks Relating to Our Organization and Our Common Stock

•	We have insufficient quantity of dedicated resources and experienced personnel involved in reviewing and designing internal controls. As a result, a material misstatement of the interim and annual financial statements could occur and not be prevented or detected on a timely basis.

•	We do not have an audit committee. While not being legally obligated to have an audit committee, it is our view that to have an audit committee, comprised of independent board members, is an important entity-level control over our financial statements.

•	We did not perform an entity level risk assessment to evaluate the implication of relevant risks on financial reporting, including the impact of potential fraud-related risks and the risks related to non-routine transactions, if any, on our internal control over financial reporting. Lack of an entity-level risk assessment constituted an internal control design deficiency which resulted in more than a remote likelihood that a material error would not have been prevented or detected, and constituted a material weakness.

•	We lack personnel with formal training to properly analyze and record complex transactions in accordance with U.S. GAAP.

•	We have not achieved the optimal level of segregation of duties relative to key financial reporting functions.

Public company compliance may make it more difficult for us to attract and retain officers and directors.

The market price and trading volume of shares of our common stock may be volatile.

We may not pay dividends in the future. Any return on investment may be limited to the value of our common stock.

Our common stock is currently considered a “penny stock,” which may make it more difficult for our investors to sell their shares.

Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES.

The Company’s business office is located at 1999 Avenue of the Stars Suite 1100 Century City, California 90067. The former Company headquarters and head of our discontinued operations was located at 5 Garbary, Gdansk, Poland 80327. On May 29, 2015 the Company purchased a 500 sq. feet of office in a stand along the building for $13,653, reflected in assets from discontinued operations. During the year ended May 31, 2018, the Company has fully reserved the value of this building for loss as it has no access or economic use of the building an is in the process of formally disposing of the building.

ITEM 3. LEGAL PROCEEDINGS.

We are not currently a party to any legal proceedings, and we are not aware of any pending or potential legal actions.

ITEM 4. MINE SAFETY DISCLOSURES.

None.

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

Holders of our Common Stock

As of September 27, 2018, there were 17 registered stockholders, holding 50,000,502 shares of our issued and outstanding common stock.

Dividend Policy

There are no restrictions in our articles of incorporation or bylaws that prevent us from declaring dividends. The Nevada Revised Statutes, however, do prohibit us from declaring dividends where, after giving effect to the distribution of the dividend:

	1.	We would not be able to pay our debts as they become due in the usual course of business; or

	2.	Our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of shareholders who have preferential rights superior to those receiving the distribution.

We have not declared any dividends and we do not plan to declare any dividends in the foreseeable future.

Recent Sales of Unregistered Securities

n/a

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

We did not purchase any of our shares of common stock or other securities during our fiscal year ended May 31, 2018.

Securities Authorized for Issuance Under Equity Compensation Plans

We do not have any equity compensation plans.

ITEM 6. SELECTED FINANCIAL DATA.

Not Applicable.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

The information contained in this report, including in the documents incorporated by reference into this prospectus, includes some statements that are not purely historical and that are "forward-looking statements." Such forward-looking statements include, but are not limited to, statements regarding our Company and management's expectations, hopes, beliefs, intentions or strategies regarding the future, including our financial condition, results of operations, and financial performance. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipates," "believes," "continue," "could," "estimates," "expects," "intends," "may," "might," "plans," "possible," "potential," "predicts," "projects," "seeks," "should," "will," "would" and similar expressions, or the negatives of such terms, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements contained in this prospectus are based on current expectations and beliefs concerning future developments and the potential effects on the parties and the transaction. There can be no assurance that future developments actually affecting us will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the parties' control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.

Results of Discontinued and Continuing Operations

Discontinued Operations

We have generated no revenue for the year ended May 31, 2018 compared to $73,171 for the same period in the prior year. We had no cost of goods sold for the year ended May 31, 2018 compared to $53,197 for the same period in the prior year resulting in no gross profit of compared to $19,974 for the year ended May 31, 2017. For the years ended May 31, 2018 and 2017, our operating expenses were comprised of selling, general and administrative expenses of $11,757 and $3,910, respectively, resulting in a net loss of $11,757 compared to a net profit of $16,064 for the year ended May 31, 2017. Our selling, general and administrative expenses consisted of an impairment loss on assets from discontinued operations and administrative fees and depreciation.

Continuing Operations

During the years ended May 31, 2018 and 2017, we generated no revenue with no cost of goods sold being, resulting in no gross profit. Our operating expenses for the same period were comprised of general and administrative expenses of $638,777 and $218,257, respectively resulting in a net losses of $892,248 and $205,187. Our general and administrative expenses consisted of filing fees, banks fees, travel expense, rent, stock issuance costs, marketing and advertising.

Liquidity and Capital Resources

At May 31, 2018, we had no cash or cash equivalents compared to $8,415 in the prior year. We will need to raise cash through a combination of proceeds from private placements of our securities, loans and convertible notes. Our cash requirements are generally for research and development, product development, general and administrative activities. We believe that our cash balance is not sufficient to finance our cash requirements for expected operational activities, capital improvements, and settlement of debt through the next 12 months.

Our operating activities used cash of $356,344 for the year ended May 31, 2018, and we used cash in operations of $192,050 during the same period in 2017. The principal elements of cash flow from operations for the year ended May 31, 2018 included our net loss of $892,248, warrants and stock issued to consultants of $66,567, accrued expenses and payables of $204,962, increased accrued interest of $43,170 and $30,000 of non-cash interest expense.

For the years ended May 31, 2018 and 2017 the Company didn’t receive any cash through investing activities. During the year ended May 31, 2018, the Company used $101,939 in investing activities which included $100,000 paid for a license agreement and $1,939 paid for equipment.

Cash provided in our financing activities was $449,858 for the year ended May 31, 2018, compared to $$200,000 of cash generated during the comparable period in 2017 primarily as the result of $215,000 more in proceeds from convertible notes and $34,630 provided by a related party in the form of loans and direct payments.

Our total assets at May 31, 2018 were $1,481 which was equipment net of depreciation. Our total assets at May 31, 2017 were $22,172 which was $8,415 in cash, $2,000 of prepaid expenses and $11,757 in assets from discontinued operations. Current liabilities increased from $215,077 at May 31, 2017 to $343,067 at May 31, 2018. The increase in liabilities was primarily attributable to accrued payroll of $185,152, increase in funds provided from a related party in the amount $34,630, an increase in accrued interest of $43,170 and an increase in accounts payable of $19,811 offset by a decrease in Convertible notes of $155,000.

On November 15, 2017, the Company entered into an Equity Financing Agreement and Registration Rights Agreement with GHS pursuant to which GHS has agreed to purchase up to $7,000,000 in shares of Company common stock. The obligations of GHS to purchase the shares of Company common stock are subject to the conditions set forth in the Equity Financing Agreement, including, without limitation, the condition that a registration statement on Form S-1 registering the shares of Company common stock to be sold to GHS be filed with the Securities and Exchange Commission and become effective. The Registration Rights Agreement provides that the Company shall use commercially reasonable efforts to file the registration statement within 30 days after the date of the Registration Rights Agreement and have the registration statement become effective within 90 days after it is filed. The purchase price of the shares of Company common stock will be equal to 80% of the market price (as determined in the Equity Financing Agreement) calculated at the time of purchase. The Company filed the Form S-1 Registration Statement for the Equity Financing Agreement on December 7, 2017. The Company withdrew the Form S-1 Registration Statement on February 12, 2018 based on the comments from the SEC regarding the Company’s inability to use the Form S-1 Registration Statement to register the shares of common stock.

In connection with the Equity Financing Agreement, the Company executed a convertible promissory note in the principal amount of $15,000 (the “Note”) as payment of the commitment fee for the Equity Financing Agreement. The Note bear interests at the rate of 10% and must be repaid on or before August 14, 2018 (the “Maturity Date”). The Company may repay the Note at any time before the Maturity Date. The amounts under the Note may be converted by GHS at any time after the Maturity Date into shares of Company common stock at a conversion price equal to 80% of the average closing bid price during the 5-day period prior to conversion (as determined in the Note).

GOING CONCERN CONSIDERATION

We have generated $236,866 revenues since inception, as reflected in discontinued operations. As of May 31, 2018, the Company had an accumulated deficit of $1,129,153. Our independent auditors included an explanatory paragraph in their report on the accompanying financial statements regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors. Our financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

OFF BALANCE SHEET ARRANGEMENTS.

We have no off-balance sheet arrangements including arrangements that would affect our liquidity, capital resources, market risk support and credit risk support or other benefits.

Critical Accounting Policies

Stock-Based Compensation

The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in shareholders’ equity/(deficit) over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.

The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (1) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (2) the date at which the counterparty’s performance is complete. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services.

Impairment of Long-Lived Assets

Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

Recent Accounting Pronouncements

In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815),” which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The Company does not anticipate this standard having an impact on its consolidated financials.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As the Company is a “smaller reporting company,” this item is inapplicable.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

Report of Independent Registered Public Accounting Firm (Current Firm)	F-1
Report of Independent Registered Public Accounting Firm (Predecessor Firm)	F-2
Balance Sheets	F-3
Statements of Operations	F-4
Statements of Cash Flows	F-5
Statements of Changes in Stockholders’ Deficit	F-6
Notes to Financial Statements	F-7

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders
of Hypgen, Inc.
Century City, California

Opinion on the Financial Statements

We have audited the accompanying balance sheet of Hypgen, Inc. (“the Company”) as of May 31, 2018 and the related statements of operations, changes in shareholders’ deficit, and cash flows for the year then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of May 31, 2018, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

Consideration of the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has a significant working capital deficit, has not yet received significant revenue from sales, and has incurred significant losses since inception. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Fruci & Associates II, PLLC

We have served as the Company’s auditor since 2017.

Spokane, Washington

October 3, 2018

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Shareholders of

Hypgen Inc. (fka Mega Bridge Inc.)

State of Nevada,

USA.

We have audited the balance sheet of Hypgen Inc. (formerly known as Mega Bridge Inc.) as of May 31, 2017 and the related statements of operations, stockholders' equity and cash flows for the fiscal year then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of May 31, 2017 and the results of its operations and its cash flows for the fiscal year then ended in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note I to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regards to these matters are also described in Note I. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

For Bharat Parikh & Associates

Chartered Accountants

/s/ Bharat Parikh

CA Bharat Parikh

(Senior Managing Partner)

Registered with PCAOB

Date :- 08/28/2017

Place:- HQ Vadodara GJ, India

F-2

HYPGEN INC
BALANCE SHEETS
	May 31,
	2018			2017
ASSETS
CURRENT ASSETS
Cash	$	—		$	8,415
Prepaid Expenses		—			2,000
License asset agreement, net		—			—
Assets from discontinued operations		—			11,757
Total current assets		—			22,172
Property and equipment, net		1,481			—
TOTAL ASSETS	$	1,481		$	22,172

LIABILITIES AND SSHAREHOLDERS' EQUITY
LIABILITIES
Current Liabilities:
Accrued expenses and payables	$	31,044		$	11,233
Loan payable - related party		34,630			—
Bank overdraft		228			—
Accrued salary, wages and taxes		185,152			—
Liabilities from discontinued operations		—			—
Accrued interest -including related party		47,014			3,844
Convertible Note Payable - related party, current portion		—			200,000
Convertible Notes Payable, net of discounts		45,000			—
Total Current Liabilities		343,067			215,077
Other Liabilities
Convertible Note Payable - related party, net of current portion		400,000			—
Total Liabilities		743,067			215,077

Commitments and contingencies		—			—

SHAREHOLDERS' DEFICIT
Preferred stock: authorized 2,000,000; $0.001 par value; shares issued and outstanding at May 31, 2018 and no shares issued or authorized as of May 31, 2017		2,000			—
Common stock: authorized 1,000,000,000; $0.001 par value; 135,800,000 and 5,000,000 shares issued and outstanding at May 31, 2018 and May 31, 2017		135,800			5,000
Additional Paid in Capital		249,767			39,000
Accumulated deficit		(1,129,153	)		(236,905	)
Total Shareholders' Deficit		(741,586	)		(192,905	)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$	1,481		$	22,172

The accompanying notes are an integral part of these financial statements.

F-3

HYPGEN INC
STATEMENTS OF OPERATIONS
	May 31,
	2018			2017
Continuing Operations:
Revenue	$	—		$	—
Cost of Goods Sold:
Product Purchases		—			—
Gross Profit		—			—

Operating Expenses:
Depreciation and amortization		8,914			910
Salary and payroll expense		204,269			—
Professional fees		111,444			56,000
Consulting fees		270,338			54,000
General and administrative		43,812			107,347
Total operating expense		638,777			218,257
Net income (loss) from operations		(638,777	)		(218,257	)

OTHER (INCOME) EXPENSE
Interest expense and financing cost, net		73,170			3,844
Loss on impairment		168,544			—
Forgiveness of related party debt		—			(750	)
Total other (income) expense		241,714			3,094

Discontinued Operations:
Net income (loss) from discontinued operations		(76	)		16,064
Impairment loss on assets from discontinued operations		(11,681	)		—
Total Income (loss) from discontinued operations		(11,757	)		16,064
Net income before income tax provision		(892,248	)		(205,287	)
Provision for income tax		—			—
Net Loss		(892,248	)		(205,287	)

Basic and diluted net loss per share of common stock:
Continuing operations	$	(0.008	)	$	(0.044	)
Discontinued Operations		(0.000	)		0.003
Basic and diluted	$	(0.008	)	$	(0.041	)

Weighted average number of shares outstanding:
Basic and diluted		117,603,288			5,000,000

The accompanying notes are an integral part of these financial statements.

F-4

HYPGEN INC
STATEMENTS OF CASH FLOWS
	May 31,
	2018			2017
Operating activities:
Net loss from continuing operations	$	(880,491	)	$	(221,351	)
Net income (loss) from discontinuing operations		(11,757	)		16,064
Net Loss		(892,248	)		(205,287	)
Adjustment to reconcile net loss to net cash provided by operations:
Amortization and depreciation		8,990			910
Impairment loss on asset		168,544			—
Loss on impairment on assets held in discontinued operations		11,681			—
Non-cash interest charges - commitment fees		30,000			3,844
Related party forgiveness of debt		—			(750	)
Warrants and Shares issued to consultants for services		66,567			—
Changes in assets and liabilities:
Decrease (Increase) in prepaid and deposits		2,000			(2,000	)
Increase in accrued interest and finance charges		43,170			—
Increase in accrued expenses and payables		204,962			11,233
Net cash used in operating activities		(356,334	)		(192,050	)
Investing activities:
Cash paid for property and equipment		(1,939	)		—
Cash paid for license fee		(100,000	)
Net cash used in investing activities		(101,939	)		—
Financing activities:
Proceeds from Convertible note payable - related party		400,000			200,000
Bank overdraft		228			—
Proceeds from convertible notes		15,000			—
Proceeds from related party		4,814			—
Proceeds from loans - related party		29,816			—
Net cash provided by financing activities		449,858			200,000
Net increase (decrease) in cash		(8,415	)		7,950
Cash, beginning of period		8,415			465
Cash, end of period	$	—		$	8,415
Supplemental disclosure of cash flow information:
Cash paid during the period
Taxes	$	—		$	—
Interest Paid	$	—		$	—
Non-cash activity:
Common and Preferred shares issued to acquired license	$	77,000.00		$	—
Convertible notes redeemed for common stock	$	200,000.00		$	—

The accompanying notes are an integral part of these financial statements.

F-5

HYPGEN INC
STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT
For the years ended May 31, 2018 and 2017

	Preferred Stock Number of			Common Stock Number of				Additional Paid in		Total Accumulated			Shareholders'
	Shares		Par Value	Shares		Par Value		Capital		Gain (Loss)			Equity

Balance, May 31, 2016	—	$	—	5,000,000	$	5,000	$	39,000	$	(31,618	)	$	12,382

Common Shares issued:
Share issued for cash	—		—	—		—		—		—			—

Net gain (loss)	—		—	—		—		—		(205,287	)		(205,287	)
Balance, May 31, 2017	—	$	—	5,000,000	$	5,000	$	39,000	$	(236,905	)	$	(192,905	)

Common Shares issued:
Share issued for cash	—		—	—		—		—
Shares issued under consulting agreements	—		—	55,000,000		55,000		—		—			55,000
Asset assignment agreement	2,000,000		2,000	75,000,000		75,000		—		—			77,000
Shares issued for debt conversion	—		—	800,000		800		199,200		—			200,000
Warrants issued to consultants	—		—	—		—		11,567		—			11,567
Net gain (loss)	—		—	—		—		—		(892,248	)		(892,248	)
Balance, May 31, 2018	—	$	2,000	135,800,000	$	135,800	$	249,767	$	(1,129,153	)	$	(741,586	)

The accompanying notes are an integral part of these financial statements.

F-6

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 1: ORGANIZATION AND BASIS OF PRESENTATION

Nature of Business

HYPGEN INC. (formerly MEGA BRIDGE INC) (the “Company”) is a for profit corporation established under the corporate laws of the State of Nevada on March 26, 2015.

We are an emerging growth company as defined in Section 2(a)(19) of the Securities Act. We will continue to be an emerging growth company until: (i) the last day of our fiscal year during which we had total annual gross revenues of $1,000,000,000 or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (iii) the date on which we have, during the previous 3-year period, issued more than $1,000,000,000 in non-convertible debt; or (iv) the date on which we are deemed to be a large accelerated filer, as defined in Section 12b-2 of the Exchange Act.

As an emerging growth company, we are exempt from:

Section 14A (a) and (b) of the Exchange Act, which requires companies to hold stockholder advisory votes on executive compensation and golden parachute compensation;

The requirement to provide in any registration statement periodic report or other report to be filed with the Securities and Exchange Commission, certain modified executive compensation disclosure under Item 402 of Regulation S-K or selected financial data under Item 301 of Regulation S-K for any period before the earliest audited period presented in our initial registration statement;

Compliance with new or revised accounting standards until those standards are applicable to private companies;

The requirement under Section 404(b) of the Sarbanes-Oxley Act of 2002 to provide auditor attestation of our internal controls and procedures; and

Any Public Company Accounting Oversight Board ("PCAOB") rules regarding mandatory audit firm rotation, or an expanded auditor report and any other PCAOB rules subsequently adopted, unless the Securities and Exchange Commission determines the new rules are necessary for protecting the public.

We have not elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the Jumpstart Our Business Startups Act.

Unless the context otherwise requires, all references to “we,” “us,” “our” or the “Company” are to HYPGEN INC.

On January 18th, 2017, Olaf Robak, the Company's President and CEO, executed a stock purchase agreement with First Legacy Management LLC, which acquired 4,000,000 shares of common stock, representing 80% ownership of the Company. First Legacy Management LLC paid $350,000 in cash. Simultaneous with this transaction, Mr. Olaf Robak resigned from his official positions as Director, CEO, CFO, President, Treasurer and Secretary of the Company, and on the same day the shareholders of the Corporation voted Mr. Antonio Treminio as Director & CEO (Mr. Treminio subsequently resigned as a director and CEO effective as of June 28, 2017).

On March 9, 2017, FINRA notified the Company that request for symbol change was approved. Effective March 13, 2017, the Company’s common stock began trading under the symbol MGBR.

F-7

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 1: ORGANIZATION AND BASIS OF PRESENTATION (CONTINUED)

Nature of Business (Continued)

On June 28, 2017, the Company executed an Asset Assignment Agreement (“Asset Assignment Agreement”) with Richard L. Chang Holding’s LLC (“Holdings LLC”), pursuant to which Holdings was issued 60,000,000 shares of the Company’s common stock and 2,000,000 restricted, non-convertible, non-dividend paying shares of the Company’s preferred stock with 1000 to 1 voting rights over shares of the Company’s common stock. In consideration of these share issuances, Holdings LLC has assigned to the Company all of its rights, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016, titled “COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. Additionally, the Company issued 15,000,000 common shares to Rich Pharmaceuticals, Inc. for use of the clinical trial under an Investigational New Drug Application. Additionally, pursuant to the terms of the Asset Assignment Agreement, upon the Company receiving a minimum of $1,000,000 in equity financing, Holdings shall assign to the Company all of its rights, title and interest to United States Utility Patent Application No USPTO Application No. 15/385,862 filed on December 20, 2016, titled ”COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. The Asset Assignment Agreement granted to Holdings LLC the right to require the Company to assign back to Holdings LLC the Patent Application and all related intellectual property in the event the Company does not raise a minimum of $1,000,000 in equity financing by June 28, 2018. In the event that Holdings LLC exercises this right of reversion, the 2,000,000 shares of Preferred Stock issued to Holdings LLC shall be assigned to Apica Investments Limited or its assignees. As of May 31, 2018, the Company has not raised any capital towards the $1,000,000 requirement. As of the filing of this report Holdings LLC has not exercised its right of reversion under the Asset Assignment Agreement.

On June 28, 2017, the Company discontinued operations of its office products sales and distribution segment.

On July 11, 2017, the Board of Directors of the Company appointed Dr. Moretz as the Chief Financial Officer of the Company.

On August 1, 2017, the Company changed its name to HypGen Inc. to more accurately reflect the Company’s new strategic direction as it focuses its efforts on developing therapeutic treatment options for Parkinson's disease. Effective with the name change the Company’s trading symbol was changed to HPGN with OTC Markets.

Going Concern

As indicated in the accompanying financial statements, the Company has incurred net losses of $892,248 and $205,287 for the years ended May 31, 2018 and 2017, respectively. Management’s plans include the raising of capital through related and third parties to fund future operations of pushing its Parkinson’s disease drug through phase II drug trials in order to obtain approval from the food and drug administration (“FDA”). Failure to raise adequate capital during the testing and approval seeking process may force the Company to curtail or cease operations. Additionally, even if the Company raises sufficient capital to support its operating expenses, there can be no assurances that FDA approval will be granted whereby no revenue from target project will ever be recognized to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern. However, the accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

F-8

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates and Assumptions

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. At May 31, 2018 and 2017, the Company had no cash equivalents.

Property and Equipment and Depreciation

Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.

Intangible Assets

Intangible assets consisted of a licensing fee under an asset assignment agreement for a patent which was granted November 10, 2016. At the time of the assignment on June 28, 2017, the patent had a remaining life of 19 years and 135 days, which the Company had determined to be the remaining useful life of the patent whereby total investment was to be amortized on a straight-line basis over this period. In exchange for the rights to the intellectual property the Company paid $100,000 in cash, issued 2,000,000 preferred shares and 75,000,000 commons shares. The total investment was valued at $177,000.

During the year ended May 31, 2018, the Company analyzed its intangible asset for the purposes of impairment testing. Although management believes that the asset has real economic value, the expense of an independent valuation is not something the Company is interested in doing, whereby the cost of this analysis could exceed the value of the asset. Conversely, the Company’s asset analysis is not objectively able to prove with any degree of certainty that it will ever see positive cashflow from its efforts. This industry is very complicated, risky and unpredictable as it relates to ultimate drug approval or even the sale of the asset. Due to a cost prohibitive asset valuation, uncertainty that the product can be brought to market or be sold and the fact that the that acquisition was from a related party the Company feels that is should fully impair the asset at this time.

Impairment of Long-Lived Assets

F-9

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Net Loss Per Common Share

The Company computes per share amounts in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 260 Earnings per Share (“EPS”) which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to Common Stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of Common Stock and Common Stock equivalents outstanding during the periods; however, potential common shares are excluded for period in which the Company incurs losses, as their effect is anti-dilutive. For the years ended May 31, 2018 and 2017 the basic and fully diluted earnings per share were the same as the Company had a loss in each of these periods. At May 31, 2018, the Company had potentially dilutive instruments in the form of 60,000,000 common stock warrants with a cashless exercise provision outstanding as well as 1,965,954 common shares issuable upon the conversion of outstanding principal and interest on convertible notes.

Stock-Based Compensation

The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted on the grant date as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in stockholders’ equity/(deficit) over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.

The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value on the grant date of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services over the term of the related services.

Fair Value of Financial Instruments

ASC 825, “Disclosures about Fair Value of Financial Instruments”, requires disclosure of fair value information about financial instruments in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value hierarchy to classify the inputs used in measuring fair value as follows:

· Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

· Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

· Level 3-Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2018.

F-10

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Fair Value of Financial Instruments (Continued)

The respective carrying values of certain on-balance-sheet financial instruments approximate their fair values. These financial instruments include cash, accrued liabilities and notes payable. Fair values were assumed to approximate carrying values for these financial instruments since they are short term in nature and their carrying amounts approximate fair value. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet date.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current period presentation. The reclassifications had no effect on the net loss or cash flows of the Company.

Revenue Recognition

The Company recognizes revenues in accordance with FASB ASC Topic 605, “Revenue Recognition”, and with the guidelines of the Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104 “Revenue Recognition”.

Under SAB 104, four conditions must be met before revenue can be recognized: (i) there is persuasive evidence that an arrangement exists, (ii) delivery has occurred or service has been rendered, (iii) the price is fixed or determinable, and (iv) collection is reasonably assured.

Customers of our discontinued operation paid for their product at the time we are advised by the manufacturer/distributor that the product is ready for shipment or pick-up. The Company recognizes revenue when the pre-paid product has been delivered to, or picked up by, the customer. In the event there is a significant delay between the date the customer pre-pays for the product and the delivery or pick-up of the product, revenue would be deferred until the customer accepts delivery of the product. Under our current operations we do not expect to recognize revenue until we receive FDA approval to sell our Parkinson’s disease drug commercially.

Research and Development

The Company expenses research and development costs as incurred. Research and development costs were $0 for the years ended May 31, 2018 and 2017. The expense in the prior year is reflected in discontinued operations. The Company anticipates substantial expense as it conducts phase II trials and tries to move its product to market along with the development of its other products. The Company will also evaluate products and technologies in the medical products space, with its main focus on Parkinson’s Disease. As the Company continues to develop its products and relationships in these areas’ resultant expenses for trademark filings, license agreements, product development and design materials will be expensed as research and development. Some costs may be accumulated for subsidiaries prior to formation of entities.

Income Taxes

We will use the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for the reporting period presented.

The Company did not record any income tax accrual for the period from inception to May 31, 2018. We expect to incur significant expenses in future periods which will offset any net profit.

F-11

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Recent Accounting Pronouncements

In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” which addresses accounting for issuance of all share-based payments on the same accounting model. Previously, accounting for share-based payments to employees was covered by ASC Topic 718 while accounting for such payments to non-employees was covered by ASC Subtopic 505-50. As it considered recently issued updates to ASC 718, the FASB, as part of its simplification initiatives, decided to replace ASC Subtopic 505-50 with Topic 718 as the guidance for non-employee share-based awards. Under this new guidance, both sets of awards, for employees and non-employees, will essentially follow the same model, with small variations related to determining the term assumption when valuing a non-employee award as well as a different expense attribution model for non-employee awards as opposed to employee awards. The ASU is effective for public business entities beginning in 2019 calendar years and one year later for non-public business entities.

In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815),” which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The Company is currently in the process of assessing the impact the adoption of this guidance will have on the Company’s financial statements.

Subsequent Events

In accordance with ASC 855 “Subsequent Events” the Company evaluated subsequent events after the balance sheet date through the date of issuance.

NOTE 3: DISCONTINUED OPERATIONS

On June 28, 2017, the Company discontinued operations of its office products sales and distribution segment. Depreciation expense as it appears on the Statement of Cash Flows for the years ended months ended May 31, 2018 and 2017 was $76 and $910, respectively. Depreciation on the statement of operations for the years ended May 31, 2018 is recorded as Income (Loss) from Discontinued Operations.

F-12

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 3: DISCONTINUED OPERATIONS (CONTINUED)

The statement of operations was restated to reflect the reclassification of the discontinued operations.

HYPGEN INC STATEMENTS OF DISCONTINUED OPERATIONS
	For the years ended May 31,
	2018			2017
Discontinued Operations:
Revenue	$	—		$	73,171
Cost of Goods Sold:
Product Purchases		—			53,197
Gross Profit		—			19,974

Operating Expenses:
General and administrative		—			3,000
Product development		—			—
Depreciation		76			910
Impairment loss on assets from discontinued operations		11,681			—
Total operating expense		11,757			3,910
Net income (loss) from discontinued operations	$	(11,757	)	$	16,064

On May 25, 2015 the Company purchased a small office located at 5 Garbary in Gdansk Poland. The purchase price was $13,653. The Company utilized this space as its primary office for the former discontinued operations. Assets from discontinued operations are reflected net of accumulated depreciation. As of June 28, 2017, the building, classified as assets of discontinued operations, is no longer being depreciated due to the fact that it is no longer in service.

As of May 31, 2018, the Company has fully impaired the remaining net value of its former office which was held as an asset from discontinued operations. The Company no longer has access or control over this asset and believes that there is no substantial net economic value to this asset and any cost of legal disposal could easily exceed its net book value.

	May 31, 2018		May 31, 2017
Assets of discontinued operations	$	—	$	11,757
Liabilities of discontinued operations		—		—

NOTE 4: FIXED ASSETS

The Company’s property and equipment is as follows:

	May 31, 2018			May 31, 2017		Estimated Life
Computers, office furniture and equipment	$	1,939		$	—		3 years
Less: accumulated depreciation	$	(458	)	$	—
Net	$	1,481		$	—

Depreciation expense for nine months ended year ended May 31, 2018 was $458 compared to $0 for the year ended May 31, 2017.

F-13

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 5: INTANGIBLE ASSETS

On June 28, 2017, the Company executed an Asset Assignment Agreement (“Asset Assignment Agreement”) with Richard L. Chang Holding’s LLC (“Holdings LLC”), pursuant to which Holdings was issued 60,000,000 shares of the Company’s common stock and 2,000,000 restricted, non-convertible, non-dividend paying shares of the Company’s preferred stock with 1000 to 1 voting rights over shares of the Company’s common stock. In consideration of these share issuances, Holdings LLC has assigned to the Company all of its rights, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016, titled “COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. Additionally, the Company issued 15,000,000 common shares to Rich Pharmaceuticals, Inc. for use of the clinical trial under an Investigational New Drug Application. The Asset Assignment Agreement grants to Holdings LLC the right to require the Company to assign back to Holdings LLC the Patent Application and all related intellectual property in the even the Company does not raise a minimum of $1,000,000 in equity financing by June 28, 2018. In the event that Holdings LLC exercises this right of reversion, the 2,000,000 shares of Preferred Stock issued to Holdings LLC shall be assigned to Apica Investments Limited or its assignees. The common and preferred shares were valued at $77,000. Further cash compensation was given in the amount of $100,000 totaling an investment of $177,000. As of the filing of this report Holdings LLC has not exercised its right of reversion under the Asset Assignment Agreement.

The below chart analyzes the license value net of amortization:

	May 31, 2018			Estimated Life
Investment in license	$	177,000		19.4 years
Less amortization	$	(8,456	)
Less impairment loss		(168,544	)
License fee net amortization	$	—

Amortization expense for the years ended May 31, 2018 and was $8,456 compared to $0 during the same period in the prior year.

NOTE 6: CONVERTIBLE NOTES PAYABLE

On January 27, 2017, the Company entered into a one-year convertible note with the face value of $100,000 bearing 8% interest. Funds were transmitted to the Company on August 1, 2017 at which time interest started to accrue. The Company was permitted to prepay this note in full or in part at any time without penalty. This note was to become convertible at the sole discretion of the note holder if full payment had not been made when the maturity date arrived. The holder of the note was entitled to a conversion price equal to seventy percent of the average trading price computed based on the previous 7 trading days prior to notice of conversion. These shares once converted may not be offered, sold, transferred or disposed of in any other way without prior written consent of the Company. On June 28, 2017, the Company executed an amendment to this note. The amendment provides that the total outstanding amounts under the promissory notes shall convert into shares of Company common stock at the conversion price of $.25 per share and the principal was converted on August 11, 2017. Accrued interest at conversion remains at $4,244.

On April 7, 2017, the Company entered into a one-year convertible note with the face value of $100,000 bearing 8% interest. The Company was able to prepay this note in full or in part at any time without penalty. This note was to become convertible at the sole discretion of the note holder if full payment had not been made when the maturity date arrived. The holder of the note was entitled to a conversion price equal to seventy percent of the average trading price computed based on the previous 7 trading days prior to notice of conversion. These shares once converted may not be offered, sold, transferred or disposed of in any other way without prior written consent of the Company. On June 28, 2017, the Company executed an amendment to this note. The amendment provides that the total outstanding amounts under the promissory notes shall convert into shares of Company common stock at the conversion price of $.25 per share and the principal was converted on August 11, 2017. Accrued interest at conversion remains at $2,800.

F-14

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 6: CONVERTIBLE NOTES PAYABLE (CONTINUED)

On June 28, 2017, the Company executed a Promissory Convertible Note with Bakken Development LLC in the principal amount of $400,000. The convertible note accrues interest at the rate of 10% per annum; is due and payable on or before June 28, 2019; may be converted at any time by the holder into shares of Company common stock at a conversion price of $.50 per share; and automatically converts into shares of Company common stock at a conversion price of $.50 per share upon the Company’s completion of a financing in the minimum amount of $5,000,000. At May 31, 2018, accrued interest on this note was $38,889.

On August 11, 2017, the Company issued 800,000 common shares to retire convertible promissory notes dated January 27, 2017 and April 7, 2017 with Bakken Development LLC in the aggregate principal amount of $200,000. As amended, the promissory notes convert into shares of Company common stock at the conversion price of $.25 per share. Accrued interest remains unconverted on these notes in the amount of $7,044.

On November 15, 2017, the Company entered into an Equity Financing Agreement and Registration Rights Agreement with GHS Investments LLC (“GHS”) pursuant to which GHS has agreed to purchase up to $7,000,000 in shares of Company common stock. (See NOTE 8). In connection with the Equity Financing Agreement, the Company executed a convertible promissory note in the principal amount of $15,000 as payment of the commitment fee for the Equity Financing Agreement. During the year ended May 31, 2018, the Company recorded this fee as interest expense. The amount was expensed upon issuance due to the fact the that no stock was sold and there is no certainty any stock will be sold under this agreement.

Upon any event of default, the note bears interests at the rate of 10%. This note has a maturity date of August 14, 2018. The Company may repay the note at any time before the maturity date. The amounts under the Note may be converted by GHS at any time after the maturity date or upon any event of default into shares of Company common stock at a conversion price equal to 80% of the average closing bid price during the 5-day period prior to conversion, subject to a floor price of $0.00005 per share. As a penalty of default, the principal increased by 50%, to $22,500 and the charge was recorded as interest expense and an increase to principal. As of May 31, 2018, this note had accrued interest of $277.

On November 17, 2017, the Company was advanced $15,000 under a promissory executed on December 19, 2017. Upon any event of default this note bears an interest rate of 10%. This note has a maturity date of August 19, 2018. The Company may repay the note at any time before the maturity date. Upon any event of default, the note holder may convert the note in its entirety into shares of Company common stock at a conversion price equal to 80% of the average closing bid price during the 5-day period prior to conversion, subject to a floor price of $0.00005 per share. As a penalty of default, the principal increased by 50%, to $22,500 and the charge was recorded as interest expense and an increase to principal. The foregoing is only a brief description of the material terms of the promissory note and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements which are hyperlinked as an exhibit to this Annual Report. As of May 31, 2018, this note had accrued interest of $277.

On July 18, 2018, the Company became aware that it was considered to be in default of both notes held by GHS. The Company has recorded interest and default related penalty amounts due to note-holder in the amount of $10,922 on its statement of operations during the year ended May 31, 2018. The event of default, as alleged by the noteholder, occurred April 16, 2018 when the Company failed its quarterly Form 10Q for its third fiscal quarter. The Company does not believe that an event of default occurred as of July 18, 2018 and is currently trying to resolve this issue with the note-holder. Subsequently, by virtue of not repaying the notes upon maturity the Company did trigger default on the above notes as of August 14, 2018 and August 19, 2018, respectively.

NOTE 7: COMMITMENTS AND CONTINGENCIES

Pursuant to the June 28, 2017 Asset Assignment Agreement with Holdings LLC and its assignment to the Company all of its rights, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016, titled “COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all related intellectual property, inventions and trade secrets, data, and clinical study results there is a major fund-raising requirement. The Company must raise a minimum of $1,000,000 in equity financing by June 28, 2018. The Asset Assignment Agreement grants to Holdings LCC the right to require the Company to assign back to Holdings LLC the Patent Application and all related intellectual property in the event the Company does not raise a minimum of $1,000,000 in equity financing by June 28, 2018. In the event that Holdings LLC exercises this right of reversion, the 2,000,000 shares of Preferred Stock issued to Holdings LLC shall be assigned to Apica Investments Limited or its assignees. As of May 31, 2018, the Company has not raised any capital towards the $1,000,000 requirement. As of the filing of this report Holdings LLC has not exercised its right of reversion under the Asset Assignment Agreement.

Upon the Company receiving a minimum of $1,000,000 in equity financing, Holdings shall assign to the Company all of its rights, title and interest to United States Utility Patent Application No USPTO Application No. 15/385,862 filed on December 20, 2016, titled” COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE” and all related intellectual property, inventions and trade secrets, data, and clinical study results.

The Company has entered into several consulting agreements where monthly fees commence upon achieving the attainment of raising $1,000,000 in equity financing and increase upon the Company successfully raising $5,000,000. The Company is currently not accruing any expense under these contracts and it not required to compensate these consultants beyond stock, cash and warrants already issued should one of both thresholds are not achieved. Any stock and warrants issued are immediately vested to the consultants. The following agreements have been entered between the Company and the following consultants:

F-15

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 7: COMMITMENTS AND CONTINGENCIES (CONTINUED)

On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Apica Investments Limited pursuant to which the Company agreed to issue 15,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5 year anniversary of the warrant; monthly fees of $1,800 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $4,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (as defined below), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.

On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Brighton Capital Ltd. pursuant to which the Company agreed to issue 6,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5 year anniversary of the warrant; a $50,000 payment upon execution of the agreement; monthly fees of $1,800 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $4,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (as defined below), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 4.99% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.

On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Rafferty Finance S.A. pursuant to which the Company agreed to issue 5,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5 year anniversary of the warrant; a $50,000 payment upon execution of the agreement; monthly fees of $5,400 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $13,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. Common shares under this contract were issued on July 19, 2017 and cash payment was made on June 30, 2017.

Mr. Treminio, the former Chief Executive Officer is an employee of Rafferty Finance S.A. “(Rafferty”). Under the Company’s consulting agreement with Rafferty, dated June 28, 2017. Mr. Treminio is required to secure additional capital, to preserve the rights of the patent under the Asset Assignment Agreement. Mr. Treminio shall, among other things, oversee, direct and manage all aspects investor & public or media relations, corporate finance as well as strategic planning, subordinate leadership, and operations of the Company. Mr. Treminio shall report directly to the Company’s CEO and /or Board of Directors (the “Board”). Effective with Mr. Treminio’s resignation, he shall not have any authority to execute and agreements or expend or access any Company funds or accounts without approval of the Chief Executive Officer. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (as defined below), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 4.99% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.

F-16

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 7: COMMITMENTS AND CONTINGENCIES (CONTINUED)

On June 28, 2017, the Company executed a Promissory Convertible Note with Bakken Development LLC in the principal amount of $400,000. The convertible note accrues interest at the rate of 10% per annum; is due and payable on or before June 28, 2019; may be converted at any time by the holder into shares of Company common stock at a conversion price of $.50 per share; and automatically converts into share of Company common stock at a conversion price of $.50 per share upon the Company’s completion of a financing in the minimum amount of $5,000,000.

On July 8, 2017, the Company entered into a consulting agreement with Imagic, LLC. Upon the commencement of this engagement, the consultant or its designees were issued shares of the Company in the amount of 12,000,000 common shares. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (as defined below), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.

On July 8, 2017, the Company entered into an employment agreement with Dr. McCoy Moretz. Upon the commencement of this agreement, the employee or its designees were issued shares of the Company in the amount of 8,000,000 common shares. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the Excepted Issuances (as defined below), if the Company issues any shares of Company common stock, the employee shall be granted additional shares of the Company’s common stock in an amount equal to 6% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.

NOTE 8: STOCK HOLDERS’ DEFICIT

Preferred and Common Stock

The Company has authorized 1,002,000,000 total shares of stock with a par value of $0.001 per share. These shares are designated by two classes; 1,000,000,000 common shares and 2,000,000 preferred shares.

Fiscal 2017

On January 26, 2017, the Company Amended its Articles to increase the Authorized share Capital of the Company from 75,000,000 to 1,000,000,000.

F-17

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 8: STOCK HOLDERS’ DEFICIT (CONTINUED)

Preferred and Common Stock (Continued)

Fiscal 2017 (Continued)

On January 18, 2017, Olaf Robak, the Company's President and CEO, executed a stock purchase agreement with First Legacy Management LLC, which acquired 4,000,000 shares of common stock, representing 80% ownership of the Company. First Legacy Management LLC paid $350,000 in cash. Simultaneous with this transaction, Mr. Olaf Robak resigned from his official positions as Director, CEO, CFO, President, Treasurer and Secretary of the Company, and on the same day the shareholders of the Corporation voted Mr. Antonio Treminio as Director & CEO.

Fiscal 2018

On July 26, 2017, the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation with the Secretary of State of Nevada. The Certificate of Amendment amends Article III of the Company’s Articles of Incorporation to authorize the issuance of up to two million (2,000,000) shares of Preferred Stock, par value $0.001 per share, which have the right to cast one thousand (1,000) votes for each share held of record on all matters submitted to a vote of holders of the Corporation’s common stock, including the election of directors, and all other matters required by law.

On November 15, 2017, the Company entered into an Equity Financing Agreement and Registration Rights Agreement with GHS pursuant to which GHS has agreed to purchase up to $7,000,000 in shares of Company common stock. The obligations of GHS to purchase the shares of Company common stock are subject to the conditions set forth in the Equity Financing Agreement, including, without limitation, the condition that a registration statement on Form S-1 registering the shares of Company common stock to be sold to GHS be filed with the Securities and Exchange Commission and become effective. The Company filed the Form S-1 registration statement on December 7, 2017. The Registration Rights Agreement provides that the Company shall use commercially reasonable efforts to file the registration statement within 30 days after the date of the Registration Rights Agreement and have the registration statement become effective within 90 days after it is filed. The purchase price of the shares of Company common stock will be equal to 80% of the market price (as determined in the Equity Financing Agreement) calculated at the time of purchase.

On February 13, 2018, the Company filed a registration withdrawal request with regards to S-1 registration statement filed on December 17, 2017. The Company may refile a Form S-1 registration in the future.

Under the terms of the equity financing agreement so long as this term is in effect and the $7,000,000 has not been fulfilled for a period of twenty-four months following the effective date the Company shall be permitted to PUT shares to the investor. The price of the Put shall be eighty (80%) percent of the “Market Price”, which is the lowest closing price of the Company’s Common Stock for ten (10) consecutive trading days preceding the Put Date. During the Open Period, the Company shall not be entitled to submit a Put Notice until after the previous Closing has been completed. There will be a minimum of ten (10) trading days between Put Notices.

In connection with the Equity Financing Agreement, the Company executed a convertible promissory note in the principal amount of $15,000 as payment of the commitment fee for the Equity Financing Agreement. The Note bear interests at the rate of 10% with a maturity date of August 14, 2018. (See NOTE 6)

During the year ended May 31, 2018, the Company issued 2,000,000 preferred shares, 75,000,000 commons shares in exchange for rights to certain intellectual property pursuant to an Asset Assignment Agreement. (See NOTE 1). The total investment was valued at $177,000.

F-18

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 8: STOCK HOLDERS’ DEFICIT (CONTINUED)

Preferred and Common Stock (Continued)

Fiscal 2018 (Continued)

During the year ended May 31, 2018, the Company issued 50,000,000 stock warrants with a cashless exercise provision (“cashless warrants”) and 44,725,000 common shares to consultants under consulting agreements.

During the year ended May 31, 2018, the Company issued 10,000,000 stock warrants with a cashless exercise provision (“cashless warrants”) and 10,275,000 common shares to employees.

As of May 31, 2018, there were no outstanding stock options.

Warrants for common stock

On June 28, 2017, the Company issued 60,000,000 common stock warrants pursuant to an Asset Assignment Agreement with Richard L. Chang Holding’s LLC (“Holdings LLC”), pursuant to which Holdings. In consideration of these share issuances, Holdings LLC has assigned to the Company all of its rights, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016, titled “COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. Of the 60,000,000 common stock warrants issued, 50,000,000 warrants were issued to consultants and 10,000,000 were issued to an employee.

The following table summarizes warrant activity for the year ended May 31, 2018 and 2017:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
			Exercise		Contractual		Intrinsic
	Shares		Price		Term		Value
Outstanding at May 31, 2017		—	$	—			$	—
Granted		60,000,000	$	0.25		5.00	$	—
Expired		—		—		—		—
Exercised		—		—		—		—
Canceled		—		—		—		—
Outstanding at May 31, 2018		60,000,000	$	0.25		4.32		—

Warrants issued to consultants during the year ended May 31, 2018 to six different consultants were valued at $11,567. The warrants expire June 28, 2022.

NOTE 9: INCOME TAXES

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

F-19

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 9: INCOME TAXES (CONTINUED)

ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for the reporting period presented.

The Company did not record any income tax accrual for the period from inception to May 31, 2018. We expect to incur significant expenses in future periods which will offset any future net income.

As of May 31, 2018 and 2017, the Company had a net operating loss carry-forward of approximately $1,129,153 and $236,905. Losses that were incurred prior to December 31, 2017 may be used to offset future taxable income and expire ended in 2037. Losses incurred after December 31, 2017 may be used to offset future taxable income and do not expire. Because of the change in ownership that occurred on June 28, 2017, net operating loss carry forwards could be limited as to use in future years.

Deferred tax assets of $188,800 and $49,700 as of May 31, 2018 and 2017, respectively, resulting from net operating have been offset by a valuation allowance, due to the uncertainty of their realization. The change in the valuation allowance for the year ended May 31, 2018 and 2017 was $188,800 and $49,700, respectively. As a result, there were no current or deferred tax provisions for the year ended May 31, 2018 and 2017. There was no uncertain tax position taken since inception and the Company’s tax returns for the past three year remain open for examination. Hypgen is a United States, State of Nevada domiciled corporation for tax purposes. Deferred tax assets consist of the following:

	May 31, 2018			May 31, 2017
Net operating losses	$	267,900		$	80,500
Effect of TCJA recalculation		(79,100	)		(30,800	)
Change in valuation allowance		(188,800	)		(49,700	)
Provision for income taxes	$	—		$	—

On December 22, 2017, Public Law 115-97, informally referred to as the Tax Cuts and Jobs Act (“the TCJA”) was enacted into law. The TCJA provides for significant changes to the U.S. Internal Revenue Code of 1986, as amended, that impact corporate taxation requirements. Effective January 1, 2018, the federal tax rate for corporations was reduced from 35% to 21% for US taxable income and requires one-time re-measurement of deferred taxes to reflect their value at a lower tax rate of 21%. Also, mandatory repatriation of untaxed foreign earnings and profits will be taxed at 15.5% to the extent the underlying assets are liquid and 8% on the remaining balance. There are other provisions to the TCJA, such as conversion of a worldwide system to a territorial system, limitations on interest expense and domestic production deductions, which will be effective in fiscal 2019. The Company anticipates its effective tax rate to be 28% to 30%, excluding the one-time impact of the TCJA for fiscal 2018 primarily due to the reduction in the federal tax rate. The Company’s actual effective tax rate for fiscal 2018 may differ from management’s estimate due to changes in interpretations and assumptions. Due to the timing of enactment and complexity of the TCJA, the Company is unable to estimate a reasonable range of the one-time impact associated with mandatory repatriation, re-measurement of deferred taxes and other provisions of the TCJA. For tax losses that straddle tax years a blended rate is used. Since the Company is not expected to utilize any portion of net loss carryforward in the current tax year, the entire valuation is estimated using the newly enacted rates.

NOTE 10: RELATED PARTY TRANSACTIONS

A former director of the Company made the initial $100 deposit to on the bank account. In September 2015, the former director paid audit fees on behalf of the company in the amount of $650. These amounts, totaling $750, are being carried as a Related Party Loan which bears no interest and is payable on demand. The related party loan was forgiven effective January 18, 2017 under terms of change in control (SEE NOTE 1).

On January 27, 2017, the Company entered into a one-year convertible note from a related party with the face value of $100,000 bearing 8% interest (SEE NOTE 6). On June 28, 2017, the Company executed an amendment to this note.

On June 28, 2017, Richard L. Chang was appointed as a director of the Company. Mr. Richard Chang is the controlling interest of Holdings, LLC.

F-20

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 10: RELATED PARTY TRANSACTIONS (CONTINUED)

On June 28, 2017, Ben Chang, a senior management consultant, loaned the Company, $100 to initially fund the operating bank account of the Company. Mr. Ben Chang is also the Chief Executive Officer of Rich Pharmaceuticals, Inc.

On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Apica Investments Limited (“Apica”). Apica is controlled by Chew Chuan Tin who is the beneficial owner of greater than 10% of the outstanding shares of the Company through Bakken, Apica and First Legacy. Pursuant to that agreement the Company agreed issued 15,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5-year anniversary of the warrant; monthly fees of $1,800 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $4,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (SEE NOTE 7), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside “Excepted issuances”.

On June 28, 2017, the Company executed a one-year promissory convertible note with Bakken Development LLC (“Bakken”) in the principal amount of $400,000. Bakken is a related party controlled by Chew Chuan Tin who is the beneficial owner of greater than 10% of the outstanding shares of the Company through Bakken, Apica and First Legacy (See NOTE 6).

On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Rafferty Finance S.A. (“Raferty”). Raferty is controlled by Antonio Treminio, former CEO of the Company. Pursuant to this agreement the Company agreed to issue 5,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5-year anniversary of the warrant; a $50,000 payment upon execution of the agreement; monthly fees of $5,400 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $13,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. Common shares under this contract were issued on July 19, 2017 and cash payment was made on June 30, 2017. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (SEE NOTE 7) if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 4.99% of the amount of the shares of Company common stock issued by the Company outside “Excepted issuances”.

On July 8, 2017, the Company entered into a consulting agreement with Imagic, LLC (“Imagic”). Imagic, is wholly owned by Ben Chang, son of Director Richard L. Chang and Chief Executive Officer of Rich Pharmaceuticals, Inc. Upon the commencement of this engagement, the consultant or it’s designees were issued shares of the Company in the amount of 12,000,000 common shares. Imagic was also issued a warrant to acquire 10,000,000 shares of the Company at an exercise price of $0.25. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (SEE NOTE 7), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside “Excepted issuances”.

On September 14, 2017, the Company issued a promissory note in the amount of $6,000 to Imagic LLC. Imagic, is wholly owned by Ben Chang, son of Director Richard L. Chang and Chief Executive Officer of Rich Pharmaceuticals, Inc. The note matures on September 14, 2018 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $213.

On November 3, 2017, the Company issued a promissory note in the amount of $5,000 to one of its directors, Richard L. Chang Holdings. The note matures on November 3, 2018 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $143.

On January 11, 2018, the Company issued a promissory note in the amount of $5,000 to Imagic. The note matures on January 11, 2019 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $96.

On February 14, 2018, the Company issued a promissory note in the amount of $3,000 to Imagic. The note matures on February 14, 2019 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $44.

On March 6, 2018, the Company issued a promissory note in the amount of $2,375 to Imagic, a related party. The note matures on March 16, 2019 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $28.

F-21

HYPGEN INC.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

NOTE 10: RELATED PARTY TRANSACTIONS (CONTINUED)

On March 12, 2018, the Company issued a promissory note in the amount of $250 to Imagic, a related party. The note matures on March 12, 2019 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $3.

From time to time certain operational expenses of the Company are paid for by Ben Chang, a senior management consultant to the Company. These items are funded by Mr. Ben Chang or by its 100% owned entity Imagic. At June 30, 2018, the Company owed $4,814 and $8,191 to Mr. Ben Chang and Imagic, respectively.

As of June 30, 2018, the Company had three employment agreements. Under these agreements the Company accrued $170,250. Total annual compensation under these agreements is $233,000. As a stipulation to these agreements, the employees are to be compensated until such time that the board approves them as full-time employees. Prior to board approval the employees will be compensated for actual hours worked.

NOTE 11: SUBSEQUENT EVENTS

On June 25, 2018, the Company issued a promissory note in the amount of $4,000 to Imagic, a related party. The note matures on June 25, 2019 and bears 5% interest.

F-22

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company carried out, under the supervision and with the participation of the Company's management, including its Chief Executive Officer and Chief Financial Officer, an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) in ensuring that information required to be disclosed by the Company in its reports is recorded, processed, summarized and reported within the required time periods. In carrying out that evaluation, management identified a material weakness (as defined in Public Company Accounting Oversight Board Standard No. 2) in our internal control over financial reporting regarding a lack of adequate segregation of duties. Accordingly, based on their evaluation of our disclosure controls and procedures as of May 31, 2018, the Company's Chief Executive Officer and its Chief Financial Officer have concluded that, as of that date, the Company's controls and procedures were not effective for the purposes described above.

There was no change in the Company's internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) during the year ended May 31, 2018 that has materially affected or is reasonably likely to materially affect the Company's internal control over financial reporting.

Management's Report on Internal Control over Financial Reporting

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. We have assessed the effectiveness of those internal controls as of May 31, 2018, using the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") Internal Control – Integrated Framework (2013) as a basis for our assessment.

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

A material weakness in internal controls is a deficiency in internal control, or combination of control deficiencies, that adversely affects the Company's ability to initiate, authorize, record, process, or report external financial data reliably in accordance with accounting principles generally accepted in the United States of America such that there is more than a remote likelihood that a material misstatement of the Company's annual or interim financial statements that is more than inconsequential will not be prevented or detected. In the course of making our assessment of the effectiveness of internal controls over financial reporting, we identified a material weakness in our internal control over financial reporting. This material weakness consisted of inadequate staffing and supervision within the bookkeeping and accounting operations of our company. The relatively small number of employees who have bookkeeping and accounting functions prevents us from segregating duties within our internal control system. The inadequate segregation of duties is a weakness because it could lead to the untimely identification and resolution of accounting and disclosure matters or could lead to a failure to perform timely and effective reviews.

As we are not aware of any instance in which the company failed to identify or resolve a disclosure matter or failed to perform a timely and effective review, we determined that the addition of personnel to our bookkeeping and accounting operations is not an efficient use of our resources at this time and not in the interest of shareholders.

Because of the above condition, the Company's internal controls over financial reporting were not effective as of May 31, 2018.

This annual report does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to the rules of the Securities and Exchange Commission that permit the Company to provide only management's report in this annual report.

ITEM 9B. OTHER INFORMATION.

None.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The name, age and titles of our executive officer and director are as follows:

Name and Address of Executive

Officer and/or Director

Age

Position

Dr. McCoy L. Moretz

Chief Executive Officer, Chief Financial Officer and Director

(Principal Executive, Financial and Accounting Officer)

Richard L. Chang

Director

Biographies of Directors and Officers

Dr. McCoy L. Moretz, is Board Certified in Otolaryngology and ABO Certified in Microvascular Anastomosis. He is a member of the American Board of Medical Specialties; a Fellow of the American College of Surgeons; American Board of Otolaryngology/Head & Neck Surgery; American Academy of Facial Plastic & Reconstructive Surgery; and the American Academy of Otolaryngology / Head & Neck Surgery. He was also the Chief Medical Officer of Ermis Labs; Medical Advisor Board Member of Rich Pharmaceuticals, and Advisor to Torii Labs. From 2006 to the present, he has been the founder and principal surgeon of F.A.C.E of Beverly Hills. He has been involved with numerous Clinical Investigations over the past decade and has authored prestigious medical publications in the Archives of Otolaryngology. Dr. Moretz graduated with a BA in chemistry from the University of North Carolina in 1978 (Dean’s List); received his Medical Degree from the Medical College of Georgia, 1982 (with Honors); and completed his internship at Emory University Hospital in Atlanta, Georgia in 1983.

Mr. Richard Chang, a world-renowned scientist in the field of oncology including the study of voluminous molecules’ mechanism(s) of action. During Mr. Chang’s distinguished career, he has authored 121 peer-reviewed journal publications and has presented over 150 scientific abstracts across the world in the field of cancer research. Prior to joining Rich Pharmaceuticals advisory board, Mr. Chang worked at Biosuccess Biotech Co. LTD., Hoffman-LaRoche, Schering Corp and Burroughs Wellcome in various scientific roles spanning from Chief Scientific officer to Scientist. He was a full professor at Rutgers, The State University of New Jersey, College of Pharmacy & The Laboratory for Cancer Research. In addition, Mr. Chang was a Director of Biochemical Pharmacology Research Laboratories at Rutgers, continuing his pursuit to finding innovative compounds for the treatments of cancer since 1987. After he retired in 2003, Mr. Chang continues to be an adjunct professor there. Mr. Chang’s years of dedication to cancer research has led him to file five significant patents for the treatment of cancer, Infectious disease and neurological disorders. Mr. Chang is a member of American Association for Cancer Research, American Society for Pharmacology and Experimental Therapeutics and the Society of Chinese Bio-Scientists in America and is a member of Who’s Who in the world. Mr. Chang obtained his Masters of Science in Biochemistry and Nutrition from Utah State University and his Bachelors of Science in Agriculture Chemistry from National Taiwan Chung Hsing University.

Dr. Moretz’s roles and responsibilities were:

	1.	to lead the development of the Company's strategy;

	2.	to lead and oversee the implementation of the Company's long and short-term plans in accordance with its strategy;

	3.	to ensure the Company is appropriately organized and staffed and to have the authority to hire and terminate staff as necessary to enable it to achieve the approved strategy;

	4.	to ensure that expenditures of the Company are within the authorized annual budget of the Company;

	5.	to assess the principal risks of the Company and to ensure that these risks are being monitored and managed;

	6.	to ensure effective internal controls and management information systems are in place;

	7.	to ensure that the Company has appropriate systems to enable it to conduct its activities both lawfully and ethically;

	8.	to ensure that the Company maintains high standards of corporate citizenship and social responsibility wherever it does business;

	10.	to communicate effectively with shareholders, employees, Government authorities, other stakeholders and the public;

	11.	to keep abreast of all material undertakings and activities of the Company and all material external factors affecting the Company and to ensure that processes and systems are in place to ensure that the CEO and management of the Company are adequately informed;

	12.	to ensure that the Directors are properly informed and that sufficient information is provided to the Board to enable the Directors to form appropriate judgments;

	13.	to ensure the integrity of all public disclosure by the Company;

	14.	to develop Board agendas;

	15.	to request that special meetings of the Board be called when appropriate;

	16.	to determine the date, time and location of the annual meeting of shareholders and to develop the agenda for the meeting;

	17.	to sit on committees of the Board where appropriate as determined by the Board;

	18.	to abide by specific internally established control systems and authorities, to lead by personal example and encourage all employees to conduct their activities in accordance with all applicable laws and the Company's standards and policies, including its environmental, safety and health policies.

TERM OF OFFICE

Each of our directors is appointed to hold office until the next annual meeting of our stockholders or until his respective successor is elected and qualified, or until he resigns or is removed in accordance with the provisions of the Nevada Revised Statues. Our officers are appointed by our Board of Directors and hold office until removed by the Board or until their resignation.

DIRECTOR INDEPENDENCE

As of May 31, 2018, the board of directors was currently composed two members, Richard L. Chang and Dr. McCoy L. Moretz, who do not qualify as an independent director in accordance with the published listing requirements of the NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of her family members has engaged in various types of business dealings with us. In his consulting role as Chief Executive Officer, we believe that his independence is impaired. In addition, our board of directors has not made a subjective determination as to each director that no relationships exist which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our board of directors made these determinations, our board of directors would have reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities and relationships as they may late to us and our management.

Directors’ and Officers’ Liability Insurance

The Company currently does not have directors’ and officers’ liability insurance insuring our directors and officers against liability for acts or omissions in their capacities as directors or officers.

Code of Ethics

We intend to adopt a code of ethics that applies to our officers, directors and employees, including our principal executive officer and principal accounting officer, but have not done so to date due to our relatively small size. We intend to adopt a written code of ethics in the near future.

Board Committees

The Company does not have any committees.

ITEM 11. EXECUTIVE COMPENSATION.

The following tables set forth certain information about compensation earned by our executive officers and directors for May 31, 2018 and 2017:

Name and Principal Position	Year	Salary		Deferred Compensation		Bonus		Stock Awards		Option/ Warrant Awards		All Other Compensation		Total

Dr. McCoy Moretz (1)	2018	$	103,000	$	-	$	-	$	8,000	$	-	$	-	$	111,000
Chief Executive Officer/Chief Financial Officer, director	2017	$	-	$	-	$	-	$	-	$	-	$	-	$	-

Antonio Treminio (2)	2018	$	-	$	-	$	-	$	-	$	-	$	-	$	-
Former Chief Executive Officer/Chief Financial Officer, former director	2017	$	43,500	$	-	$	-	$	-	$	-	$	-	$	43,500

______

(1)	Dr. McCoy Moretz was appointed as Chief Executive Officer and Chief Financial Officer and director on June 28, 2017 upon change of control and asset assignment agreement

(2)	Mr. Treminio was appointed Chief Executive Officer and Chief Financial Officer upon the upon First Legacy Management LLC change of control.

(3)	Mr. Treminio resigned June 29, 2017 as Chief Executive Officer and Chief Financial Officer.

The general policy of the Board of Directors is that compensation for independent Directors should be a nominal cash fee plus equity-based compensation. We do not pay employee Directors for Board service in addition to their regular employee compensation. The Board of Directors have the primary responsibility for considering and determining the amount of Director compensation.

As of May 31, 2018, there was an employment agreement between the company and its officer.

There are no annuity, pension or retirement benefits proposed to be paid to the officer or director or employees in the event of retirement at normal retirement date pursuant to any presently existing plan provided or contributed to by the company or any of its subsidiaries, if any.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

The following table sets forth certain information concerning the number of shares of our common stock owned beneficially as of September 28, 2018 by: (i) each person (including any group) known to us to own more than five percent (5%) of any class of our voting securities, (ii) our director, and or (iii) our officer. Unless otherwise indicated, the stockholder listed possesses sole voting and investment power with respect to the shares shown.

	Number of Shares		Percentage of
	Beneficially		Outstanding
Name	Owned⁽¹⁾		Common Stock

Non-employees and directors:
Richard L. Chang, director (2)		19,847,718		39.70	%
Ben Chang		4,947,570		9.90	%
Chew Chuan Tin		4,750,000		9.50	%
Livat PTE. LTD.		4,250,000		8.50	%
Arcview Global PTE. LTD.		2,500,000		5.00	%

Named Executive Officers:
Dr. McCoy Moretz, Chief Executive Officer and Chief Financial Officer		2,945,508		5.89	%
Common shares beneficially owned by affiliates, directors and officers as a group (6 persons)		39,240,796		78.48	%

___________

(1)

A beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights. As of September 3, 2018, there were 135,800,000 shares of our common stock issued and outstanding.

(2)

As of September 27, 2018, the Company issued 2,000,000 preferred shares beneficially owned by Richard L. Chang, director representing 100% of the issued and outstanding preferred stock having 1000 to 1 voting rights over shares of the Company’s common stock.

Future sales by existing stockholders

A total of 120,000,000 shares of common stock were issued to directors and consultants, all of which are restricted securities, as defined in Rule 144 of the Rules and Regulations of the SEC promulgated under the Securities Act. Under Rule 144, the shares can be publicly sold, subject to volume restrictions and restrictions on the manner of sale. Such shares can only be sold after six months provided that the issuer of the securities is, and has been for a period of at least 90 days immediately before the sale, subject to the reporting requirements of section 13 or 15(d) of the Exchange Act. Shares purchased in this offering, which will be immediately resalable, and sales of all of our other shares after applicable restrictions expire, could have a depressive effect on the market price, if any, of our common stock and the shares we are offering.

There is no public trading market for our common stock. There are currently 60,000,000 outstanding five-year cashless warrants outstanding, $400,000 in face value of promissory convertible notes plus accrued interest outstanding to be converted into common shares at any time by the holder at a conversion price of $.50 per share; and automatically converts into share of Company common stock at a conversion price of $.50 per share upon the Company’s completion of a financing in the minimum amount of $5,000,000. There are 18 holders of record for our common stock who owns 135,800,000 shares of our common stock and one holder of 2,000,000 of preferred restricted shares. No stock options have been issued by the Company.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

On January 27, 2017, the Company entered into a twelve-month convertible promissory note with a related party. The note has a face value of $100,000 and bears an annual interest rate of 8%. The Company may prepay this note in whole or in part at any time upon its sole discretion. Upon maturity, if full payment has not been made by the Company to the holder, at the exclusive option of holder, common shares of the Company, issuable from Treasury shall be issued to it. Applicable conversion shall be at a 30% discount to the then trading market average of the last 7 (seven) trading days. On June 28, 2017, the Company executed an amendment to this note. The amendment provides that the total outstanding amounts under the promissory notes shall convert into shares of Company common stock at the conversion price of $.25 per share.

On April 7, 2017, the Company entered into a twelve-month convertible promissory note with a related party. The note has a face value of $100,000 and bears an annual interest rate of 8%. The Company may prepay this note in whole or in part at any time upon its sole discretion. Upon maturity, if full payment has not been made by the Company to the holder, at the exclusive option of holder, common shares of the Company, issuable from Treasury shall be issued to it. Applicable conversion shall be at a 30% discount to the then trading market average of the last 7 (seven) trading days. On June 28, 2017, the Company executed an amendment to this note. The amendment provides that the total outstanding amounts under the promissory notes shall convert into shares of Company common stock at the conversion price of $.25 per share.

On July 8, 2017, the Company entered into an Employment Agreement for a two-year term with Dr. McCoy Moretz, the Company’s Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, and a director. Dr. McCoy was also granted 8,000,000 shares of Company common stock and a warrant to purchase up to 10,000,000 shares of Company common stock. The stock was issued on July 19, 2017.

On August 3, 2017, the Company issued 2,000,000 preferred shares beneficially owned by Richard L. Chang, director representing 100% of the issued and outstanding preferred stock with 1000 to 1 voting rights over shares of the Company’s common stock.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The following table sets forth the fees billed by our principal independent accountants, Fruci & Associates II, PLLC and

Bharat Parikh & Associates for the fiscal years ended May 31, 2018 and 2017, for the categories of services indicated.

	Years Ended May 31,
Category	2017		2016
Audit Fees	$	15,900	$	6,500
Audit related fees		-		-
Tax Fees		-		-
All Other Fees		-		-
Total	$	15,900	$	6,500

Audit fees. Consists of fees billed for the audit of our annual financial statements and review of our interim financial information and services that are normally provided by the accountant in connection with year-end and quarter-end statutory and regulatory filings or engagements.

Audit-related fees. Consists of fees billed for services relating to review of other regulatory filings including registration statements, periodic reports and audit related consulting.

Tax fees. Consists of professional services rendered by our principal accountant for tax compliance, tax advice and tax planning.

Other fees. Other services provided by our accountants.

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.

The following exhibits are included with this registration statement:

Exhibit Number	Description
3.1	Articles of Incorporation (1)
3.1.1	Certificate of Amendment (2)
3.1.2	Certificate of Amendment (2)
3.1.3	Articles of Merger, dated July 18, 2017 (3)
3.1.4	Certificate of Amendment, dated July 26, 2017 (3)
3.2	Bylaws (1)
10.2	Asset Assignment Agreement (4)
10.3	Amendment dated June 28, 2017 to Promissory Notes dated January 27, 2017 and April 7, 2017 with Bakken Development LLC (4)
10.4	Promissory Convertible Noted dated June 28, 2017 with Bakken Development LLC in the principal amount of $400,000 (4)
10.5	Consulting Agreement dated June 28, 2017 with Apica Investments Limited (4)
10.6	Common Stock Purchase Warrant dated June 28, 2017 with Apica Investments Limited (4)
10.7	Consulting Agreement dated June 28, 2017 with Brighton Capital, Ltd. (4)
10.8	Common Stock Purchase Warrant dated June 28. 2017 with Brighton Capital, Ltd. (4)
10.9	Consulting Agreement dated June 28, 2017 with Rafferty Finance S.A. (4)
10.1	Common Stock Purchase Warrant dated June 28, 2017 with Rafferty Finance S.A. (4)
10.11	Common Stock Purchase Warrant dated June 28, 2017 with Dr. McCoy Moretz (4)
10.12	Common Stock Purchase Warrant dated June 28, 2017 with Imagic, LLC (4)
10.13	Common Stock Purchase Warrant dated June 28, 2017 with SD Law Group APC (4)
10.14	Resignation of Antonio Treminio (4)
10.16	Employment Agreement dated July 8, 2017 with Dr. McCoy Moretz (5)
10.17	Consulting Agreement dated July 8, 2017 with Richard L. Chang Holdings LLC (5)
10.18	Support and Collaboration Agreement dated July 11, 2017 with Rich Pharmaceuticals, Inc. (5)
10.19	Equity Financing Agreement dated November 15, 2017 with GHS Investments, LLC (6)
10.2	Registration Rights Agreement dated November 15, 2017 with GHS Investments, LLC (6)
10.21	Promissory Note in the amount of $15,000 dated November 15, 2017 with GHS Investments, LLC (6)
10.22	Consulting Agreement dated June 1, 2018 with Richard L. Chang Holdings, LLC
31.1	Certification of Chief Executive Officer Required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Accounting Officer of Required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 Of 18 U.S.C. 63
32.2	Certification of Principal Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 Of 18 U.S.C. 63
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

_______________

(1)	Incorporated by reference to the Company’s Form S-1, as amended, filed with the SEC on October 13, 2015.
(2)	Incorporated by reference to the Company’s Form 8-K filed with the SEC on January 31, 2017
(3)	Incorporated by reference to the Company’s Form 8-K filed with the SEC on August 1, 2017
(4)	Incorporated by reference to the Company’s Form 8-K filed with the SEC on July 10, 2017
(5)	Incorporated by reference to the Company’s Form 8-K filed with the SEC on July 12, 2017
(6)	Incorporated by reference to the Company’s Form 8-K filed with the SEC on November 16, 2017

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	HYPGEN INC.

Date: October 3, 2018	By:	/s/ Dr. McCoy Moretz
	Name:	Dr. McCoy Moretz
	Title:	President, Treasurer and Secretary (Principal Executive, Financial and Accounting Officer)

EX-10.22 2 hppgen_ex1022.htm EX-10.22

HYPGEN INC.

CONSULTING AGREEMENT

THIS AGREEMENT, dated this 1st day of JUNE 2018, is made by and between HYPGEN INC., a Nevada Corporation with primary place of business at 1999 Avenue of the Stars, Suite 1100, Century City, CA 90067 and its successors (the “Company”), and Richard L. Chang Holdings, LLC with primary address at 5511 Paseo Del Lago West, Laguna Woods, CA 92637 (the “CONSULTANT”).

In consideration of the mutual covenants herein contained and of the mutual benefits herein provided, the Company and the CONSULTANT agree as follows:

1. Representations and Warranties.

The CONSULTANT represents and warrants to the Company that the CONSULTANT is not bound by any restrictive covenants and has no prior or other obligations or commitments of any kind that would in any way prevent, restrict, hinder or interfere with the CONSULTANT’s acceptance of continued engagement or the performance of all duties and services to the fullest extent of the CONSULTANT’s ability and knowledge.

2. Term of Consultancy.

The Company will engage the CONSULTANT for a term commencing on June 1, 2018 and continuing until the date which is 2 years after the date.

3. Duties and Functions.

The Consultant agrees to provide the following services:

Assist the Company with Clinical operations;

Assist the Company in managing their patents/Intellectual Property;

Assist the company in technical matters in manufacturing the drug, R&D and science.

The CONSULTANT shall report directly to the Company’s CEO and /or Board of Directors (the “Board”). The CONSULTANT agrees to perform such modified, different or additional duties as may, from time to time, be assigned by the Board. At the CONSULTANT’s discretion, the CONSULTANT may perform his duties under this Agreement at an office provided by the Company or elsewhere.

4. Compensation.

(a) Fees: As compensation for his services, the Company agrees to pay the CONSULTANT a base fee of $240,000/year payable on a monthly basis ($20,000 per month), initial first payment on the 15^th day of the following month starting July 15^th, 2018. In the event the Company is unable to pay the CONSULTANT monthly, the fees shall accrue without interest. This rate may be adjusted if agreed upon by the CEO and /or Board.

(bc) Equity: Intentionally left blank

(c) Other Expenses: In addition to the compensation provided for above, the Company agrees to pay or to reimburse the CONSULTANT during his engagement for all travel, reasonable, ordinary and necessary, properly documented and client-related business or entertainment expenses incurred in the performance of his services hereunder in accordance with Company policy in effect, on a monthly basis; provided that all such expenses are pre-approved in writing by the Company’s CEO. The CONSULTANT shall submit invoices and receipts on a monthly basis for all expenses for which reimbursement is sought. The CONSULTANT shall be granted business class tickets for all flights to Europe, Asia or flights of over 5 hours flight time.

5. Indemnification, Legal Expenses.

The Company and CONSULTANT understand that the CONSULTANT and any and all costs, including legal fees, incurred by the CONSULTANT in his capacity as legally performing his duties as a consultant will be indemnified and reimbursed by the Company.

6. Termination.

(a) Voluntary Termination By CONSULTANT. Notwithstanding the foregoing, the CONSULTANT may terminate the relationship at any time for any reason by giving the Company at least sixty (60) days’ written notice. The Company, at its election, may (i) require the CONSULTANT to continue to perform his duties hereunder for the full notice period, or (ii) terminate the CONSULTANT at any time during such notice period, provided that any such termination shall not be deemed to be a Termination Without Cause of the CONSULTANT by the Company.

(b) Termination By Company For Cause. Notwithstanding the foregoing, the Company may terminate the CONSULTANT under this Agreement for cause at any time during the Agreement Term, upon providing the CONSULTANT with written notice of the Termination For Cause. If the CONSULTANT is terminated for cause, the CONSULTANT will not be entitled to and shall not receive any compensation or benefits of any type following the effective date of termination, although all compensation accrued prior thereto shall remain the CONSULTANT’s (including the shares granted in this Agreement). As used in this Agreement, the term “Cause” shall include, without limitation: dishonesty; fraud; serious dereliction of duty; criminal activity; acts of moral turpitude; conviction of a felony, plea of guilty or nolo contendere to a felony charge or any criminal act involving moral turpitude.

(c) Termination By Company Without Cause. Upon thirty (60) days’ written notice, the Company may terminate the CONSULTANT without cause. If the CONSULTANT’s engagement is terminated by the Company without cause at any time after the $1M Financing Date, the CONSULTANT shall continue to receive his base fee and any bonus payments for a period of six (6) months from the effective date of termination (the “Severance Period”).

The compensation to be paid or provided under this Section 5(c) are referred to herein as the “Termination Compensation.” The CONSULTANT shall not be entitled to any Termination Compensation unless: (i) the CONSULTANT complies with all surviving provisions of any non-competition agreement, non-solicitation agreement, confidentiality agreement or inventions assignment agreement that he signed, and (ii) the CONSULTANT executes and delivers to the Company after a notice of termination a release in form and substance acceptable to the Company, by which the CONSULTANT releases the Company from any obligations and liabilities of any type whatsoever under this Agreement, except for the Company’s obligations with respect to the Termination Compensation, and that release shall not affect the CONSULTANT’s right to indemnification, if any, for actions taken within the scope of his engagement. Notwithstanding anything herein, no Termination Compensation shall be paid or otherwise provided until all applicable revocation periods have fully expired, and the mutual release becomes fully and finally enforceable. The parties hereto acknowledge that the Termination Compensation to be provided under this Section 5(c) is in consideration for CONSULTANT’s release.

(d) Termination for CONSULTANT’s Permanent Disability. To the extent permissible under applicable law, in the event the CONSULTANT becomes permanently disabled during the term of this Agreement with the Company, the Company may terminate the CONSULTANT’s under this Agreement by giving thirty (30) days’ notice to the CONSULTANT of its intent to terminate his engagement, and unless the CONSULTANT resumes performance of the duties set forth in Paragraph 3 within five (5) days of the date of the notice and continues performance for the remainder of the notice period, the CONSULTANT shall terminate at the end of the thirty (30)-day period. The CONSULTANT will not be entitled to and shall not receive any compensation or benefits of any type following the effective date of termination except as available under any disability policy covering the CONSULTANT as of his termination date. “Permanently disabled” for the purposes of this Agreement means the CONSULTANT’s inability, due to physical or mental ill health, to perform the essential functions of his job, with or without a reasonable accommodation, for the period of six (6) months during any one engagement year.

(e) Termination Due to CONSULTANT’s Death. The CONSULTANT’s engagement under this Agreement will terminate immediately upon his death and the Company shall not have any further liability or obligations to the CONSULTANT’s estate, his executors, heirs, assigns or any other person claiming under or through his estate, except that CONSULTANT’s estate shall receive any accrued but unpaid compensation or bonuses and any life insurance benefits to be paid pursuant to the CONSULTANT’s beneficiary designation and shall have the right to exercise the options granted under this Agreement.

(g) Expiration of the Agreement and its Effect on Termination Compensation. If the Agreement expires at the end of the Initial Term or any renewal term after proper advance notice by either party of its/his intent not to renew, the Agreement shall expire, and the CONSULTANT shall not be entitled to any Termination Compensation of any kind, except as required by law.

7. Company Property.

All correspondence, records, documents, software, promotional materials, and other Company property, including all copies, which come into the CONSULTANT’s possession by, through or in the course his engagement, regardless of the source and whether created by the CONSULTANT, are the sole and exclusive property of the Company, and immediately upon the termination of the CONSULTANT’s engagement, with or without cause, or at any time on the Company’s request, the CONSULTANT shall return to the Company all such property of the Company, without retaining any copies, summaries or excerpts of any kind or in any format whatsoever.

8. Non-Competition/Non-Solicitation:

(a) The CONSULTANT agrees and acknowledges that, in connection with his engagement with the Company, he will be provided with access to and become familiar with confidential and proprietary information and trade secrets belonging to the Company. In consideration of his engagement with the Company pursuant to this Agreement and for other good and valuable consideration, the receipt of which is hereby acknowledged, the CONSULTANT agrees that, while he is engaged by the Company and for a one (1) year period after the termination of his engagement, with or without cause, he shall not, either on his own behalf or on behalf of any third party, except on behalf of the Company, directly or indirectly, engage in any of the following activities.

(1) Other than through his ownership of stock of the Company, directly or indirectly, own, manage, operate, join, control, or participate in the ownership, management, operation control, or be connected as proprietor, partners, stockholder, officer, director, principal, agent, representative, joint venturer, investor, lender, consultant or otherwise with, or use or permit his name to be used in connection with, any business or enterprise engaged directly or indirectly in competition with the business conducted by the Company, at any time during such period, The foregoing restriction shall not be construed to prohibit the CONSULTANT’s ownership of not more than one percent (1%) of any class of securities of any corporation that is engaged in any of the foregoing businesses having a class of securities registered pursuant to the Securities Exchange Act of 1934, as amended; or

(2) Attempt in any manner to solicit from any client or customer of the Company at the time of the CONSULTANT’s termination, business of the type performed by the Company or to persuade any client of the Company to cease to do business or to reduce the amount of business which any such client has customarily done or actively contemplates doing with the Company; or

(3) Recruit, solicit or induce, or attempt to induce, any employee or employees of the Company or its affiliates to terminate their employment with, or otherwise cease their relationship with the Company or its affiliates.

(b) The parties acknowledge and agree that the restrictions placed upon the CONSULTANT herein are reasonable and necessary to protect the Company’s legitimate interests. The CONSULTANT further acknowledges that, based upon his education, experience, and training, this non-compete provision will not prevent him from earning a livelihood and supporting himself and his family during the relevant time period.

(c) If any restriction set forth in this Section 7 is found by any court of competent jurisdiction to be unenforceable as overbroad, it shall be reformed and interpreted to extend over the maximum period of time, range of activities or geographic areas as to which it may be enforceable.

(d) The provisions of this Section 7 shall survive termination or expiration of this Agreement.

9. Protection of Confidential Information.

The CONSULTANT agrees that all information, whether or not in writing, relating to the business, technical or financial affairs of the Company and that is generally understood in the industry as being confidential and/or proprietary information is the sole and exclusive property of the Company. The CONSULTANT agrees to hold in a fiduciary capacity for the sole benefit of the Company all secret, confidential or proprietary information, knowledge, data, or trade secret (“Confidential Information”) relating to the Company or any of its affiliates or their respective clients, which Confidential Information shall have been obtained during his engagement with the Company. This Confidential Information shall include, but not be limited to, information regarding the Company’s trade secrets, inventions, patent, trademark and copyright applications, cost and pricing data, customer and supplier lists, specifications, financial data, schematics and prototypes. The CONSULTANT agrees that he will not, at any time, either during the Term of this Agreement or after its termination, disclose to anyone any Confidential Information, or utilize such Confidential Information for his own benefit, or for the benefit of third parties without written approval by an officer of the Company. The CONSULTANT further agrees that all memoranda, notes, records, data, schematics, sketches, computer programs, prototypes or written, photographic, magnetic or other documents or tangible objects compiled by him or made available to him during the Term of his engagement concerning the business of the Company and/or its clients, including any copies of such materials, shall be the sole and exclusive property of the Company and shall be delivered to the Company on the termination of his engagement, or at any other time upon the Company’s request.

10. Injunctive Relief.

The CONSULTANT understands that, in the event he breaches this Agreement, the Company may suffer irreparable harm and will, therefore, be entitled to injunctive relief without the posting of a bond or other guarantee, to enforce this Agreement. This provision is not a waiver of any other rights that the Company may have under this Agreement, including the right to recover attorneys’ fees and costs to cover the expenses it incurs in seeking to enforce this Agreement, as well as to any other remedies available to it, including money damages.

11. Binding Agreement.

This Agreement shall be binding upon and inure to the benefit of the parties hereto, their heirs, personal representatives, successors and assigns. In the event the Company is acquired, is a non-surviving party in a merger, or transfers substantially all of its assets, this Agreement shall not be terminated and the transferee or surviving company shall be bound by the provisions of this Agreement. The parties understand that the obligations of the CONSULTANT are personal and may not be assigned by him. This Agreement can only be modified if mutually agreeable and in writing executed by both parties.

12. Nonassignability.

This Agreement and all rights, liabilities and obligations hereunder will be binding upon and inure to the benefit of each party’s successors, but neither party will assign, transfer or subcontract this Agreement or any of its obligations hereunder without the other party’s express, prior written consent.

13. Severability.

In the event that any term or provision of this Agreement is held invalid, void or unenforceable, then the remainder of this Agreement will not be affected, impaired or invalidated, and each such term and provision of this Agreement will be valid and enforceable to the fullest extent permitted by law.

14. Governing Law.

Regardless of the place of execution or performance, this Agreement and any related indemnification and confidentiality agreements between the parties will be deemed made in California. All actions arising hereunder or in connection herewith will fall under the exclusive jurisdiction and venue of the American Arbitration Association located in Los Angeles, CA and each of the parties hereto hereby agrees to the personal jurisdiction and venue of said arbitrator. The parties hereto agree to service of process by certified mail or receipted courier. Any right to trial by jury with respect to any claim or proceeding related to or arising out of this engagement, or any transaction or conduct in connection herewith, is waived.

15.. Advisory Services. Consultant is not a registered broker-dealer, attorney, accountant, negotiator, or financial advisor to the Company. Consultant will not make any recommendations about the Services and the Company will seek its own professional advice with respect to the Services. All payments made hereunder are nonrefundable.

16. Notices. All notices, requests and demands hereunder will be in writing and will be deemed to have been duly given (a) upon personal delivery, (b) five (5) days after being mailed by registered or certified mail, return receipt requested, (c) one (1) business day after being sent by email, or (c) one (1) business day after being sent by nationally recognized overnight courier.

17. Independent Contractor. The parties expressly intend and agree that Consultant is acting as an independent contractor of Company and is not providing the services under the direction or control of the Company. Nothing contained in this Agreement shall be deemed to create a partnership, joint venture or agency or employer/employee relationship between the parties, nor does it grant either party any authority to assume or create any obligation on behalf of or in the name of the other. The Consultant has no authority to obligate or bind the Company by contract or otherwise. The Consultant will not be eligible for any employee benefits, and the Company will not make deductions from the Consultant’s fees for taxes (except as otherwise required by applicable law or regulation). Any taxes imposed on the Consultant due to the services performed hereunder will be the sole responsibility of the Consultant. Consultant shall have the sole responsibility for ensuring that it complies with all laws in the performance of the services, and all tax payment and reporting obligations of the United States and the country, state and city in which Consultant resides.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first above written.

Richard L. Chang Holdings, LLC

By: /s/ Richard L. Chang

Name: Prof. Richard L. Chang

HYPGEN INC

By: /s/ McCoy Moretz

Name: McCoy Moretz, MD

Title: CEO

EX-31.1 3 hypgen_ex311.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

REQUIRED BY RULE 13A-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 AS AMENDED,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Dr. McCoy Moretz, certify that:

1.	I have reviewed this annual report on Form 10-K of Hypgen Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 3, 2018	By:	/s/ Dr. McCoy Moretz
		Dr. McCoy Moretz
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 4 hypgen_ex312.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

REQUIRED BY RULE 13A-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 AS AMENDED,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Dr. McCoy Moretz, certify that:

1.	I have reviewed this annual report on Form 10-K of Hypgen Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 3, 2018	By:	/s/ Dr. McCoy Moretz
		Dr. McCoy Moretz
		Chief Financial Officer
		(Principal Accounting Officer)

EX-32.1 5 hypgen_ex321.htm CERTIFICATION OF

EXHIBIT 32.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

I, Dr. McCoy Moretz, Chief Executive Officer of HYPGEN INC. (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	the Annual Report on Form 10-K of the Company for the year ended May 31, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 3, 2018

By:

/s/ Dr. McCoy Moretz

Dr. McCoy Moretz

Chief Executive Officer

(Principal Executive Officer)

EX-32.2 6 hypgen_ex322.htm CERTIFICATION OF

EXHIBIT 32.2

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

I, Dr. McCoy Moretz, Chief Financial Officer of HYPGEN INC. (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	the Annual Report on Form 10-K of the Company for the year ended May 31, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 3, 2018	By:	/s/ Dr. McCoy Moretz
		Dr. McCoy Moretz
		Chief Financial Officer
		(Principal Accounting Officer)

GRAPHIC 7 image2.jpg GRAPHIC begin 644 image2.jpg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end GRAPHIC 8 image3.jpg GRAPHIC begin 644 image3.jpg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end GRAPHIC 9 image_001.gif GRAPHIC begin 644 image_001.gif M1TE&.#EAS0 J /< /______S/__F?__9O__,___ /_,___,S/_,F?_,9O_, M,__, /^9__^9S/^9F?^99O^9,_^9 /]F__]FS/]FF?]F9O]F,_]F /\S__\S MS/\SF?\S9O\S,_\S /\ __\ S/\ F?\ 9O\ ,_\ ,S__\S_S,S_F(**(%,F=HSU2-3 MA598Q0STU H4*%RK9N29E=56*"6_)LRJLL0*GE;VF(IF*N_3KAI+0+%".&O? MEWFU]H6;<4]/AG(/KHCV^&/2@WN(.K:B=<_&%5N5LG*KF"_9IRV3[MW#F&,@ MSPQ- 1YH)=KLE*;(VP3MBMP*'>-E M *:&9_UKJC5#Y)41(O^'6M0E;,E:IQ)G/7"/V^J@FR.\G;Y]M/,8\P( O9#P M0-#5$;1'-(%0]A!_%R5EW'"]Z2=><@3]MIE 2K6FH'J4.3;7?0<])U!M837E M(46ZH>506(>5()] F?T7#5P:GIA==/X5!*!!DVG%2@G#:9:9;@B1->-^MJW M(P!0V"9@<@0.=!A/" T(6HL$N>5D4;K5IB1%P,4(67G8@2D0%%+1)M9^ 1+$ MF4!WZ97577R&!Y4W>V7 M6T%T49@=<$F*&1&""\[5%)D&'380A!*!IQ590AF6W%;NT594DDU9<:1XN9W_ M&AZ+N7'VVI".YM9JD_$-5,*+Q'VH)FR3#62@FEO6IA56DIVQ. M)JA>$[DG*(5T K#FG5CB^M^L;'Z*GT%,_8:C4L#%AQ:NG)G8Z6/?#CAK@945 MR I?O1W+YVS(.>K0==CUY29789DVJ$34UGGFI^755A2B!A&E$*CS2:7N026$ MZ"V!V-(FF[.3E8>MEN$19B^2K.Q1PJLK2Z;7;'#JF1EAKAZT')N9.:;>72Q& M0QJYSGGGI+B>[E74HS;RE9"N0!^TYK?C#B256=A9R>96V'757;L$9@CF=0/. M271M%B(W:E-VP9F9CJ>9=9:P:AH],&%I.FDW=N<>__:F6*D6M)>X U6:6[1A M>BNN;JHYV#*!S,YH\=8]8:L:7(5V+%_;<['"F2E+;;M?"!& MDUXF=7P9&NAD>Z,I<(="4=O!(:WG5:5Z74O:7G3RA=J&DVN$H(- M)2E?3X<*+32] 08,%N&#,0;:>_UAW5#4,AZ:_$,YKP3]^/^>3R'1!*W/)TQO M1:/6<*FK'J"*[J>5 MZ3L$K* &+9/!^'5K@R!TBK.>-L(0FA C&&-(H4[(0HVP#B(%NDNF6DA#R/3/ @/0VKH0X7@KB%O&J'0%2(Z V"2,2+I*^(2$SB#@," #L! end GRAPHIC 10 image_002.gif GRAPHIC begin 644 image_002.gif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end EX-101.INS 11 hpgn-20180531.xml XBRL INSTANCE FILE 0001653629 2017-06-01 2018-05-31 0001653629 2018-10-01 0001653629 2018-05-31 0001653629 2017-05-31 0001653629 2016-06-01 2017-05-31 0001653629 2016-05-31 0001653629 HPGN:AssetAssignmentAgreementMember HPGN:RichardLChangHoldingsLLCMember 2017-06-01 2018-05-31 0001653629 HPGN:AssetAssignmentAgreementMember HPGN:RichardLChangHoldingsLLCMember 2018-05-31 0001653629 HPGN:FirstLegacyManagementLLCMember 2018-05-31 0001653629 HPGN:FirstLegacyManagementLLCMember 2017-06-01 2018-05-31 0001653629 HPGN:StatementsOfDiscontinuedOperationsMember 2017-06-01 2018-05-31 0001653629 HPGN:StatementsOfDiscontinuedOperationsMember 2016-06-01 2017-05-31 0001653629 us-gaap:DiscontinuedOperationsHeldforsaleMember 2017-06-01 2018-05-31 0001653629 us-gaap:DiscontinuedOperationsHeldforsaleMember 2018-05-31 0001653629 us-gaap:DirectorMember 2017-06-01 2018-05-31 0001653629 us-gaap:PatentsMember 2017-06-01 2018-05-31 0001653629 us-gaap:PatentsMember 2018-05-31 0001653629 HPGN:ConvertibleNote1Member 2017-06-01 2018-05-31 0001653629 HPGN:ConvertibleNote1Member 2018-05-31 0001653629 HPGN:ConvertibleNote2Member 2017-06-01 2018-05-31 0001653629 HPGN:ConvertibleNote2Member 2018-05-31 0001653629 HPGN:ConvertibleNote1And2Member 2017-06-01 2018-05-31 0001653629 HPGN:ConvertibleNote1And2Member 2018-05-31 0001653629 HPGN:ConvertibleNote3Member 2017-06-01 2018-05-31 0001653629 HPGN:ConvertibleNote3Member 2018-05-31 0001653629 HPGN:ConsultingAgreement1Member 2017-06-01 2018-05-31 0001653629 HPGN:ConsultingAgreement2Member 2017-06-01 2018-05-31 0001653629 HPGN:ConsultingAgreement3Member 2017-06-01 2018-05-31 0001653629 HPGN:ConsultingAgreement4Member 2017-06-01 2018-05-31 0001653629 us-gaap:EmploymentContractsMember 2017-06-01 2018-05-31 0001653629 HPGN:ConsultingAgreement1Member 2018-05-31 0001653629 HPGN:ConsultingAgreement1Member srt:MinimumMember 2017-06-01 2018-05-31 0001653629 HPGN:ConsultingAgreement1Member srt:MaximumMember 2017-06-01 2018-05-31 0001653629 HPGN:ConsultingAgreement2Member srt:MinimumMember 2017-06-01 2018-05-31 0001653629 HPGN:ConsultingAgreement2Member srt:MaximumMember 2017-06-01 2018-05-31 0001653629 srt:MinimumMember 2017-06-01 2018-05-31 0001653629 srt:MaximumMember 2017-06-01 2018-05-31 0001653629 HPGN:ConsultingAgreement4Member 2018-05-31 0001653629 us-gaap:EmploymentContractsMember 2018-05-31 0001653629 2017-01-26 0001653629 HPGN:StockPurchaseAgreementMember 2017-06-01 2018-05-31 0001653629 HPGN:AssetAssignmentAgreementMember HPGN:RichPharmaceuticalsIncMember 2018-05-31 0001653629 HPGN:ConsultantMember 2017-06-01 2018-05-31 0001653629 HPGN:ConsultantingAgreementsMember 2017-06-01 2018-05-31 0001653629 HPGN:PotentiallyDilutiveInstrumentsMember 2017-06-01 2018-05-31 0001653629 HPGN:EmployeesMember 2017-06-01 2018-05-31 0001653629 HPGN:PromissoryNote1Member 2017-06-01 2018-05-31 0001653629 HPGN:PromissoryNote1Member 2018-05-31 0001653629 HPGN:PromissoryNote2Member 2017-06-01 2018-05-31 0001653629 HPGN:PromissoryNote2Member 2018-05-31 0001653629 HPGN:ConvertibleNote4Member 2017-06-01 2018-05-31 0001653629 HPGN:ConvertibleNote4Member 2018-05-31 0001653629 us-gaap:EquityUnitPurchaseAgreementsMember 2018-05-31 0001653629 us-gaap:EquityUnitPurchaseAgreementsMember 2017-06-01 2018-05-31 0001653629 HPGN:PromissoryNote3Member 2017-06-01 2018-05-31 0001653629 HPGN:PromissoryNote3Member 2018-05-31 0001653629 HPGN:PromissoryNote4Member 2017-06-01 2018-05-31 0001653629 HPGN:PromissoryNote4Member 2018-05-31 0001653629 HPGN:PromissoryNote5Member 2017-06-01 2018-05-31 0001653629 HPGN:PromissoryNote5Member 2018-05-31 0001653629 HPGN:PromissoryNote6Member 2017-06-01 2018-05-31 0001653629 HPGN:PromissoryNote6Member 2018-05-31 0001653629 HPGN:PromissoryNote7Member 2018-03-01 2018-05-31 0001653629 HPGN:PromissoryNote7Member 2018-05-31 0001653629 HPGN:ConsultingAgreement3Member 2018-03-01 2018-05-31 0001653629 HPGN:ConsultingAgreement3Member 2018-05-31 0001653629 HPGN:ConsultingAgreement2Member 2018-03-01 2018-05-31 0001653629 HPGN:ConsultingAgreement2Member 2018-05-31 0001653629 HPGN:CancellationAgreementMember 2018-03-01 2018-05-31 0001653629 HPGN:WarrantAmendmentAgreementMember 2018-03-01 2018-05-31 0001653629 us-gaap:PreferredStockMember 2015-06-01 2016-05-31 0001653629 us-gaap:PreferredStockMember 2017-06-01 2018-05-31 0001653629 us-gaap:PreferredStockMember 2016-05-31 0001653629 us-gaap:PreferredStockMember 2017-05-31 0001653629 us-gaap:PreferredStockMember 2018-05-31 0001653629 us-gaap:CommonStockMember 2017-06-01 2018-05-31 0001653629 us-gaap:CommonStockMember 2016-05-31 0001653629 us-gaap:CommonStockMember 2017-05-31 0001653629 us-gaap:CommonStockMember 2018-05-31 0001653629 us-gaap:AdditionalPaidInCapitalMember 2017-06-01 2018-05-31 0001653629 us-gaap:AdditionalPaidInCapitalMember 2016-05-31 0001653629 us-gaap:AdditionalPaidInCapitalMember 2017-05-31 0001653629 us-gaap:AdditionalPaidInCapitalMember 2018-05-31 0001653629 us-gaap:RetainedEarningsMember 2016-06-01 2017-05-31 0001653629 us-gaap:RetainedEarningsMember 2017-06-01 2018-05-31 0001653629 us-gaap:RetainedEarningsMember 2016-05-31 0001653629 us-gaap:RetainedEarningsMember 2017-05-31 0001653629 us-gaap:RetainedEarningsMember 2018-05-31 0001653629 HPGN:EmploymentAgreementsMember 2018-05-31 0001653629 HPGN:SeniorConsultantMember 2017-06-01 2018-05-31 0001653629 HPGN:SeniorConsultantEntityMember 2017-06-01 2018-05-31 0001653629 2017-11-30 0001653629 HPGN:ConsultingAgreement2Member 2017-06-01 2018-05-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:D HypGen Inc 0001653629 10-K 2018-05-31 false --05-31 No No Yes Non-accelerated Filer FY 2019 50000502 8415 465 2000 11757 22172 1481 22172 47014 3844 249767 39000 -1129153 -236905 1481 22172 2000 135800 5000 43812 107347 638777 218257 -638777 -218257 73170 3844 10922 241714 3094 -76 16064 -11757 16064 -892248 -205287 -205287 -892248 2000 -2000 -101939 449858 200000 135800000 5000000 60000000 75000000 12000000 8000000 15000000 5000000 2000000 0 2000000 2000000 1000 to 1 voting rights over shares of the Companys common stock State of Nevada 2015-03-26 We will continue to be an emerging growth company until: (i) the last day of our fiscal year during which we had total annual gross revenues of $1,000,000,000 or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (iii) the date on which we have, during the previous 3-year period, issued more than $1,000,000,000 in non-convertible debt; or (iv) the date on which we are deemed to be a large accelerated filer, as defined in Section 12b-2 of the Exchange Act. 2017-06-28 2017-01-18 2015-05-25 2016-11-10 2017-06-28 2017-06-28 2017-06-28 2017-07-08 2017-07-08 2017-01-18 2017-11-15 2018-07-05 2018-07-05 2018-07-09 2018-07-09 2018-06-01 0 0 73171 53197 19974 3000 76 910 11757 3910 -11757 16064 13653 29816 750 100 650 100 45000 100000 100000 400000 22500 22500 0.25 0.25 0.25 0.50 7 0.21 -168544 31044 11233 34630 185152 170250 8456 -8456 204269 117603288 5000000 -892248 -205287 8990 910 204962 11233 -356334 -192050 -8415 7950 77000 200000 4000000 0.80 350000 100000 50000 50000 0.001 0.001 2000000 0 0.001 0.001 1000000000 1000000000 75000000 0 0 P3Y P19Y135D 77000 0.08 0.08 0.10 0.10 0.10 4244 2800 7044 38889 213 143 277 277 96 4 3 28 P1Y P1Y P24M 2019-06-28 2018-09-14 2018-11-03 2018-08-19 2018-08-14 2019-01-11 2019-02-14 2019-03-12 2019-03-16 2019-06-25 The holder of the note was entitled to a conversion price equal to seventy percent of the average trading price computed based on the previous 7 trading days prior to notice of conversion. The holder of the note was entitled to a conversion price equal to seventy percent of the average trading price computed based on the previous 7 trading days prior to notice of conversion. may be converted at any time by the holder into shares of Company common stock at a conversion price of $.50 per share; and automatically converts into shares of Company common stock at a conversion price of $.50 per share upon the Company’s completion of a financing in the minimum amount of $5,000,000 Upon any event of default, the note holder may convert the note in its entirety into shares of Company common stock at a conversion price equal to 80% of the average closing bid price during the 5-day period prior to conversion, subject to a floor price of $0.00005 per share The amounts under the Note may be converted by GHS at any time after the maturity date or upon any event of default into shares of Company common stock at a conversion price equal to 80% of the average closing bid price during the 5-day period prior to conversion, subject to a floor price of $0.00005 per share. 2017-01-27 2017-04-07 2017-06-28 2017-09-14 2017-11-03 2017-11-17 2018-01-11 2018-02-14 2018-03-12 2018-03-06 2018-06-25 800000 200000 2017-08-11 2017-07-19 1000000 1000000 1000000 1000000 1000000 2018-06-28 2019-06-28 2019-06-28 0 60000000 60000000 0.25 0.25 50000000 60000000 10000000 P4Y6M 5000000 5000000 5000000 15000000 6000000 5000000 500000 10000000 10000000 10000000 10000000 -10000000 0.25 0.25 0.25 0.25 P5Y P5Y P5Y 1800 4500 1800 4500 5400 13500 This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. 0.80 4000000 350000 0.08 0.05 0.05 0.05 0.05 0.05 0.05 0.05 -0.000 0.003 -0.008 -0.044 66567 the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company 1114329 236905 188800 49700 44725000 55000000 100000 111444 56000 1965954 10275000 1481 -1939 15000 -880491 -221351 1939 458 458 0 6000 5000 5000 5000 250 2375 4000 7000000 200000 -0.008 -0.041 8914 910 30000 3844 400000 200000 4814 4814 8191 267900 80500 -188800 -49700 -79100 -30800 -5496500 -5500000 -74999998 In consideration of the share cancellations and provided that the Company raises a minimum of $1,000,000 in equity financing on or before June 28, 2019, Richard L. Chang Holding’s, LLC agreed to waive its right of reversion of the patent assets contributed to the Company pursuant to the Asset Assignment Agreement dated June 28, 2017. In consideration of the amendment and provided that the Company raises a minimum of $1,000,000 in equity financing on or before June 28, 2019, Richard L. Chang Holding’s, LLC agreed to waive its right of reversion of the patent assets contributed to the Company pursuant to the Asset Assignment Agreement dated June 28, 2017. 11681 -11681 43170 343067 215077 743067 215077 Nature of Business   HYPGEN INC. (formerly MEGA BRIDGE INC) (the “Company”) is a for profit corporation established under the corporate laws of the State of Nevada on March 26, 2015.   We are an emerging growth company as defined in Section 2(a)(19) of the Securities Act. We will continue to be an emerging growth company until: (i) the last day of our fiscal year during which we had total annual gross revenues of $1,000,000,000 or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (iii) the date on which we have, during the previous 3-year period, issued more than $1,000,000,000 in non-convertible debt; or (iv) the date on which we are deemed to be a large accelerated filer, as defined in Section 12b-2 of the Exchange Act.   As an emerging growth company, we are exempt from:   Section 14A (a) and (b) of the Exchange Act, which requires companies to hold stockholder advisory votes on executive compensation and golden parachute compensation;   The requirement to provide in any registration statement periodic report or other report to be filed with the Securities and Exchange Commission, certain modified executive compensation disclosure under Item 402 of Regulation S-K or selected financial data under Item 301 of Regulation S-K for any period before the earliest audited period presented in our initial registration statement;   Compliance with new or revised accounting standards until those standards are applicable to private companies;   The requirement under Section 404(b) of the Sarbanes-Oxley Act of 2002 to provide auditor attestation of our internal controls and procedures; and   Any Public Company Accounting Oversight Board ("PCAOB") rules regarding mandatory audit firm rotation, or an expanded auditor report and any other PCAOB rules subsequently adopted, unless the Securities and Exchange Commission determines the new rules are necessary for protecting the public.   We have not elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the Jumpstart Our Business Startups Act.   Unless the context otherwise requires, all references to “we,” “us,” “our” or the “Company” are to HYPGEN INC.   On January 18th, 2017, Olaf Robak, the Company's President and CEO, executed a stock purchase agreement with First Legacy Management LLC, which acquired 4,000,000 shares of common stock, representing 80% ownership of the Company. First Legacy Management LLC paid $350,000 in cash. Simultaneous with this transaction, Mr. Olaf Robak resigned from his official positions as Director, CEO, CFO, President, Treasurer and Secretary of the Company, and on the same day the shareholders of the Corporation voted Mr. Antonio Treminio as Director & CEO (Mr. Treminio subsequently resigned as a director and CEO effective as of June 28, 2017).   On March 9, 2017, FINRA notified the Company that request for symbol change was approved. Effective March 13, 2017, the Company’s common stock began trading under the symbol MGBR.   On June 28, 2017, the Company executed an Asset Assignment Agreement (“Asset Assignment Agreement”) with Richard L. Chang Holding’s LLC (“Holdings LLC”), pursuant to which Holdings was issued 60,000,000 shares of the Company’s common stock and 2,000,000 restricted, non-convertible, non-dividend paying shares of the Company’s preferred stock with 1000 to 1 voting rights over shares of the Company’s common stock. In consideration of these share issuances, Holdings LLC has assigned to the Company all of its rights, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016, titled “COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. Additionally, the Company issued 15,000,000 common shares to Rich Pharmaceuticals, Inc. for use of the clinical trial under an Investigational New Drug Application. Additionally, pursuant to the terms of the Asset Assignment Agreement, upon the Company receiving a minimum of $1,000,000 in equity financing, Holdings shall assign to the Company all of its rights, title and interest to United States Utility Patent Application No USPTO Application No. 15/385,862 filed on December 20, 2016, titled ”COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. The Asset Assignment Agreement granted to Holdings LLC the right to require the Company to assign back to Holdings LLC the Patent Application and all related intellectual property in the event the Company does not raise a minimum of $1,000,000 in equity financing by June 28, 2018. In the event that Holdings LLC exercises this right of reversion, the 2,000,000 shares of Preferred Stock issued to Holdings LLC shall be assigned to Apica Investments Limited or its assignees. As of May 31, 2018, the Company has not raised any capital towards the $1,000,000 requirement. As of the filing of this report Holdings LLC has not exercised its right of reversion under the Asset Assignment Agreement.   On June 28, 2017, the Company discontinued operations of its office products sales and distribution segment.   On July 11, 2017, the Board of Directors of the Company appointed Dr. Moretz as the Chief Financial Officer of the Company.   On July 18, 2017, we filed Articles of Merger with the Secretary of State of Nevada in order to effectuate a merger with our wholly-owned subsidiary, HypGen Inc. Shareholder approval was not required under Section 92A.180 of the Nevada Revised Statutes. As part of the merger, our board of directors authorized a change in our name to “HypGen Inc” and our Articles of Incorporation have been amended to reflect this name change.   On August 1, 2017, the Company changed its name to HypGen Inc. to more accurately reflect the Company’s new strategic direction as it focuses its efforts on developing therapeutic treatment options for Parkinson's disease. Effective with the name change the Company’s trading symbol was changed to HPGN with OTC Markets.   Going Concern   As indicated in the accompanying financial statements, the Company has incurred net losses of $892,248 and $205,287 for the years ended May 31, 2018 and 2017, respectively. Management’s plans include the raising of capital through related and third parties to fund future operations of pushing its Parkinson’s disease drug through phase II drug trials in order to obtain approval from the food and drug administration (“FDA”). Failure to raise adequate capital during the testing and approval seeking process may force the Company to curtail or cease operations. Additionally, even if the Company raises sufficient capital to support its operating expenses, there can be no assurances that FDA approval will be granted whereby no revenue from target project will ever be recognized to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern. However, the accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. Use of Estimates and Assumptions   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.   Cash and Cash Equivalents   The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. At May 31, 2018 and 2017, the Company had no cash equivalents.   Property and Equipment and Depreciation   Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.   Intangible Assets   Intangible assets consisted of a licensing fee under an asset assignment agreement for a patent which was granted November 10, 2016. At the time of the assignment on June 28, 2017, the patent had a remaining life of 19 years and 135 days, which the Company had determined to be the remaining useful life of the patent whereby total investment was to be amortized on a straight-line basis over this period. In exchange for the rights to the intellectual property the Company paid $100,000 in cash, issued 2,000,000 preferred shares and 75,000,000 commons shares. The total investment was valued at $177,000.   During the year ended May 31, 2018, the Company analyzed its intangible asset for the purposes of impairment testing. Although management believes that the asset has real economic value, the expense of an independent valuation is not something the Company is interested in doing, whereby the cost of this analysis could exceed the value of the asset.  Conversely, the Company’s asset analysis is not objectively able to prove with any degree of certainty that it will ever see positive cashflow from its efforts.  This industry is very complicated, risky and unpredictable as it relates to ultimate drug approval or even the sale of the asset.  Due to a cost prohibitive asset valuation, uncertainty that the product can be brought to market or be sold and the fact that the that acquisition was from a related party the Company feels that is should fully impair the asset at this time.     Impairment of Long-Lived Assets   Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.   Net Loss Per Common Share   The Company computes per share amounts in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 260 Earnings per Share (“EPS”) which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to Common Stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of Common Stock and Common Stock equivalents outstanding during the periods; however, potential common shares are excluded for period in which the Company incurs losses, as their effect is anti-dilutive. For the years ended May 31, 2018 and 2017 the basic and fully diluted earnings per share were the same as the Company had a loss in each of these periods. At May 31, 2018, the Company had potentially dilutive instruments in the form of 60,000,000 common stock warrants with a cashless exercise provision outstanding as well as 1,965,954 common shares issuable upon the conversion of outstanding principal and interest on convertible notes.   Stock-Based Compensation   The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.   The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted on the grant date as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in stockholders’ equity/(deficit) over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.   The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value on the grant date of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services over the term of the related services.   Fair Value of Financial Instruments   ASC 825, “Disclosures about Fair Value of Financial Instruments”, requires disclosure of fair value information about financial instruments in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value hierarchy to classify the inputs used in measuring fair value as follows:   · Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.  · Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. · Level 3-Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.   The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820.   Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2018.   The respective carrying values of certain on-balance-sheet financial instruments approximate their fair values. These financial instruments include cash, accrued liabilities and notes payable. Fair values were assumed to approximate carrying values for these financial instruments since they are short term in nature and their carrying amounts approximate fair value. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet date.   Reclassifications   Certain prior year amounts have been reclassified to conform to the current period presentation. The reclassifications had no effect on the net loss or cash flows of the Company.   Revenue Recognition   The Company recognizes revenues in accordance with FASB ASC Topic 605, “Revenue Recognition”, and with the guidelines of the Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104 “Revenue Recognition”.   Under SAB 104, four conditions must be met before revenue can be recognized: (i) there is persuasive evidence that an arrangement exists, (ii) delivery has occurred or service has been rendered, (iii) the price is fixed or determinable, and (iv) collection is reasonably assured.   Customers of our discontinued operation paid for their product at the time we are advised by the manufacturer/distributor that the product is ready for shipment or pick-up. The Company recognizes revenue when the pre-paid product has been delivered to, or picked up by, the customer. In the event there is a significant delay between the date the customer pre-pays for the product and the delivery or pick-up of the product, revenue would be deferred until the customer accepts delivery of the product. Under our current operations we do not expect to recognize revenue until we receive FDA approval to sell our Parkinson’s disease drug commercially.   Research and Development   The Company expenses research and development costs as incurred. Research and development costs were $0 for the years ended May 31, 2018 and 2017. The expense in the prior year is reflected in discontinued operations. The Company anticipates substantial expense as it conducts phase II trials and tries to move its product to market along with the development of its other products. The Company will also evaluate products and technologies in the medical products space, with its main focus on Parkinson’s Disease. As the Company continues to develop its products and relationships in these areas’ resultant expenses for trademark filings, license agreements, product development and design materials will be expensed as research and development. Some costs may be accumulated for subsidiaries prior to formation of entities.    Income Taxes   We will use the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.   ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for the reporting period presented.   The Company did not record any income tax accrual for the period from inception to May 31, 2018. We expect to incur significant expenses in future periods which will offset any net profit.   Recent Accounting Pronouncements   In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” which addresses accounting for issuance of all share-based payments on the same accounting model. Previously, accounting for share-based payments to employees was covered by ASC Topic 718 while accounting for such payments to non-employees was covered by ASC Subtopic 505-50. As it considered recently issued updates to ASC 718, the FASB, as part of its simplification initiatives, decided to replace ASC Subtopic 505-50 with Topic 718 as the guidance for non-employee share-based awards. Under this new guidance, both sets of awards, for employees and non-employees, will essentially follow the same model, with small variations related to determining the term assumption when valuing a non-employee award as well as a different expense attribution model for non-employee awards as opposed to employee awards. The ASU is effective for public business entities beginning in 2019 calendar years and one year later for non-public business entities.   In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815),” which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The Company is currently in the process of assessing the impact the adoption of this guidance will have on the Company’s financial statements.   Subsequent Events   In accordance with ASC 855 “Subsequent Events” the Company evaluated subsequent events after the balance sheet date through the date of issuance. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. At May 31, 2018 and 2017, the Company had no cash equivalents. Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations. Intangible assets consisted of a licensing fee under an asset assignment agreement for a patent which was granted November 10, 2016. At the time of the assignment on June 28, 2017, the patent had a remaining life of 19 years and 135 days, which the Company had determined to be the remaining useful life of the patent whereby total investment was to be amortized on a straight-line basis over this period. In exchange for the rights to the intellectual property the Company paid $100,000 in cash, issued 2,000,000 preferred shares and 75,000,000 commons shares. The total investment was valued at $177,000.   During the year ended May 31, 2018, the Company analyzed its intangible asset for the purposes of impairment testing. Although management believes that the asset has real economic value, the expense of an independent valuation is not something the Company is interested in doing, whereby the cost of this analysis could exceed the value of the asset.  Conversely, the Company’s asset analysis is not objectively able to prove with any degree of certainty that it will ever see positive cashflow from its efforts.  This industry is very complicated, risky and unpredictable as it relates to ultimate drug approval or even the sale of the asset.  Due to a cost prohibitive asset valuation, uncertainty that the product can be brought to market or be sold and the fact that the that acquisition was from a related party the Company feels that is should fully impair the asset at this time.  Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value. The Company computes per share amounts in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 260 Earnings per Share (“EPS”) which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to Common Stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of Common Stock and Common Stock equivalents outstanding during the periods; however, potential common shares are excluded for period in which the Company incurs losses, as their effect is anti-dilutive. For the years ended May 31, 2018 and 2017 the basic and fully diluted earnings per share were the same as the Company had a loss in each of these periods. At May 31, 2018, the Company had potentially dilutive instruments in the form of 60,000,000 common stock warrants with a cashless exercise provision outstanding as well as 1,965,954 common shares issuable upon the conversion of outstanding principal and interest on convertible notes. The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.   The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted on the grant date as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in stockholders’ equity/(deficit) over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.   The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value on the grant date of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services over the term of the related services. ASC 825, “Disclosures about Fair Value of Financial Instruments”, requires disclosure of fair value information about financial instruments in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value hierarchy to classify the inputs used in measuring fair value as follows:   · Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.  · Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. · Level 3-Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.   The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820.   Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2018.   The respective carrying values of certain on-balance-sheet financial instruments approximate their fair values. These financial instruments include cash, accrued liabilities and notes payable. Fair values were assumed to approximate carrying values for these financial instruments since they are short term in nature and their carrying amounts approximate fair value. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet date. Certain prior year amounts have been reclassified to conform to the current period presentation. The reclassifications had no effect on the net loss or cash flows of the Company. The Company recognizes revenues in accordance with FASB ASC Topic 605, “Revenue Recognition”, and with the guidelines of the Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104 “Revenue Recognition”.   Under SAB 104, four conditions must be met before revenue can be recognized: (i) there is persuasive evidence that an arrangement exists, (ii) delivery has occurred or service has been rendered, (iii) the price is fixed or determinable, and (iv) collection is reasonably assured.   Customers of our discontinued operation paid for their product at the time we are advised by the manufacturer/distributor that the product is ready for shipment or pick-up. The Company recognizes revenue when the pre-paid product has been delivered to, or picked up by, the customer. In the event there is a significant delay between the date the customer pre-pays for the product and the delivery or pick-up of the product, revenue would be deferred until the customer accepts delivery of the product. Under our current operations we do not expect to recognize revenue until we receive FDA approval to sell our Parkinson’s disease drug commercially. The Company expenses research and development costs as incurred. Research and development costs were $0 for the years ended May 31, 2018 and 2017. The expense in the prior year is reflected in discontinued operations. The Company anticipates substantial expense as it conducts phase II trials and tries to move its product to market along with the development of its other products. The Company will also evaluate products and technologies in the medical products space, with its main focus on Parkinson’s Disease. As the Company continues to develop its products and relationships in these areas’ resultant expenses for trademark filings, license agreements, product development and design materials will be expensed as research and development. Some costs may be accumulated for subsidiaries prior to formation of entities. We will use the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.   ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for the reporting period presented.   The Company did not record any income tax accrual for the period from inception to May 31, 2018. We expect to incur significant expenses in future periods which will offset any net profit. In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” which addresses accounting for issuance of all share-based payments on the same accounting model. Previously, accounting for share-based payments to employees was covered by ASC Topic 718 while accounting for such payments to non-employees was covered by ASC Subtopic 505-50. As it considered recently issued updates to ASC 718, the FASB, as part of its simplification initiatives, decided to replace ASC Subtopic 505-50 with Topic 718 as the guidance for non-employee share-based awards. Under this new guidance, both sets of awards, for employees and non-employees, will essentially follow the same model, with small variations related to determining the term assumption when valuing a non-employee award as well as a different expense attribution model for non-employee awards as opposed to employee awards. The ASU is effective for public business entities beginning in 2019 calendar years and one year later for non-public business entities.   In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815),” which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The Company is currently in the process of assessing the impact the adoption of this guidance will have on the Company’s financial statements. In accordance with ASC 855 “Subsequent Events” the Company evaluated subsequent events after the balance sheet date through the date of issuance. On June 28, 2017, the Company discontinued operations of its office products sales and distribution segment. Depreciation expense as it appears on the Statement of Cash Flows for the years ended months ended May 31, 2018 and 2017 was $76 and $910, respectively. Depreciation on the statement of operations for the years ended May 31, 2018 is recorded as Income (Loss) from Discontinued Operations.   The statement of operations was restated to reflect the reclassification of the discontinued operations.   <table cellspacing="0" cellpadding="0" align="center" style="font: 12pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="8" style="text-align: center">HYPGEN INC STATEMENTS OF DISCONTINUED OPERATIONS</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="7" style="text-align: center">For the years ended May 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2017</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Discontinued Operations:</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 55%; padding-left: 5.4pt">Revenue</td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">—  </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">73,171</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Cost of Goods Sold:</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Product Purchases</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">53,197</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Gross Profit</td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">19,974</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt"> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Operating Expenses:</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">General and administrative</td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Product development</td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Depreciation</td> <td> </td> <td style="text-align: right">76</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">910</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Impairment loss on assets from discontinued operations</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">11,681</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-indent: 20pt">Total operating expense</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">11,757</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,910</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Net income (loss) from discontinued operations</td> <td>$</td> <td style="text-align: right">(11,757</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">16,064</td> <td> </td></tr> </table>    On May 25, 2015 the Company purchased a small office located at 5 Garbary in Gdansk Poland. The purchase price was $13,653. The Company utilized this space as its primary office for the former discontinued operations. Assets from discontinued operations are reflected net of accumulated depreciation. As of June 28, 2017, the building, classified as assets of discontinued operations, is no longer being depreciated due to the fact that it is no longer in service.   As of May 31, 2018, the Company has fully impaired the remaining net value of its former office which was held as an asset from discontinued operations. The Company no longer has access or control over this asset and believes that there is no substantial net economic value to this asset and any cost of legal disposal could easily exceed its net book value.    <table cellspacing="0" cellpadding="0" align="center" style="font: 12pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">May 31, 2018</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">May 31, 2017</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; padding-left: 5.4pt">Assets of discontinued operations</td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">—  </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">11,757</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Liabilities of discontinued operations</td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> </table>    <table cellspacing="0" cellpadding="0" align="center" style="font: 12pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="8" style="text-align: center">HYPGEN INC STATEMENTS OF DISCONTINUED OPERATIONS</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="7" style="text-align: center">For the years ended May 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2017</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Discontinued Operations:</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 55%; padding-left: 5.4pt">Revenue</td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">—  </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">73,171</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Cost of Goods Sold:</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Product Purchases</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">53,197</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Gross Profit</td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">19,974</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt"> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Operating Expenses:</td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">General and administrative</td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Product development</td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Depreciation</td> <td> </td> <td style="text-align: right">76</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">910</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Impairment loss on assets from discontinued operations</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">11,681</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt; text-indent: 20pt">Total operating expense</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">11,757</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,910</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt">Net income (loss) from discontinued operations</td> <td>$</td> <td style="text-align: right">(11,757</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">16,064</td> <td> </td></tr> </table> <table cellspacing="0" cellpadding="0" align="center" style="font: 12pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">May 31, 2018</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">May 31, 2017</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; padding-left: 5.4pt">Assets of discontinued operations</td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">—  </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">11,757</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Liabilities of discontinued operations</td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> </table>   The Company’s property and equipment is as follows:    <table cellspacing="0" cellpadding="0" align="center" style="font: 12pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-indent: 9pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">May 31, 2018</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">May 31, 2017</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Estimated Life</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%; padding-left: 5.4pt">Computers, office furniture and equipment</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,939</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">—  </td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 11%; padding-left: 5.4pt; text-align: center"> 3 years</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Less: accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(458</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; padding-left: 5.4pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,481</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td></tr> </table>   Depreciation expense for nine months ended year ended May 31, 2018 was $458 compared to $0 for the year ended May 31, 2017. <table cellspacing="0" cellpadding="0" align="center" style="font: 12pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-indent: 9pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">May 31, 2018</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">May 31, 2017</td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Estimated Life</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%; padding-left: 5.4pt">Computers, office furniture and equipment</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,939</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">—  </td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 11%; padding-left: 5.4pt; text-align: center"> 3 years</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Less: accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(458</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; padding-left: 5.4pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,481</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td></tr> </table> On June 28, 2017, the Company executed an Asset Assignment Agreement (“Asset Assignment Agreement”) with Richard L. Chang Holding’s LLC (“Holdings LLC”), pursuant to which Holdings was issued 60,000,000 shares of the Company’s common stock and 2,000,000 restricted, non-convertible, non-dividend paying shares of the Company’s preferred stock with 1000 to 1 voting rights over shares of the Company’s common stock. In consideration of these share issuances, Holdings LLC has assigned to the Company all of its rights, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016, titled “COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. Additionally, the Company issued 15,000,000 common shares to Rich Pharmaceuticals, Inc. for use of the clinical trial under an Investigational New Drug Application. The Asset Assignment Agreement grants to Holdings LLC the right to require the Company to assign back to Holdings LLC the Patent Application and all related intellectual property in the even the Company does not raise a minimum of $1,000,000 in equity financing by June 28, 2018. In the event that Holdings LLC exercises this right of reversion, the 2,000,000 shares of Preferred Stock issued to Holdings LLC shall be assigned to Apica Investments Limited or its assignees. The common and preferred shares were valued at $77,000. Further cash compensation was given in the amount of $100,000 totaling an investment of $177,000. As of the filing of this report Holdings LLC has not exercised its right of reversion under the Asset Assignment Agreement.   During the year ended May 31, 2018, the Company analyzed its intangible asset for the purposes of impairment testing. Although management believes that the asset has real economic value, the expense of an independent valuation is not something the Company is interested in doing, whereby the cost of this analysis could exceed the value of the asset.  Conversely, the Company’s asset analysis is not objectively able to prove with any degree of certainty that it will ever see positive cashflow from its efforts.  This industry is very complicated, risky and unpredictable as it relates to ultimate drug approval or even the sale of the asset.  Due to a cost prohibitive asset valuation, uncertainty that the product can be brought to market or be sold and the fact that the that acquisition was from a related party the Company feels that is should fully impair the asset at this time.     The below chart analyzes the license value net of amortization:   <table cellspacing="0" cellpadding="0" align="center" style="font: 12pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">May 31, 2018</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Estimated Life</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 57%; padding-left: 5.4pt">Investment in license</td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">177,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; padding-left: 5.4pt; text-align: center"> 19.4 years</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Less amortization</td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(8,456</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; padding-left: 5.4pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Less impairment loss</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(168,544</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; padding-left: 5.4pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">License fee net amortization</td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td></tr> </table>   Amortization expense for the years ended May 31, 2018 and was $8,456 compared to $0 during the same period in the prior year.   <table cellspacing="0" cellpadding="0" align="center" style="font: 12pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">May 31, 2018</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Estimated Life</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 57%; padding-left: 5.4pt">Investment in license</td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">177,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; padding-left: 5.4pt; text-align: center"> 19.4 years</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Less amortization</td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">(8,456</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; padding-left: 5.4pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Less impairment loss</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(168,544</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; padding-left: 5.4pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">License fee net amortization</td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td></tr> </table> On January 27, 2017, the Company entered into a one-year convertible note with the face value of $100,000 bearing 8% interest. Funds were transmitted to the Company on August 1, 2017 at which time interest started to accrue. The Company was permitted to prepay this note in full or in part at any time without penalty. This note was to become convertible at the sole discretion of the note holder if full payment had not been made when the maturity date arrived. The holder of the note was entitled to a conversion price equal to seventy percent of the average trading price computed based on the previous 7 trading days prior to notice of conversion. These shares once converted may not be offered, sold, transferred or disposed of in any other way without prior written consent of the Company. On June 28, 2017, the Company executed an amendment to this note. The amendment provides that the total outstanding amounts under the promissory notes shall convert into shares of Company common stock at the conversion price of $.25 per share and the principal was converted on August 11, 2017. Accrued interest at conversion remains at $4,244.   On April 7, 2017, the Company entered into a one-year convertible note with the face value of $100,000 bearing 8% interest. The Company was able to prepay this note in full or in part at any time without penalty. This note was to become convertible at the sole discretion of the note holder if full payment had not been made when the maturity date arrived. The holder of the note was entitled to a conversion price equal to seventy percent of the average trading price computed based on the previous 7 trading days prior to notice of conversion. These shares once converted may not be offered, sold, transferred or disposed of in any other way without prior written consent of the Company. On June 28, 2017, the Company executed an amendment to this note. The amendment provides that the total outstanding amounts under the promissory notes shall convert into shares of Company common stock at the conversion price of $.25 per share and the principal was converted on August 11, 2017. Accrued interest at conversion remains at $2,800.   On June 28, 2017, the Company executed a Promissory Convertible Note with Bakken Development LLC in the principal amount of $400,000. The convertible note accrues interest at the rate of 10% per annum; is due and payable on or before June 28, 2019; may be converted at any time by the holder into shares of Company common stock at a conversion price of $.50 per share; and automatically converts into shares of Company common stock at a conversion price of $.50 per share upon the Company’s completion of a financing in the minimum amount of $5,000,000. At May 31, 2018, accrued interest on this note was $38,889.   On August 11, 2017, the Company issued 800,000 common shares to retire convertible promissory notes dated January 27, 2017 and April 7, 2017 with Bakken Development LLC in the aggregate principal amount of $200,000. As amended, the promissory notes convert into shares of Company common stock at the conversion price of $.25 per share. Accrued interest remains unconverted on these notes in the amount of $7,044.   On November 15, 2017, the Company entered into an Equity Financing Agreement and Registration Rights Agreement with GHS Investments LLC (“GHS”) pursuant to which GHS has agreed to purchase up to $7,000,000 in shares of Company common stock. (See NOTE 8). In connection with the Equity Financing Agreement, the Company executed a convertible promissory note in the principal amount of $15,000 as payment of the commitment fee for the Equity Financing Agreement. During the year ended May 31, 2018, the Company recorded this fee as interest expense. The amount was expensed upon issuance due to the fact the that no stock was sold and there is no certainty any stock will be sold under this agreement.   Upon any event of default, the note bears interests at the rate of 10%. This note has a maturity date of August 14, 2018. The Company may repay the note at any time before the maturity date. The amounts under the Note may be converted by GHS at any time after the maturity date or upon any event of default into shares of Company common stock at a conversion price equal to 80% of the average closing bid price during the 5-day period prior to conversion, subject to a floor price of $0.00005 per share. As a penalty of default, the principal increased by 50%, to $22,500 and the charge was recorded as interest expense and an increase to principal. As of May 31, 2018, this note had accrued interest of $277.   On November 17, 2017, the Company was advanced $15,000 under a promissory executed on December 19, 2017. Upon any event of default this note bears an interest rate of 10%. This note has a maturity date of August 19, 2018. The Company may repay the note at any time before the maturity date. Upon any event of default, the note holder may convert the note in its entirety into shares of Company common stock at a conversion price equal to 80% of the average closing bid price during the 5-day period prior to conversion, subject to a floor price of $0.00005 per share. As a penalty of default, the principal increased by 50%, to $22,500 and the charge was recorded as interest expense and an increase to principal. The foregoing is only a brief description of the material terms of the promissory note and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements which are hyperlinked as an exhibit to this Annual Report. As of May 31, 2018, this note had accrued interest of $277.   On July 18, 2018, the Company became aware that it was considered to be in default of both notes held by GHS. The Company has recorded interest and default related penalty amounts due to note-holder in the amount of $10,922 on its statement of operations during the year ended May 31, 2018. The event of default, as alleged by the noteholder, occurred April 16, 2018 when the Company failed its quarterly Form 10Q for its third fiscal quarter. The Company does not believe that an event of default occurred as of July 18, 2018 and is currently trying to resolve this issue with the note-holder. Subsequently, by virtue of not repaying the notes upon maturity the Company did trigger default on the above notes as of August 14, 2018 and August 19, 2018, respectively. Pursuant to the June 28, 2017 Asset Assignment Agreement with Holdings LLC and its assignment to the Company all of its rights, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016, titled “COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all related intellectual property, inventions and trade secrets, data, and clinical study results there is a major fund-raising requirement. The Company must raise a minimum of $1,000,000 in equity financing by June 28, 2018. The Asset Assignment Agreement grants to Holdings LCC the right to require the Company to assign back to Holdings LLC the Patent Application and all related intellectual property in the event the Company does not raise a minimum of $1,000,000 in equity financing by June 28, 2018. In the event that Holdings LLC exercises this right of reversion, the 2,000,000 shares of Preferred Stock issued to Holdings LLC shall be assigned to Apica Investments Limited or its assignees. As of May 31, 2018, the Company has not raised any capital towards the $1,000,000 requirement. As of the filing of this report Holdings LLC has not exercised its right of reversion under the Asset Assignment Agreement.   Upon the Company receiving a minimum of $1,000,000 in equity financing, Holdings shall assign to the Company all of its rights, title and interest to United States Utility Patent Application No USPTO Application No. 15/385,862 filed on December 20, 2016, titled” COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE” and all related intellectual property, inventions and trade secrets, data, and clinical study results.    The Company has entered into several consulting agreements where monthly fees commence upon achieving the attainment of raising $1,000,000 in equity financing and increase upon the Company successfully raising $5,000,000. The Company is currently not accruing any expense under these contracts and it not required to compensate these consultants beyond stock, cash and warrants already issued should one of both thresholds are not achieved. Any stock and warrants issued are immediately vested to the consultants. The following agreements have been entered between the Company and the following consultants:   On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Apica Investments Limited pursuant to which the Company agreed to issue 15,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5 year anniversary of the warrant; monthly fees of $1,800 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $4,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (as defined below), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.   On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Brighton Capital Ltd. pursuant to which the Company agreed to issue 6,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5 year anniversary of the warrant; a $50,000 payment upon execution of the agreement; monthly fees of $1,800 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $4,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (as defined below), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 4.99% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.   On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Rafferty Finance S.A. pursuant to which the Company agreed to issue 5,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5 year anniversary of the warrant; a $50,000 payment upon execution of the agreement; monthly fees of $5,400 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $13,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. Common shares under this contract were issued on July 19, 2017 and cash payment was made on June 30, 2017.   Mr. Treminio, the former Chief Executive Officer is an employee of Rafferty Finance S.A. “(Rafferty”). Under the Company’s consulting agreement with Rafferty, dated June 28, 2017. Mr. Treminio is required to secure additional capital, to preserve the rights of the patent under the Asset Assignment Agreement. Mr. Treminio shall, among other things, oversee, direct and manage all aspects investor & public or media relations, corporate finance as well as strategic planning, subordinate leadership, and operations of the Company. Mr. Treminio shall report directly to the Company’s CEO and /or Board of Directors (the “Board”). Effective with Mr. Treminio’s resignation, he shall not have any authority to execute and agreements or expend or access any Company funds or accounts without approval of the Chief Executive Officer. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (as defined below), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 4.99% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.   On June 28, 2017, the Company executed a Promissory Convertible Note with Bakken Development LLC in the principal amount of $400,000. The convertible note accrues interest at the rate of 10% per annum; is due and payable on or before June 28, 2019; may be converted at any time by the holder into shares of Company common stock at a conversion price of $.50 per share; and automatically converts into share of Company common stock at a conversion price of $.50 per share upon the Company’s completion of a financing in the minimum amount of $5,000,000.    On July 8, 2017, the Company entered into a consulting agreement with Imagic, LLC. Upon the commencement of this engagement, the consultant or its designees were issued shares of the Company in the amount of 12,000,000 common shares. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (as defined below), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.   On July 8, 2017, the Company entered into an employment agreement with Dr. McCoy Moretz. Upon the commencement of this agreement, the employee or its designees were issued shares of the Company in the amount of 8,000,000 common shares. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the Excepted Issuances (as defined below), if the Company issues any shares of Company common stock, the employee shall be granted additional shares of the Company’s common stock in an amount equal to 6% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding. Preferred and Common Stock   The Company has authorized 1,002,000,000 total shares of stock with a par value of $0.001 per share. These shares are designated by two classes; 1,000,000,000 common shares and 2,000,000 preferred shares.   Fiscal 2017   On January 26, 2017, the Company Amended its Articles to increase the Authorized share Capital of the Company from 75,000,000 to 1,000,000,000.   On January 18, 2017, Olaf Robak, the Company's President and CEO, executed a stock purchase agreement with First Legacy Management LLC, which acquired 4,000,000 shares of common stock, representing 80% ownership of the Company. First Legacy Management LLC paid $350,000 in cash. Simultaneous with this transaction, Mr. Olaf Robak resigned from his official positions as Director, CEO, CFO, President, Treasurer and Secretary of the Company, and on the same day the shareholders of the Corporation voted Mr. Antonio Treminio as Director & CEO.   Fiscal 2018   On July 26, 2017, the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation with the Secretary of State of Nevada. The Certificate of Amendment amends Article III of the Company’s Articles of Incorporation to authorize the issuance of up to two million (2,000,000) shares of Preferred Stock, par value $0.001 per share, which have the right to cast one thousand (1,000) votes for each share held of record on all matters submitted to a vote of holders of the Corporation’s common stock, including the election of directors, and all other matters required by law.    On August 11, 2017, the Company issued 800,000 common shares to retire convertible promissory notes dated January 27, 2017 and April 7, 2017 with Bakken Development LLC in the aggregate principal amount of $200,000. As amended, the promissory notes convert into shares of Company common stock at the conversion price of $.25 per share.   On November 15, 2017, the Company entered into an Equity Financing Agreement and Registration Rights Agreement with GHS pursuant to which GHS has agreed to purchase up to $7,000,000 in shares of Company common stock. The obligations of GHS to purchase the shares of Company common stock are subject to the conditions set forth in the Equity Financing Agreement, including, without limitation, the condition that a registration statement on Form S-1 registering the shares of Company common stock to be sold to GHS be filed with the Securities and Exchange Commission and become effective. The Company filed the Form S-1 registration statement on December 7, 2017. The Registration Rights Agreement provides that the Company shall use commercially reasonable efforts to file the registration statement within 30 days after the date of the Registration Rights Agreement and have the registration statement become effective within 90 days after it is filed. The purchase price of the shares of Company common stock will be equal to 80% of the market price (as determined in the Equity Financing Agreement) calculated at the time of purchase.   On February 13, 2018, the Company filed a registration withdrawal request with regards to S-1 registration statement filed on December 17, 2017. The Company may refile a Form S-1 registration in the future.   Under the terms of the equity financing agreement so long as this term is in effect and the $7,000,000 has not been fulfilled for a period of twenty-four months following the effective date the Company shall be permitted to PUT shares to the investor. The price of the Put shall be eighty (80%) percent of the “Market Price”, which is the lowest closing price of the Company’s Common Stock for ten (10) consecutive trading days preceding the Put Date. During the Open Period, the Company shall not be entitled to submit a Put Notice until after the previous Closing has been completed. There will be a minimum of ten (10) trading days between Put Notices.   In connection with the Equity Financing Agreement, the Company executed a convertible promissory note in the principal amount of $15,000 as payment of the commitment fee for the Equity Financing Agreement. The Note bear interests at the rate of 10% with a maturity date of August 14, 2018. (See NOTE 6)   During the year ended May 31, 2018, the Company issued 2,000,000 preferred shares, 75,000,000 commons shares in exchange for rights to certain intellectual property pursuant to an Asset Assignment Agreement. (See NOTE 1). The total investment was valued at $177,000.   Fiscal 2018   During the year ended May 31, 2018, the Company issued 50,000,000 stock warrants with a cashless exercise provision (“cashless warrants”) and 44,725,000 common shares to consultants under consulting agreements.   During the year ended May 31, 2018, the Company issued 10,000,000 stock warrants with a cashless exercise provision (“cashless warrants”) and 10,275,000 common shares to employees.   As of May 31, 2018, there were no outstanding stock options.   Warrants for common stock   On June 28, 2017, the Company issued 60,000,000 common stock warrants pursuant to an Asset Assignment Agreement with Richard L. Chang Holding’s LLC (“Holdings LLC”), pursuant to which Holdings. In consideration of these share issuances, Holdings LLC has assigned to the Company all of its rights, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016, titled “COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. Of the 60,000,000 common stock warrants issued, 50,000,000 warrants were issued to consultants and 10,000,000 were issued to an employee.   The following table summarizes warrant activity for the year ended May 31, 2018 and 2017:   <table cellspacing="0" cellpadding="0" align="center" style="font: 12pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Weighted</td> <td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Weighted</td> <td> </td> <td colspan="3" style="text-align: center">Average</td> <td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Average</td> <td> </td> <td colspan="3" style="text-align: center">Remaining</td> <td> </td> <td colspan="3" style="text-align: center">Aggregate</td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Exercise</td> <td> </td> <td colspan="3" style="text-align: center">Contractual</td> <td> </td> <td colspan="3" style="text-align: center">Intrinsic</td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Term</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Value</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Outstanding at May 31, 2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 1%"> </td> <td style="width: 44%; text-align: right">Granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">60,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">5.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—  </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td style="text-align: right">Expired</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right">Exercised</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Canceled</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Outstanding at May 31, 2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">60,000,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.25</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4.32</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> </table>   Warrants issued to consultants during the year ended May 31, 2018 to six different consultants were valued at $11,567. The warrants expire June 28, 2022. <table cellspacing="0" cellpadding="0" align="center" style="font: 12pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Weighted</td> <td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Weighted</td> <td> </td> <td colspan="3" style="text-align: center">Average</td> <td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Average</td> <td> </td> <td colspan="3" style="text-align: center">Remaining</td> <td> </td> <td colspan="3" style="text-align: center">Aggregate</td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Exercise</td> <td> </td> <td colspan="3" style="text-align: center">Contractual</td> <td> </td> <td colspan="3" style="text-align: center">Intrinsic</td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Term</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Value</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Outstanding at May 31, 2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 1%"> </td> <td style="width: 44%; text-align: right">Granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">60,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">5.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—  </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td style="text-align: right">Expired</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right">Exercised</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Canceled</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Outstanding at May 31, 2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">60,000,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.25</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4.32</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> </table> The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.   The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.    ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for the reporting period presented.   The Company did not record any income tax accrual for the period from inception to May 31, 2018. We expect to incur significant expenses in future periods which will offset any future net income.   As of May 31, 2018 and 2017, the Company had a net operating loss carry-forward of approximately $1,129,153 and $236,905. Losses that were incurred prior to December 31, 2017 may be used to offset future taxable income and expire ended in 2037. Losses incurred after December 31, 2017 may be used to offset future taxable income and do not expire. Because of the change in ownership that occurred on June 28, 2017, net operating loss carry forwards could be limited as to use in future years.   Deferred tax assets of $188,800 and $49,700 as of May 31, 2018 and 2017, respectively, resulting from net operating have been offset by a valuation allowance, due to the uncertainty of their realization. The change in the valuation allowance for the year ended May 31, 2018 and 2017 was $188,800 and $49,700, respectively.  As a result, there were no current or deferred tax provisions for the year ended May 31, 2018 and 2017.  There was no uncertain tax position taken since inception and the Company’s tax returns for the past three year remain open for examination. Hypgen is a United States, State of Nevada domiciled corporation for tax purposes. Deferred tax assets consist of the following:   <table cellspacing="0" cellpadding="0" align="center" style="font: 12pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">May 31, 2018</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">May 31, 2017</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; padding-left: 5.4pt">Net operating losses</td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">267,900</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">80,500</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Effect of TCJA recalculation</td> <td> </td> <td style="text-align: right">(79,100</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(30,800</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Change in valuation allowance</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(188,800</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(49,700</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Provision for income taxes</td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   On December 22, 2017, Public Law 115-97, informally referred to as the Tax Cuts and Jobs Act (“the TCJA”) was enacted into law. The TCJA provides for significant changes to the U.S. Internal Revenue Code of 1986, as amended, that impact corporate taxation requirements. Effective January 1, 2018, the federal tax rate for corporations was reduced from 35% to 21% for US taxable income and requires one-time re-measurement of deferred taxes to reflect their value at a lower tax rate of 21%. Also, mandatory repatriation of untaxed foreign earnings and profits will be taxed at 15.5% to the extent the underlying assets are liquid and 8% on the remaining balance. There are other provisions to the TCJA, such as conversion of a worldwide system to a territorial system, limitations on interest expense and domestic production deductions, which will be effective in fiscal 2019. The Company anticipates its effective tax rate to be 28% to 30%, excluding the one-time impact of the TCJA for fiscal 2018 primarily due to the reduction in the federal tax rate. The Company’s actual effective tax rate for fiscal 2018 may differ from management’s estimate due to changes in interpretations and assumptions. Due to the timing of enactment and complexity of the TCJA, the Company is unable to estimate a reasonable range of the one-time impact associated with mandatory repatriation, re-measurement of deferred taxes and other provisions of the TCJA. For tax losses that straddle tax years a blended rate is used. Since the Company is not expected to utilize any portion of net loss carryforward in the current tax year, the entire valuation is estimated using the newly enacted rates. A former director of the Company made the initial $100 deposit to on the bank account. In September 2015, the former director paid audit fees on behalf of the company in the amount of $650. These amounts, totaling $750, are being carried as a Related Party Loan which bears no interest and is payable on demand. The related party loan was forgiven effective January 18, 2017 under terms of change in control (SEE NOTE 1).   On January 27, 2017, the Company entered into a one-year convertible note from a related party with the face value of $100,000 bearing 8% interest (SEE NOTE 6). On June 28, 2017, the Company executed an amendment to this note.   On June 28, 2017, Richard L. Chang was appointed as a director of the Company. Mr. Richard Chang is the controlling interest of Holdings, LLC.   On June 28, 2017, Ben Chang, a senior management consultant, loaned the Company, $100 to initially fund the operating bank account of the Company. Mr. Ben Chang is also the Chief Executive Officer of Rich Pharmaceuticals, Inc.   On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Apica Investments Limited (“Apica”). Apica is controlled by Chew Chuan Tin who is the beneficial owner of greater than 10% of the outstanding shares of the Company through Bakken, Apica and First Legacy. Pursuant to that agreement the Company agreed issued 15,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5-year anniversary of the warrant; monthly fees of $1,800 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $4,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (SEE NOTE 7), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside “Excepted issuances”.   On June 28, 2017, the Company executed a one-year promissory convertible note with Bakken Development LLC (“Bakken”) in the principal amount of $400,000.  Bakken is a related party controlled by Chew Chuan Tin who is the beneficial owner of greater than 10% of the outstanding shares of the Company through Bakken, Apica and First Legacy (See NOTE 6).    On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Rafferty Finance S.A. (“Raferty”). Raferty is controlled by Antonio Treminio, former CEO of the Company. Pursuant to this agreement the Company agreed to issue 5,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5-year anniversary of the warrant; a $50,000 payment upon execution of the agreement; monthly fees of $5,400 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $13,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. Common shares under this contract were issued on July 19, 2017 and cash payment was made on June 30, 2017. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (SEE NOTE 7) if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 4.99% of the amount of the shares of Company common stock issued by the Company outside “Excepted issuances”. On July 8, 2017, the Company entered into a consulting agreement with Imagic, LLC (“Imagic”). Imagic, is wholly owned by Ben Chang, son of Director Richard L. Chang and Chief Executive Officer of Rich Pharmaceuticals, Inc. Upon the commencement of this engagement, the consultant or it’s designees were issued shares of the Company in the amount of 12,000,000 common shares. Imagic was also issued a warrant to acquire 10,000,000 shares of the Company at an exercise price of $0.25. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (SEE NOTE 7), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside “Excepted issuances”.   On September 14, 2017, the Company issued a promissory note in the amount of $6,000 to Imagic LLC. Imagic, is wholly owned by Ben Chang, son of Director Richard L. Chang and Chief Executive Officer of Rich Pharmaceuticals, Inc. The note matures on September 14, 2018 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $213.   On November 3, 2017, the Company issued a promissory note in the amount of $5,000 to one of its directors, Richard L. Chang Holdings. The note matures on November 3, 2018 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $143.   On January 11, 2018, the Company issued a promissory note in the amount of $5,000 to Imagic. The note matures on January 11, 2019 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $96.   On February 14, 2018, the Company issued a promissory note in the amount of $3,000 to Imagic. The note matures on February 14, 2019 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $44.   On March 6, 2018, the Company issued a promissory note in the amount of $2,375 to Imagic, a related party. The note matures on March 16, 2019 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $28.   On March 12, 2018, the Company issued a promissory note in the amount of $250 to Imagic, a related party. The note matures on March 12, 2019 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $3.   From time to time certain operational expenses of the Company are paid for by Ben Chang, a senior management consultant to the Company. These items are funded by Mr. Ben Chang or by its 100% owned entity Imagic. At June 30, 2018, the Company owed $4,814 and $8,191 to Mr. Ben Chang and Imagic, respectively.   As of June 30, 2018, the Company had three employment agreements. Under these agreements the Company accrued $170,250. Total annual compensation under these agreements is $233,000. As a stipulation to these agreements, the employees are to be compensated until such time that the board approves them as full-time employees. Prior to board approval the employees will be compensated for actual hours worked. <table cellspacing="0" cellpadding="0" align="center" style="font: 12pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">May 31, 2018</td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">May 31, 2017</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 55%; padding-left: 5.4pt">Net operating losses</td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">267,900</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">80,500</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt">Effect of TCJA recalculation</td> <td> </td> <td style="text-align: right">(79,100</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(30,800</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Change in valuation allowance</td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(188,800</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(49,700</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Provision for income taxes</td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> On June 1, 2018, the Company entered into a two-year consulting agreement with Richard L. Chang, Holdings LLC, a related party, an entity controlled by director, Richard L. Chang. Under the terms of the agreement the Company will compensate the consultant at the rate of $20,000 per monthly for services provided assisting in the area clinical operations, managing their patents and other intellectual property as well as assisting the Company in scientific and technical matters concerning manufacturing the drug, research and development.   On June 25, 2018, the Company issued a promissory note in the amount of $4,000 to Imagic, a related party. The note matures on June 25, 2019 and bears 5% interest.   On July 5, 2018, the Company entered into a Termination and Share Cancellation Agreement with Rafferty Finances, S.A. (“Rafferty”) pursuant to which the Company and Rafferty agreed to (i) the rescission and termination of the Consulting Agreement and Common Stock Purchase Warrant dated June 28, 2017 between the Company and Rafferty; (ii) the cancellation of 5,000,000 shares of Company common stock previously issued to Rafferty; (iii) Rafferty’s assistance to the Company to complete the cancellation of an additional 469,500 shares of Company common stock; and (iv) the issuance of 500,000 shares of Company common stock to Rafferty.   The foregoing is only a brief description of the material terms of the Termination and Share Cancellation Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreement which is filed as an exhibit to this Current Report. The issuance of the shares of common stock was made in reliance on the exemption provided by Section 4(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company’s reliance upon Section 4(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the securities was an accredited investor.   On July 5, 2018, the Company entered into a Termination and Share Cancellation Agreement with Brighton Capital Ltd. (“Brighton”) pursuant to which the Company and Brighton agreed to (i) the rescission and termination of the Consulting Agreement and Common Stock Purchase Warrant dated June 28, 2017 between the Company and Brighton; and (ii) the cancellation of 5,500,000 shares of Company common stock from the 6,000,000 shares of Company common stock previously issued to Brighton.  The foregoing is only a brief description of the material terms of the Termination and Share Cancellation Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder.   On July 9, 2018, the Company entered into a Cancellation Agreement with certain shareholders of the Company pursuant to which the Company and the shareholders agreed to the cancellation of a total of 74,999,998 shares.  In consideration of the share cancellations and provided that the Company raises a minimum of $1,000,000 in equity financing on or before June 28, 2019, Richard L. Chang Holding’s, LLC agreed to waive its right of reversion of the patent assets contributed to the Company pursuant to the Asset Assignment Agreement dated June 28, 2017.  The foregoing is only a brief description of the material terms of the Cancellation Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder.   On July 9, 2018, the Company entered into a Warrant Amendment Agreement with certain warrant holders of the Company pursuant to which the Company and the warrant holders agreed to amend warrants previously issued to them to reduce the number of warrants in the total amount of 10,000,000.  In consideration of the amendment and provided that the Company raises a minimum of $1,000,000 in equity financing on or before June 28, 2019, Richard L. Chang Holding’s, LLC agreed to waive its right of reversion of the patent assets contributed to the Company pursuant to the Asset Assignment Agreement dated June 28, 2017.  The foregoing is only a brief description of the material terms of the Warrant Amendment Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder.    On October 1, 2018, Imagic, LLC granted the Company a two-year extension to a 5%, one-year, promissory note dated September 14, 2017, having a principal amount of $6,000. Imagic, LLC, is wholly owned by Ben Chang, son of Director Richard L. Chang and Chief Executive Officer of Rich Pharmaceuticals, Inc.   On October 1, 2018, Richard L. Chang Holdings granted a two-year extension to a 5%, one-year, promissory note dated November 3, 2017, having a principal amount of $5,000. Richard L. Chang Holdings is controlled by director Richard L. Chang. The note matures on November 3, 2018 and bears 5% interest.  228 400000 270338 54000 -168544 750 228 5000000 5000000 135800000 -741586 -192905 12382 2000 5000 5000 135800 39000 3900 249767 -31618 -236905 -1129153 55000 55000 2000000 75000000 77000 2000 75000 800000 200000 800 199200 11567 11567 233000 0 177700 20000 false true true false EX-101.SCH 12 hpgn-20180531.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Changes in Shareholders Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - FIXED ASSETS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCK HOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - FIXED ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - STOCK HOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - DISCONTINUED OPERATIONS - Schedule of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - FIXED ASSETS - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - FIXED ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - INTANGIBLE ASSETS - Schedule of License Value Net of Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - STOCK HOLDERS' EQUITY - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - STOCK HOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Income Taxes - Schedule of Federal Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 hpgn-20180531_cal.xml XBRL CALCULATION FILE EX-101.DEF 14 hpgn-20180531_def.xml XBRL DEFINITION FILE EX-101.LAB 15 hpgn-20180531_lab.xml XBRL LABEL FILE Business Acquisition [Axis] Asset Assignment Agreement Related Party Transaction [Axis] Richard L. Chang Holdings LLC First Legacy Management LLC Disposal Group Classification [Axis] Statements Of Discontinued Operations Discontinued Operations, Held-for-sale Richard L. Chang, Director Finite-Lived Intangible Assets by Major Class [Axis] Patent Debt Instrument [Axis] Conv Note #1 Conv Note #2 Conv Note #1&2 Conv Note #3 Other Commitments [Axis] Apica Investments Ltd Brighton Capital Ltd Rafferty Finance S.A. Imagic, LLC Employment Agmt Range [Axis] Minimum Maximum Shareholders' Equity Class [Axis] SPA RCHA Consultant Consulting Agmts Potentially Dilutive Instruments Employees Prom Note #1 Prom Note #2 Conv Note #4 GHS Prom Note #3 Prom Note #4 Prom Note #5 Prom Note #6 Prom Note #7 Cancellation Agmt Warrant Amdt Agmt Equity Components [Axis] Preferred Stock Common Stock Additional Paid-In Capital Accumulated Gain (Loss) Employment Agmts Senior Consultant Senior Consultant Entity ConsultingAgmt #2 Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Shell Company Entity Small Business Emerging Growth Company Entity Ex Transition Period Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Prepaid Expenses License asset agreement, net Assets from discontinued operations Total current assets Property and equipment, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS EQUITY Current Liabilities: Accrued expenses and payables Loan payable - related party Bank overdraft Accrued salary, wages and taxes Liabilities from discontinued operations Accrued interest including related party Convertible Note Payable related party, current portion Convertible Notes Payable, net of discounts Total Current Liabilities Other Liabilities Convertible Note Payable related party, net of current portion Total Liabilities Commitments and contingencies STOCKHOLDERS DEFICIT Preferred stock: authorized 2,000,000; $0.001 par value; shares issued and outstanding at May 31, 2018 and no shares issued or authorized as of May 31, 2017 Common stock: authorized 1,000,000,000; $0.001 par value; 135,800,000 and 5,000,000 shares issued and outstanding at May 31, 2018 and May 31, 2017 Additional Paid in Capital Accumulated deficit Total Stockholders Deficit TOTAL LIABILITIES AND STOCKHOLDER DEFICIT Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Issued Preferred Stock, Par Value Preferred Stock, Shares Authorized Preferred Stock, Issued Income Statement [Abstract] Continuing Operations: Revenue Cost of Goods Sold: Product Purchases Gross Profit Operating Expenses: Depreciation and amortization Salary and payroll expense Professional fees Consulting fees General and administrative Total operating expense Net income (loss) from operations OTHER (INCOME) EXPENSE Interest expense and financing cost, net Loss on impairment Forgiveness of related party debt Total other (income) expense Discontinued Operations: Net income (loss) from discontinued operations Impairment loss on assets from discontinued operations Total Income (loss) from discontinued operations Net income before income tax provision Provision for income tax Net Loss Basic and diluted net loss per share of common stock: Continuing operations Discontinued Operations Basic and diluted Weighted average number of shares outstanding: Basic and diluted Statement [Table] Statement [Line Items] Beginning Balance, Shares Beginning Balance, Amount Common Shares issued for, Shares Common Shares issued for, Amount Stock Issued for Services, Shares Stock Issued for Services, Amount Asset Assignment Agreement, Shares Asset Assignment Agreement, Amount Stock Issued for Debt Conversion, Shares Stock Issued for Debt Conversion, Amount Warrants issued to consultants Net gain (loss) Ending Balance, Shares Ending Balance, Amount Statement of Cash Flows [Abstract] Operating activities: Net loss from continuing operations Net income (loss) from discontinuing operations Net Loss Adjustment to reconcile net loss to net cash provided by operations: Amortization and depreciation Loss on impairment on assets held in discontinued operations Non-cash interest charges - commitment fees Warrants and Shares issued to consultants for services Changes in assets and liabilities: Decrease (Increase) in prepaid and deposits Increase in accrued interest and finance charges Increase in accrued expenses and payables Net cash used in operating activities Investing activities: Cash paid for property and equipment Cash paid for license fee Net cash used in investing activities Financing activities: Proceeds from Convertible note payable - related party Bank overdraft Proceeds from convertible notes Proceeds from related party Proceeds from loans - related party Net cash provided by financing activities Net increase (decrease) in cash Cash, beginning of period Cash, end of period Supplemental disclosure of cash flow information: Cash paid during the period Taxes Cash paid during the period Interest Paid Non-cash activity: Common and Preferred shares issued to acquired license Convertible notes redeemed for common stock Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND BASIS OF PRESENTATION Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Discontinued Operations and Disposal Groups [Abstract] DISCONTINUED OPERATIONS Property, Plant and Equipment [Abstract] FIXED ASSETS Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS Debt Disclosure [Abstract] CONVERTIBLE NOTES PAYABLE Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Stockholders' Equity Attributable to Parent [Abstract] STOCK HOLDERS' EQUITY Income Tax Disclosure [Abstract] INCOME TAXES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Use of Estimates and Assumptions Cash and Cash Equivalents Property and Equipment and Depreciation Intangible Assets Impairment of Long-Lived Assets Net Loss Per Common Share Stock-Based Compensation Fair Value of Financial Instruments Reclassifications Revenue Recognition Research and Development Income Taxes Recent Accounting Pronouncements Subsequent Events Schedule of Discontinued Operations Schedule of Property and Equipment Schedule of License Value Net of Amortization Stock Holders Equity Schedule of Warrant Activity Income Taxes Schedule of Federal Income Tax State of incorporation Date of incorporation Date of Agreement Acquired common stock shares Ownership percentage Cash paid Net Income (loss) Common stock, shares issued Preferred stock, shares issued Common stock, voting right Equity financing, minimum raise Emerging growth company, description Cash Equivalents Estimated Useful Life Noncash Investment Investment in license Research and development expenses Stock Issuable Upon Conversion Warrants Issued Discontinued Operations: Revenue Product Purchases Gross Profit General and administrative Product development Depreciation Total operating expense Loss from discontinued operations Assets of discontinued operations Liabilities of discontinued operations Purchase Price Fixed Assets - Schedule Of Property And Equipment Computers, office furniture and equipment Less: accumulated depreciation Depreciation expense Amortization expense License asset agreement, net of amortization Date of Debt Instrument Term of Note Due Date Convertible Notes Payable Interest rate Accrued interest Debt instrument, convertible, conversion price Debt instrument, convertible, trading days Description of conversion price Date of Issuance Stock Issued, Shares Stock Issued, Value Equity Registration Rights, Shares to be Registered PPM, minimum raise Financing Due Date Proceeds from PPM, current PPM, maximum raise Stock to be Issued Warrants to be Issued Warrants, exercise price Warrant, term Cash Paid Monthly Consultant Fees Contract Expiration Description Additional Share Grant, Description Stock Holders Equity - Schedule Of Warrant Activity Beginning Balance, Issued Warrants Beginning Balance, Average Exercise Price Issued, Warrants Issued, Average Exercise Price Weighted Average, Term Aggregate Intrinsic Value Expired Warrants Expired Average Exercise Price Exercised, Warrants Exercised, Average Exercise Price Cancelled, Warrants Cancelled, Average Exercise Price Ending Balance, Issued Warrants Ending Balance, Average Exercise Price Stock Issued, Shares Payment for Stock Equity Interest Stock Issued, Employee Compensation Federal income tax benefit attributable to: Net operating losses Effect of TCJA recalculation Change in valuation allowance Provision for income taxes Effective Income Tax Rate, Federal Effective Income Tax Rate, State Net Operating Loss Carry-Forwards Deferred tax assets Related Party Loan Audit fees by related party Related party bank deposit Interest rate Debt Instrument Annual Compensation Common stock, shares cancelled Agreement Description Monthly Salary Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Gross Profit [Default Label] Operating Expenses Goodwill, Impairment Loss ForgivenessOfRelatedPartyDebt Nonoperating Income (Expense) Weighted Average Number of Shares Outstanding, Basic and Diluted Shares, Issued Payments to Acquire Intangible Assets Proceeds from (Repayments of) Bank Overdrafts Net Cash Provided by (Used in) Financing Activities Disposal Group, Including Discontinued Operation, Revenue Disposal Group, Including Discontinued Operation, Costs of Goods Sold Disposal Group, Including Discontinued Operation, General and Administrative Expense Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment WarrantsOutstanding WarrantsOutstandingAverageExercisePrice Stock Issued During Period, Shares, Acquisitions Federal Income Tax Expense (Benefit), Continuing Operations Debt Instrument, Interest Rate, Stated Percentage EX-101.PRE 16 hpgn-20180531_pre.xml XBRL PRESENTATION FILE XML 17 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1

Document and Entity Information - USD ($)
12 Months Ended

May 31, 2018

Oct. 01, 2018

Nov. 30, 2017

Document And Entity Information

Entity Registrant Name HypGen Inc

Entity Central Index Key 0001653629

Document Type 10-K

Document Period End Date May 31, 2018

Amendment Flag false

Current Fiscal Year End Date --05-31

Is Entity a Well-known Seasoned Issuer? No

Is Entity a Voluntary Filer? No

Is Entity's Reporting Status Current? Yes

Entity Filer Category Non-accelerated Filer

Entity Public Float $ 0

Entity Common Stock, Shares Outstanding 50,000,502

Document Fiscal Period Focus FY

Document Fiscal Year Focus 2019

Entity Shell Company false

Entity Small Business true

Emerging Growth Company true

Entity Ex Transition Period false

X

- References
No definition available.
+ Details

Name: HPGN_DocumentAndEntityInformationAbstract

Namespace Prefix: HPGN_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

XML 18 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1

Balance Sheets - USD ($)

May 31, 2018

May 31, 2017

CURRENT ASSETS

Cash $ 8,415

Prepaid Expenses 2,000

License asset agreement, net

Assets from discontinued operations 11,757

Total current assets 22,172

Property and equipment, net 1,481

TOTAL ASSETS 1,481 22,172

Current Liabilities:

Accrued expenses and payables 31,044 11,233

Loan payable - related party 34,630

Bank overdraft 228

Accrued salary, wages and taxes 185,152

Liabilities from discontinued operations

Accrued interest including related party 47,014 3,844

Convertible Note Payable related party, current portion 200,000

Convertible Notes Payable, net of discounts 45,000

Total Current Liabilities 343,067 215,077

Other Liabilities

Convertible Note Payable related party, net of current portion 400,000

Total Liabilities 743,067 215,077

Commitments and contingencies

STOCKHOLDERS DEFICIT

Preferred stock: authorized 2,000,000; $0.001 par value; shares issued and outstanding at May 31, 2018 and no shares issued or authorized as of May 31, 2017 2,000

Common stock: authorized 1,000,000,000; $0.001 par value; 135,800,000 and 5,000,000 shares issued and outstanding at May 31, 2018 and May 31, 2017 135,800 5,000

Additional Paid in Capital 249,767 39,000

Accumulated deficit (1,129,153) (236,905)

Total Stockholders Deficit (741,586) (192,905)

TOTAL LIABILITIES AND STOCKHOLDER DEFICIT $ 1,481 $ 22,172

X

- References
No definition available.
+ Details

Name: HPGN_LoansPayableCurrentRelatedParty

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedSalariesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230
+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_BankOverdrafts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.23)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_DueToRelatedPartiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedLicenseAgreementsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1

Balance Sheets (Parenthetical) - $ / shares

May 31, 2018

May 31, 2017

Jan. 26, 2017

Statement of Financial Position [Abstract]

Common Stock, Par Value $ 0.001 $ 0.001

Common Stock, Shares Authorized 1,000,000,000 1,000,000,000 75,000,000

Common Stock, Issued 135,800,000 5,000,000

Preferred Stock, Par Value $ 0.001 $ 0.001

Preferred Stock, Shares Authorized 2,000,000 0

Preferred Stock, Issued 2,000,000 0

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1

Statements of Operations - USD ($)
12 Months Ended

May 31, 2018

May 31, 2017

Continuing Operations:

Revenue

Cost of Goods Sold:

Product Purchases

Gross Profit

Operating Expenses:

Depreciation and amortization 8,914 910

Salary and payroll expense 204,269

Professional fees 111,444 56,000

Consulting fees 270,338 54,000

General and administrative 43,812 107,347

Total operating expense 638,777 218,257

Net income (loss) from operations (638,777) (218,257)

OTHER (INCOME) EXPENSE

Interest expense and financing cost, net 73,170 3,844

Loss on impairment 168,544

Forgiveness of related party debt (750)

Total other (income) expense 241,714 3,094

Discontinued Operations:

Net income (loss) from discontinued operations (76) 16,064

Impairment loss on assets from discontinued operations (11,681)

Total Income (loss) from discontinued operations (11,757) 16,064

Net income before income tax provision (892,248) (205,287)

Provision for income tax

Net Loss $ (892,248) $ (205,287)

Basic and diluted net loss per share of common stock:

Continuing operations $ (0.008) $ (0.044)

Discontinued Operations (0.000) 0.003

Basic and diluted $ (0.008) $ (0.041)

Weighted average number of shares outstanding:

Basic and diluted 117,603,288 5,000,000

X

- References
No definition available.
+ Details

Name: HPGN_ConsultingFees

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_ForgivenessOfRelatedPartyDebt

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostOfGoodsAndServicesSoldAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760
+ Details

Name: us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266
+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 220
-Section 45
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114873921&loc=SL114875236-224282

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228
+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net amount of operating interest income (expense).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.10)
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.2(a),(b),(c),(d))
-URI http://asc.fasb.org/extlink&oid=114873854&loc=SL114874292-224272

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section 45
-Paragraph 3
-Subparagraph (k)
-URI http://asc.fasb.org/extlink&oid=114873831&loc=SL114874205-224268
+ Details

Name: us-gaap_ProfessionalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(4))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_SalariesAndWages

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 21 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1

Statements of Changes in Shareholders Deficit - USD ($)

Preferred Stock

Common Stock

Additional Paid-In Capital

Accumulated Gain (Loss)

Total

Beginning Balance, Shares at May. 31, 2016 5,000,000

Beginning Balance, Amount at May. 31, 2016 $ 5,000 $ 39,000 $ (31,618) $ 12,382

Net gain (loss) (205,287) (205,287)

Ending Balance, Shares at May. 31, 2017 5,000,000

Ending Balance, Amount at May. 31, 2017 $ 5,000 3,900 (236,905) (192,905)

Stock Issued for Services, Shares 55,000,000

Stock Issued for Services, Amount $ 55,000 55,000

Asset Assignment Agreement, Shares 2,000,000 75,000,000

Asset Assignment Agreement, Amount $ 2,000 $ 75,000 77,000

Stock Issued for Debt Conversion, Shares 800,000

Stock Issued for Debt Conversion, Amount $ 800 199,200 200,000

Warrants issued to consultants 11,567 11,567

Net gain (loss) (892,248) (892,248)

Ending Balance, Shares at May. 31, 2018 135,800,000

Ending Balance, Amount at May. 31, 2018 $ 2,000 $ 135,800 $ 249,767 $ (1,129,153) $ (741,586)

X

- References
No definition available.
+ Details

Name: HPGN_WarrantsIssuedToConsultants

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 22 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1

Statements of Cash Flows - USD ($)
12 Months Ended

May 31, 2018

May 31, 2017

Operating activities:

Net loss from continuing operations $ (880,491) $ (221,351)

Net income (loss) from discontinuing operations (11,757) 16,064

Net Loss (892,248) (205,287)

Adjustment to reconcile net loss to net cash provided by operations:

Amortization and depreciation 8,990 910

Loss on impairment 168,544

Loss on impairment on assets held in discontinued operations 11,681

Non-cash interest charges - commitment fees 30,000 3,844

Forgiveness of related party debt (750)

Warrants and Shares issued to consultants for services 66,567

Changes in assets and liabilities:

Decrease (Increase) in prepaid and deposits 2,000 (2,000)

Increase in accrued interest and finance charges 43,170

Increase in accrued expenses and payables 204,962 11,233

Net cash used in operating activities (356,334) (192,050)

Investing activities:

Cash paid for property and equipment (1,939)

Cash paid for license fee (100,000)

Net cash used in investing activities (101,939)

Financing activities:

Proceeds from Convertible note payable - related party 400,000 200,000

Bank overdraft 228

Proceeds from convertible notes 15,000

Proceeds from related party 4,814

Proceeds from loans - related party 29,816

Net cash provided by financing activities 449,858 200,000

Net increase (decrease) in cash (8,415) 7,950

Cash, beginning of period 8,415 465

Cash, end of period 8,415

Supplemental disclosure of cash flow information:

Cash paid during the period Taxes

Cash paid during the period Interest Paid

Non-cash activity:

Common and Preferred shares issued to acquired license 77,000

Convertible notes redeemed for common stock $ 200,000

X

- References
No definition available.
+ Details

Name: HPGN_CommonAndPreferredSharesIssuedToAcquiredLicense

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_ConvertibleNotesRedeemedForCommonStock

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_ForgivenessOfRelatedPartyDebt

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_ProceedsFromConvertibleDebtRelatedParty

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266
+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 220
-Section 45
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114873921&loc=SL114875236-224282

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228
+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of income (loss) from continuing operations attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.13)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3095-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 230
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784
+ Details

Name: us-gaap_IncreaseDecreaseInDeposits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDueToRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586
+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or outflow from the excess drawing from an existing cash balance, which will be honored by the bank but reflected as a loan to the drawer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 9
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3098-108585
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfBankOverdrafts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1

ORGANIZATION AND BASIS OF PRESENTATION
12 Months Ended

May 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION AND BASIS OF PRESENTATION
Nature of Business

HYPGEN INC. (formerly MEGA BRIDGE INC) (the “Company”) is a for profit corporation established under the corporate laws of the State of Nevada on March 26, 2015.

We are an emerging growth company as defined in Section 2(a)(19) of the Securities Act. We will continue to be an emerging growth company until: (i) the last day of our fiscal year during which we had total annual gross revenues of $1,000,000,000 or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (iii) the date on which we have, during the previous 3-year period, issued more than $1,000,000,000 in non-convertible debt; or (iv) the date on which we are deemed to be a large accelerated filer, as defined in Section 12b-2 of the Exchange Act.

As an emerging growth company, we are exempt from:

Section 14A (a) and (b) of the Exchange Act, which requires companies to hold stockholder advisory votes on executive compensation and golden parachute compensation;

The requirement to provide in any registration statement periodic report or other report to be filed with the Securities and Exchange Commission, certain modified executive compensation disclosure under Item 402 of Regulation S-K or selected financial data under Item 301 of Regulation S-K for any period before the earliest audited period presented in our initial registration statement;

Compliance with new or revised accounting standards until those standards are applicable to private companies;

The requirement under Section 404(b) of the Sarbanes-Oxley Act of 2002 to provide auditor attestation of our internal controls and procedures; and

Any Public Company Accounting Oversight Board ("PCAOB") rules regarding mandatory audit firm rotation, or an expanded auditor report and any other PCAOB rules subsequently adopted, unless the Securities and Exchange Commission determines the new rules are necessary for protecting the public.

We have not elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the Jumpstart Our Business Startups Act.

Unless the context otherwise requires, all references to “we,” “us,” “our” or the “Company” are to HYPGEN INC.

On January 18th, 2017, Olaf Robak, the Company's President and CEO, executed a stock purchase agreement with First Legacy Management LLC, which acquired 4,000,000 shares of common stock, representing 80% ownership of the Company. First Legacy Management LLC paid $350,000 in cash. Simultaneous with this transaction, Mr. Olaf Robak resigned from his official positions as Director, CEO, CFO, President, Treasurer and Secretary of the Company, and on the same day the shareholders of the Corporation voted Mr. Antonio Treminio as Director & CEO (Mr. Treminio subsequently resigned as a director and CEO effective as of June 28, 2017).

On March 9, 2017, FINRA notified the Company that request for symbol change was approved. Effective March 13, 2017, the Company’s common stock began trading under the symbol MGBR.

On June 28, 2017, the Company executed an Asset Assignment Agreement (“Asset Assignment Agreement”) with Richard L. Chang Holding’s LLC (“Holdings LLC”), pursuant to which Holdings was issued 60,000,000 shares of the Company’s common stock and 2,000,000 restricted, non-convertible, non-dividend paying shares of the Company’s preferred stock with 1000 to 1 voting rights over shares of the Company’s common stock. In consideration of these share issuances, Holdings LLC has assigned to the Company all of its rights, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016, titled “COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. Additionally, the Company issued 15,000,000 common shares to Rich Pharmaceuticals, Inc. for use of the clinical trial under an Investigational New Drug Application. Additionally, pursuant to the terms of the Asset Assignment Agreement, upon the Company receiving a minimum of $1,000,000 in equity financing, Holdings shall assign to the Company all of its rights, title and interest to United States Utility Patent Application No USPTO Application No. 15/385,862 filed on December 20, 2016, titled ”COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. The Asset Assignment Agreement granted to Holdings LLC the right to require the Company to assign back to Holdings LLC the Patent Application and all related intellectual property in the event the Company does not raise a minimum of $1,000,000 in equity financing by June 28, 2018. In the event that Holdings LLC exercises this right of reversion, the 2,000,000 shares of Preferred Stock issued to Holdings LLC shall be assigned to Apica Investments Limited or its assignees. As of May 31, 2018, the Company has not raised any capital towards the $1,000,000 requirement. As of the filing of this report Holdings LLC has not exercised its right of reversion under the Asset Assignment Agreement.

On June 28, 2017, the Company discontinued operations of its office products sales and distribution segment.

On July 11, 2017, the Board of Directors of the Company appointed Dr. Moretz as the Chief Financial Officer of the Company.

On July 18, 2017, we filed Articles of Merger with the Secretary of State of Nevada in order to effectuate a merger with our wholly-owned subsidiary, HypGen Inc. Shareholder approval was not required under Section 92A.180 of the Nevada Revised Statutes. As part of the merger, our board of directors authorized a change in our name to “HypGen Inc” and our Articles of Incorporation have been amended to reflect this name change.

On August 1, 2017, the Company changed its name to HypGen Inc. to more accurately reflect the Company’s new strategic direction as it focuses its efforts on developing therapeutic treatment options for Parkinson's disease. Effective with the name change the Company’s trading symbol was changed to HPGN with OTC Markets.

Going Concern

As indicated in the accompanying financial statements, the Company has incurred net losses of $892,248 and $205,287 for the years ended May 31, 2018 and 2017, respectively. Management’s plans include the raising of capital through related and third parties to fund future operations of pushing its Parkinson’s disease drug through phase II drug trials in order to obtain approval from the food and drug administration (“FDA”). Failure to raise adequate capital during the testing and approval seeking process may force the Company to curtail or cease operations. Additionally, even if the Company raises sufficient capital to support its operating expenses, there can be no assurances that FDA approval will be granted whereby no revenue from target project will ever be recognized to enable it to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about the Company’s ability to continue as a going concern. However, the accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1

SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended

May 31, 2018

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates and Assumptions

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. At May 31, 2018 and 2017, the Company had no cash equivalents.

Property and Equipment and Depreciation

Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.

Intangible Assets

Intangible assets consisted of a licensing fee under an asset assignment agreement for a patent which was granted November 10, 2016. At the time of the assignment on June 28, 2017, the patent had a remaining life of 19 years and 135 days, which the Company had determined to be the remaining useful life of the patent whereby total investment was to be amortized on a straight-line basis over this period. In exchange for the rights to the intellectual property the Company paid $100,000 in cash, issued 2,000,000 preferred shares and 75,000,000 commons shares. The total investment was valued at $177,000.

During the year ended May 31, 2018, the Company analyzed its intangible asset for the purposes of impairment testing. Although management believes that the asset has real economic value, the expense of an independent valuation is not something the Company is interested in doing, whereby the cost of this analysis could exceed the value of the asset. Conversely, the Company’s asset analysis is not objectively able to prove with any degree of certainty that it will ever see positive cashflow from its efforts. This industry is very complicated, risky and unpredictable as it relates to ultimate drug approval or even the sale of the asset. Due to a cost prohibitive asset valuation, uncertainty that the product can be brought to market or be sold and the fact that the that acquisition was from a related party the Company feels that is should fully impair the asset at this time.

Impairment of Long-Lived Assets

Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

Net Loss Per Common Share

The Company computes per share amounts in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 260 Earnings per Share (“EPS”) which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to Common Stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of Common Stock and Common Stock equivalents outstanding during the periods; however, potential common shares are excluded for period in which the Company incurs losses, as their effect is anti-dilutive. For the years ended May 31, 2018 and 2017 the basic and fully diluted earnings per share were the same as the Company had a loss in each of these periods. At May 31, 2018, the Company had potentially dilutive instruments in the form of 60,000,000 common stock warrants with a cashless exercise provision outstanding as well as 1,965,954 common shares issuable upon the conversion of outstanding principal and interest on convertible notes.

Stock-Based Compensation

The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted on the grant date as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in stockholders’ equity/(deficit) over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.

The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value on the grant date of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services over the term of the related services.

Fair Value of Financial Instruments

ASC 825, “Disclosures about Fair Value of Financial Instruments”, requires disclosure of fair value information about financial instruments in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value hierarchy to classify the inputs used in measuring fair value as follows:

· Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

· Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

· Level 3-Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2018.

The respective carrying values of certain on-balance-sheet financial instruments approximate their fair values. These financial instruments include cash, accrued liabilities and notes payable. Fair values were assumed to approximate carrying values for these financial instruments since they are short term in nature and their carrying amounts approximate fair value. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet date.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current period presentation. The reclassifications had no effect on the net loss or cash flows of the Company.

Revenue Recognition

The Company recognizes revenues in accordance with FASB ASC Topic 605, “Revenue Recognition”, and with the guidelines of the Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104 “Revenue Recognition”.

Under SAB 104, four conditions must be met before revenue can be recognized: (i) there is persuasive evidence that an arrangement exists, (ii) delivery has occurred or service has been rendered, (iii) the price is fixed or determinable, and (iv) collection is reasonably assured.

Customers of our discontinued operation paid for their product at the time we are advised by the manufacturer/distributor that the product is ready for shipment or pick-up. The Company recognizes revenue when the pre-paid product has been delivered to, or picked up by, the customer. In the event there is a significant delay between the date the customer pre-pays for the product and the delivery or pick-up of the product, revenue would be deferred until the customer accepts delivery of the product. Under our current operations we do not expect to recognize revenue until we receive FDA approval to sell our Parkinson’s disease drug commercially.

Research and Development

The Company expenses research and development costs as incurred. Research and development costs were $0 for the years ended May 31, 2018 and 2017. The expense in the prior year is reflected in discontinued operations. The Company anticipates substantial expense as it conducts phase II trials and tries to move its product to market along with the development of its other products. The Company will also evaluate products and technologies in the medical products space, with its main focus on Parkinson’s Disease. As the Company continues to develop its products and relationships in these areas’ resultant expenses for trademark filings, license agreements, product development and design materials will be expensed as research and development. Some costs may be accumulated for subsidiaries prior to formation of entities.



Income Taxes

We will use the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for the reporting period presented.

The Company did not record any income tax accrual for the period from inception to May 31, 2018. We expect to incur significant expenses in future periods which will offset any net profit.

Recent Accounting Pronouncements

In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” which addresses accounting for issuance of all share-based payments on the same accounting model. Previously, accounting for share-based payments to employees was covered by ASC Topic 718 while accounting for such payments to non-employees was covered by ASC Subtopic 505-50. As it considered recently issued updates to ASC 718, the FASB, as part of its simplification initiatives, decided to replace ASC Subtopic 505-50 with Topic 718 as the guidance for non-employee share-based awards. Under this new guidance, both sets of awards, for employees and non-employees, will essentially follow the same model, with small variations related to determining the term assumption when valuing a non-employee award as well as a different expense attribution model for non-employee awards as opposed to employee awards. The ASU is effective for public business entities beginning in 2019 calendar years and one year later for non-public business entities.

In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815),” which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The Company is currently in the process of assessing the impact the adoption of this guidance will have on the Company’s financial statements.

Subsequent Events

In accordance with ASC 855 “Subsequent Events” the Company evaluated subsequent events after the balance sheet date through the date of issuance.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1

DISCONTINUED OPERATIONS
12 Months Ended

May 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

DISCONTINUED OPERATIONS
On June 28, 2017, the Company discontinued operations of its office products sales and distribution segment. Depreciation expense as it appears on the Statement of Cash Flows for the years ended months ended May 31, 2018 and 2017 was $76 and $910, respectively. Depreciation on the statement of operations for the years ended May 31, 2018 is recorded as Income (Loss) from Discontinued Operations.

The statement of operations was restated to reflect the reclassification of the discontinued operations.

HYPGEN INC
STATEMENTS OF DISCONTINUED OPERATIONS

For the years ended May 31,

2018 2017

Discontinued Operations:

Revenue $ — $ 73,171

Cost of Goods Sold:

Product Purchases — 53,197

Gross Profit — 19,974

Operating Expenses:

General and administrative — 3,000

Product development — —

Depreciation 76 910

Impairment loss on assets from discontinued operations 11,681 —

Total operating expense 11,757 3,910

Net income (loss) from discontinued operations $ (11,757 ) $ 16,064



On May 25, 2015 the Company purchased a small office located at 5 Garbary in Gdansk Poland. The purchase price was $13,653. The Company utilized this space as its primary office for the former discontinued operations. Assets from discontinued operations are reflected net of accumulated depreciation. As of June 28, 2017, the building, classified as assets of discontinued operations, is no longer being depreciated due to the fact that it is no longer in service.

As of May 31, 2018, the Company has fully impaired the remaining net value of its former office which was held as an asset from discontinued operations. The Company no longer has access or control over this asset and believes that there is no substantial net economic value to this asset and any cost of legal disposal could easily exceed its net book value.

May 31, 2018 May 31, 2017

Assets of discontinued operations $ — $ 11,757

Liabilities of discontinued operations — —



X

- References
No definition available.
+ Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2122178
+ Details

Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1

FIXED ASSETS
12 Months Ended

May 31, 2018

Property, Plant and Equipment [Abstract]

FIXED ASSETS
The Company’s property and equipment is as follows:

May 31, 2018 May 31, 2017 Estimated Life

Computers, office furniture and equipment $ 1,939 $ — 3 years

Less: accumulated depreciation $ (458 ) $ —

Net $ 1,481 $ —

Depreciation expense for nine months ended year ended May 31, 2018 was $458 compared to $0 for the year ended May 31, 2017.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1

INTANGIBLE ASSETS
12 Months Ended

May 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS
On June 28, 2017, the Company executed an Asset Assignment Agreement (“Asset Assignment Agreement”) with Richard L. Chang Holding’s LLC (“Holdings LLC”), pursuant to which Holdings was issued 60,000,000 shares of the Company’s common stock and 2,000,000 restricted, non-convertible, non-dividend paying shares of the Company’s preferred stock with 1000 to 1 voting rights over shares of the Company’s common stock. In consideration of these share issuances, Holdings LLC has assigned to the Company all of its rights, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016, titled “COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. Additionally, the Company issued 15,000,000 common shares to Rich Pharmaceuticals, Inc. for use of the clinical trial under an Investigational New Drug Application. The Asset Assignment Agreement grants to Holdings LLC the right to require the Company to assign back to Holdings LLC the Patent Application and all related intellectual property in the even the Company does not raise a minimum of $1,000,000 in equity financing by June 28, 2018. In the event that Holdings LLC exercises this right of reversion, the 2,000,000 shares of Preferred Stock issued to Holdings LLC shall be assigned to Apica Investments Limited or its assignees. The common and preferred shares were valued at $77,000. Further cash compensation was given in the amount of $100,000 totaling an investment of $177,000. As of the filing of this report Holdings LLC has not exercised its right of reversion under the Asset Assignment Agreement.

During the year ended May 31, 2018, the Company analyzed its intangible asset for the purposes of impairment testing. Although management believes that the asset has real economic value, the expense of an independent valuation is not something the Company is interested in doing, whereby the cost of this analysis could exceed the value of the asset. Conversely, the Company’s asset analysis is not objectively able to prove with any degree of certainty that it will ever see positive cashflow from its efforts. This industry is very complicated, risky and unpredictable as it relates to ultimate drug approval or even the sale of the asset. Due to a cost prohibitive asset valuation, uncertainty that the product can be brought to market or be sold and the fact that the that acquisition was from a related party the Company feels that is should fully impair the asset at this time.

The below chart analyzes the license value net of amortization:

May 31, 2018 Estimated Life

Investment in license $ 177,000 19.4 years

Less amortization $ (8,456 )

Less impairment loss (168,544 )

License fee net amortization $ —

Amortization expense for the years ended May 31, 2018 and was $8,456 compared to $0 during the same period in the prior year.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1

CONVERTIBLE NOTES PAYABLE
12 Months Ended

May 31, 2018

Debt Disclosure [Abstract]

CONVERTIBLE NOTES PAYABLE
On January 27, 2017, the Company entered into a one-year convertible note with the face value of $100,000 bearing 8% interest. Funds were transmitted to the Company on August 1, 2017 at which time interest started to accrue. The Company was permitted to prepay this note in full or in part at any time without penalty. This note was to become convertible at the sole discretion of the note holder if full payment had not been made when the maturity date arrived. The holder of the note was entitled to a conversion price equal to seventy percent of the average trading price computed based on the previous 7 trading days prior to notice of conversion. These shares once converted may not be offered, sold, transferred or disposed of in any other way without prior written consent of the Company. On June 28, 2017, the Company executed an amendment to this note. The amendment provides that the total outstanding amounts under the promissory notes shall convert into shares of Company common stock at the conversion price of $.25 per share and the principal was converted on August 11, 2017. Accrued interest at conversion remains at $4,244.

On April 7, 2017, the Company entered into a one-year convertible note with the face value of $100,000 bearing 8% interest. The Company was able to prepay this note in full or in part at any time without penalty. This note was to become convertible at the sole discretion of the note holder if full payment had not been made when the maturity date arrived. The holder of the note was entitled to a conversion price equal to seventy percent of the average trading price computed based on the previous 7 trading days prior to notice of conversion. These shares once converted may not be offered, sold, transferred or disposed of in any other way without prior written consent of the Company. On June 28, 2017, the Company executed an amendment to this note. The amendment provides that the total outstanding amounts under the promissory notes shall convert into shares of Company common stock at the conversion price of $.25 per share and the principal was converted on August 11, 2017. Accrued interest at conversion remains at $2,800.

On June 28, 2017, the Company executed a Promissory Convertible Note with Bakken Development LLC in the principal amount of $400,000. The convertible note accrues interest at the rate of 10% per annum; is due and payable on or before June 28, 2019; may be converted at any time by the holder into shares of Company common stock at a conversion price of $.50 per share; and automatically converts into shares of Company common stock at a conversion price of $.50 per share upon the Company’s completion of a financing in the minimum amount of $5,000,000. At May 31, 2018, accrued interest on this note was $38,889.

On August 11, 2017, the Company issued 800,000 common shares to retire convertible promissory notes dated January 27, 2017 and April 7, 2017 with Bakken Development LLC in the aggregate principal amount of $200,000. As amended, the promissory notes convert into shares of Company common stock at the conversion price of $.25 per share. Accrued interest remains unconverted on these notes in the amount of $7,044.

On November 15, 2017, the Company entered into an Equity Financing Agreement and Registration Rights Agreement with GHS Investments LLC (“GHS”) pursuant to which GHS has agreed to purchase up to $7,000,000 in shares of Company common stock. (See NOTE 8). In connection with the Equity Financing Agreement, the Company executed a convertible promissory note in the principal amount of $15,000 as payment of the commitment fee for the Equity Financing Agreement. During the year ended May 31, 2018, the Company recorded this fee as interest expense. The amount was expensed upon issuance due to the fact the that no stock was sold and there is no certainty any stock will be sold under this agreement.

Upon any event of default, the note bears interests at the rate of 10%. This note has a maturity date of August 14, 2018. The Company may repay the note at any time before the maturity date. The amounts under the Note may be converted by GHS at any time after the maturity date or upon any event of default into shares of Company common stock at a conversion price equal to 80% of the average closing bid price during the 5-day period prior to conversion, subject to a floor price of $0.00005 per share. As a penalty of default, the principal increased by 50%, to $22,500 and the charge was recorded as interest expense and an increase to principal. As of May 31, 2018, this note had accrued interest of $277.

On November 17, 2017, the Company was advanced $15,000 under a promissory executed on December 19, 2017. Upon any event of default this note bears an interest rate of 10%. This note has a maturity date of August 19, 2018. The Company may repay the note at any time before the maturity date. Upon any event of default, the note holder may convert the note in its entirety into shares of Company common stock at a conversion price equal to 80% of the average closing bid price during the 5-day period prior to conversion, subject to a floor price of $0.00005 per share. As a penalty of default, the principal increased by 50%, to $22,500 and the charge was recorded as interest expense and an increase to principal. The foregoing is only a brief description of the material terms of the promissory note and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements which are hyperlinked as an exhibit to this Annual Report. As of May 31, 2018, this note had accrued interest of $277.

On July 18, 2018, the Company became aware that it was considered to be in default of both notes held by GHS. The Company has recorded interest and default related penalty amounts due to note-holder in the amount of $10,922 on its statement of operations during the year ended May 31, 2018. The event of default, as alleged by the noteholder, occurred April 16, 2018 when the Company failed its quarterly Form 10Q for its third fiscal quarter. The Company does not believe that an event of default occurred as of July 18, 2018 and is currently trying to resolve this issue with the note-holder. Subsequently, by virtue of not repaying the notes upon maturity the Company did trigger default on the above notes as of August 14, 2018 and August 19, 2018, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for mortgage notes payable.
+ References
No definition available.
+ Details

Name: us-gaap_MortgageNotesPayableDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1

COMMITMENTS AND CONTINGENCIES
12 Months Ended

May 31, 2018

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES
Pursuant to the June 28, 2017 Asset Assignment Agreement with Holdings LLC and its assignment to the Company all of its rights, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016, titled “COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all related intellectual property, inventions and trade secrets, data, and clinical study results there is a major fund-raising requirement. The Company must raise a minimum of $1,000,000 in equity financing by June 28, 2018. The Asset Assignment Agreement grants to Holdings LCC the right to require the Company to assign back to Holdings LLC the Patent Application and all related intellectual property in the event the Company does not raise a minimum of $1,000,000 in equity financing by June 28, 2018. In the event that Holdings LLC exercises this right of reversion, the 2,000,000 shares of Preferred Stock issued to Holdings LLC shall be assigned to Apica Investments Limited or its assignees. As of May 31, 2018, the Company has not raised any capital towards the $1,000,000 requirement. As of the filing of this report Holdings LLC has not exercised its right of reversion under the Asset Assignment Agreement.

Upon the Company receiving a minimum of $1,000,000 in equity financing, Holdings shall assign to the Company all of its rights, title and interest to United States Utility Patent Application No USPTO Application No. 15/385,862 filed on December 20, 2016, titled” COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE” and all related intellectual property, inventions and trade secrets, data, and clinical study results.

The Company has entered into several consulting agreements where monthly fees commence upon achieving the attainment of raising $1,000,000 in equity financing and increase upon the Company successfully raising $5,000,000. The Company is currently not accruing any expense under these contracts and it not required to compensate these consultants beyond stock, cash and warrants already issued should one of both thresholds are not achieved. Any stock and warrants issued are immediately vested to the consultants. The following agreements have been entered between the Company and the following consultants:

On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Apica Investments Limited pursuant to which the Company agreed to issue 15,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5 year anniversary of the warrant; monthly fees of $1,800 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $4,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (as defined below), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.

On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Brighton Capital Ltd. pursuant to which the Company agreed to issue 6,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5 year anniversary of the warrant; a $50,000 payment upon execution of the agreement; monthly fees of $1,800 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $4,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (as defined below), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 4.99% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.

On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Rafferty Finance S.A. pursuant to which the Company agreed to issue 5,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5 year anniversary of the warrant; a $50,000 payment upon execution of the agreement; monthly fees of $5,400 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $13,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. Common shares under this contract were issued on July 19, 2017 and cash payment was made on June 30, 2017.

Mr. Treminio, the former Chief Executive Officer is an employee of Rafferty Finance S.A. “(Rafferty”). Under the Company’s consulting agreement with Rafferty, dated June 28, 2017. Mr. Treminio is required to secure additional capital, to preserve the rights of the patent under the Asset Assignment Agreement. Mr. Treminio shall, among other things, oversee, direct and manage all aspects investor & public or media relations, corporate finance as well as strategic planning, subordinate leadership, and operations of the Company. Mr. Treminio shall report directly to the Company’s CEO and /or Board of Directors (the “Board”). Effective with Mr. Treminio’s resignation, he shall not have any authority to execute and agreements or expend or access any Company funds or accounts without approval of the Chief Executive Officer. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (as defined below), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 4.99% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.

On June 28, 2017, the Company executed a Promissory Convertible Note with Bakken Development LLC in the principal amount of $400,000. The convertible note accrues interest at the rate of 10% per annum; is due and payable on or before June 28, 2019; may be converted at any time by the holder into shares of Company common stock at a conversion price of $.50 per share; and automatically converts into share of Company common stock at a conversion price of $.50 per share upon the Company’s completion of a financing in the minimum amount of $5,000,000.



On July 8, 2017, the Company entered into a consulting agreement with Imagic, LLC. Upon the commencement of this engagement, the consultant or its designees were issued shares of the Company in the amount of 12,000,000 common shares. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (as defined below), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.

On July 8, 2017, the Company entered into an employment agreement with Dr. McCoy Moretz. Upon the commencement of this agreement, the employee or its designees were issued shares of the Company in the amount of 8,000,000 common shares. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the Excepted Issuances (as defined below), if the Company issues any shares of Company common stock, the employee shall be granted additional shares of the Company’s common stock in an amount equal to 6% of the amount of the shares of Company common stock issued by the Company outside the following “Excepted issuances”: (i) shares of Company common stock in connection with a debt or equity financing; (ii) shares of common stock reserved under the Company’s equity incentive/stock option plan; (iii) the shares, warrants and shares to be issued upon exercise of the warrants and conversion of the convertible notes described in the Assignment Agreement dated June 28, 2017 between the Company and Richard L. Chang’s Holdings, LLC. Upon the written or oral request of Consultant, the Company shall within twenty-four (24) hours confirm orally and in writing to the Consultant the number of shares of Common Stock then outstanding.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1

STOCK HOLDERS' EQUITY
12 Months Ended

May 31, 2018

STOCKHOLDERS DEFICIT

STOCK HOLDERS' EQUITY
Preferred and Common Stock

The Company has authorized 1,002,000,000 total shares of stock with a par value of $0.001 per share. These shares are designated by two classes; 1,000,000,000 common shares and 2,000,000 preferred shares.

Fiscal 2017

On January 26, 2017, the Company Amended its Articles to increase the Authorized share Capital of the Company from 75,000,000 to 1,000,000,000.

On January 18, 2017, Olaf Robak, the Company's President and CEO, executed a stock purchase agreement with First Legacy Management LLC, which acquired 4,000,000 shares of common stock, representing 80% ownership of the Company. First Legacy Management LLC paid $350,000 in cash. Simultaneous with this transaction, Mr. Olaf Robak resigned from his official positions as Director, CEO, CFO, President, Treasurer and Secretary of the Company, and on the same day the shareholders of the Corporation voted Mr. Antonio Treminio as Director & CEO.

Fiscal 2018

On July 26, 2017, the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation with the Secretary of State of Nevada. The Certificate of Amendment amends Article III of the Company’s Articles of Incorporation to authorize the issuance of up to two million (2,000,000) shares of Preferred Stock, par value $0.001 per share, which have the right to cast one thousand (1,000) votes for each share held of record on all matters submitted to a vote of holders of the Corporation’s common stock, including the election of directors, and all other matters required by law.

On August 11, 2017, the Company issued 800,000 common shares to retire convertible promissory notes dated January 27, 2017 and April 7, 2017 with Bakken Development LLC in the aggregate principal amount of $200,000. As amended, the promissory notes convert into shares of Company common stock at the conversion price of $.25 per share.

On November 15, 2017, the Company entered into an Equity Financing Agreement and Registration Rights Agreement with GHS pursuant to which GHS has agreed to purchase up to $7,000,000 in shares of Company common stock. The obligations of GHS to purchase the shares of Company common stock are subject to the conditions set forth in the Equity Financing Agreement, including, without limitation, the condition that a registration statement on Form S-1 registering the shares of Company common stock to be sold to GHS be filed with the Securities and Exchange Commission and become effective. The Company filed the Form S-1 registration statement on December 7, 2017. The Registration Rights Agreement provides that the Company shall use commercially reasonable efforts to file the registration statement within 30 days after the date of the Registration Rights Agreement and have the registration statement become effective within 90 days after it is filed. The purchase price of the shares of Company common stock will be equal to 80% of the market price (as determined in the Equity Financing Agreement) calculated at the time of purchase.

On February 13, 2018, the Company filed a registration withdrawal request with regards to S-1 registration statement filed on December 17, 2017. The Company may refile a Form S-1 registration in the future.

Under the terms of the equity financing agreement so long as this term is in effect and the $7,000,000 has not been fulfilled for a period of twenty-four months following the effective date the Company shall be permitted to PUT shares to the investor. The price of the Put shall be eighty (80%) percent of the “Market Price”, which is the lowest closing price of the Company’s Common Stock for ten (10) consecutive trading days preceding the Put Date. During the Open Period, the Company shall not be entitled to submit a Put Notice until after the previous Closing has been completed. There will be a minimum of ten (10) trading days between Put Notices.

In connection with the Equity Financing Agreement, the Company executed a convertible promissory note in the principal amount of $15,000 as payment of the commitment fee for the Equity Financing Agreement. The Note bear interests at the rate of 10% with a maturity date of August 14, 2018. (See NOTE 6)

During the year ended May 31, 2018, the Company issued 2,000,000 preferred shares, 75,000,000 commons shares in exchange for rights to certain intellectual property pursuant to an Asset Assignment Agreement. (See NOTE 1). The total investment was valued at $177,000.

Fiscal 2018

During the year ended May 31, 2018, the Company issued 50,000,000 stock warrants with a cashless exercise provision (“cashless warrants”) and 44,725,000 common shares to consultants under consulting agreements.

During the year ended May 31, 2018, the Company issued 10,000,000 stock warrants with a cashless exercise provision (“cashless warrants”) and 10,275,000 common shares to employees.

As of May 31, 2018, there were no outstanding stock options.

Warrants for common stock

On June 28, 2017, the Company issued 60,000,000 common stock warrants pursuant to an Asset Assignment Agreement with Richard L. Chang Holding’s LLC (“Holdings LLC”), pursuant to which Holdings. In consideration of these share issuances, Holdings LLC has assigned to the Company all of its rights, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016, titled “COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON’S DISEASE” and all related intellectual property, inventions and trade secrets, data, and clinical study results. Of the 60,000,000 common stock warrants issued, 50,000,000 warrants were issued to consultants and 10,000,000 were issued to an employee.

The following table summarizes warrant activity for the year ended May 31, 2018 and 2017:

Weighted

Weighted Average

Average Remaining Aggregate

Exercise Contractual Intrinsic

Shares Price Term Value

Outstanding at May 31, 2017 — $ — $ —

Granted 60,000,000 $ 0.25 5.00 $ —

Expired — — — —

Exercised — — — —

Canceled — — — —

Outstanding at May 31, 2018 60,000,000 $ 0.25 4.32 —

Warrants issued to consultants during the year ended May 31, 2018 to six different consultants were valued at $11,567. The warrants expire June 28, 2022.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1

INCOME TAXES
12 Months Ended

May 31, 2018

Income Tax Disclosure [Abstract]

INCOME TAXES
The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.



ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for the reporting period presented.

The Company did not record any income tax accrual for the period from inception to May 31, 2018. We expect to incur significant expenses in future periods which will offset any future net income.

As of May 31, 2018 and 2017, the Company had a net operating loss carry-forward of approximately $1,129,153 and $236,905. Losses that were incurred prior to December 31, 2017 may be used to offset future taxable income and expire ended in 2037. Losses incurred after December 31, 2017 may be used to offset future taxable income and do not expire. Because of the change in ownership that occurred on June 28, 2017, net operating loss carry forwards could be limited as to use in future years.

Deferred tax assets of $188,800 and $49,700 as of May 31, 2018 and 2017, respectively, resulting from net operating have been offset by a valuation allowance, due to the uncertainty of their realization. The change in the valuation allowance for the year ended May 31, 2018 and 2017 was $188,800 and $49,700, respectively. As a result, there were no current or deferred tax provisions for the year ended May 31, 2018 and 2017. There was no uncertain tax position taken since inception and the Company’s tax returns for the past three year remain open for examination. Hypgen is a United States, State of Nevada domiciled corporation for tax purposes. Deferred tax assets consist of the following:

May 31, 2018 May 31, 2017

Net operating losses $ 267,900 $ 80,500

Effect of TCJA recalculation (79,100 ) (30,800 )

Change in valuation allowance (188,800 ) (49,700 )

Provision for income taxes $ — $ —

On December 22, 2017, Public Law 115-97, informally referred to as the Tax Cuts and Jobs Act (“the TCJA”) was enacted into law. The TCJA provides for significant changes to the U.S. Internal Revenue Code of 1986, as amended, that impact corporate taxation requirements. Effective January 1, 2018, the federal tax rate for corporations was reduced from 35% to 21% for US taxable income and requires one-time re-measurement of deferred taxes to reflect their value at a lower tax rate of 21%. Also, mandatory repatriation of untaxed foreign earnings and profits will be taxed at 15.5% to the extent the underlying assets are liquid and 8% on the remaining balance. There are other provisions to the TCJA, such as conversion of a worldwide system to a territorial system, limitations on interest expense and domestic production deductions, which will be effective in fiscal 2019. The Company anticipates its effective tax rate to be 28% to 30%, excluding the one-time impact of the TCJA for fiscal 2018 primarily due to the reduction in the federal tax rate. The Company’s actual effective tax rate for fiscal 2018 may differ from management’s estimate due to changes in interpretations and assumptions. Due to the timing of enactment and complexity of the TCJA, the Company is unable to estimate a reasonable range of the one-time impact associated with mandatory repatriation, re-measurement of deferred taxes and other provisions of the TCJA. For tax losses that straddle tax years a blended rate is used. Since the Company is not expected to utilize any portion of net loss carryforward in the current tax year, the entire valuation is estimated using the newly enacted rates.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1

RELATED PARTY TRANSACTIONS
12 Months Ended

May 31, 2018

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS
A former director of the Company made the initial $100 deposit to on the bank account. In September 2015, the former director paid audit fees on behalf of the company in the amount of $650. These amounts, totaling $750, are being carried as a Related Party Loan which bears no interest and is payable on demand. The related party loan was forgiven effective January 18, 2017 under terms of change in control (SEE NOTE 1).

On January 27, 2017, the Company entered into a one-year convertible note from a related party with the face value of $100,000 bearing 8% interest (SEE NOTE 6). On June 28, 2017, the Company executed an amendment to this note.

On June 28, 2017, Richard L. Chang was appointed as a director of the Company. Mr. Richard Chang is the controlling interest of Holdings, LLC.

On June 28, 2017, Ben Chang, a senior management consultant, loaned the Company, $100 to initially fund the operating bank account of the Company. Mr. Ben Chang is also the Chief Executive Officer of Rich Pharmaceuticals, Inc.

On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Apica Investments Limited (“Apica”). Apica is controlled by Chew Chuan Tin who is the beneficial owner of greater than 10% of the outstanding shares of the Company through Bakken, Apica and First Legacy. Pursuant to that agreement the Company agreed issued 15,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5-year anniversary of the warrant; monthly fees of $1,800 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $4,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (SEE NOTE 7), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside “Excepted issuances”.

On June 28, 2017, the Company executed a one-year promissory convertible note with Bakken Development LLC (“Bakken”) in the principal amount of $400,000. Bakken is a related party controlled by Chew Chuan Tin who is the beneficial owner of greater than 10% of the outstanding shares of the Company through Bakken, Apica and First Legacy (See NOTE 6).

On June 28, 2017, the Company entered into a Consulting Agreement for services to be provided by Rafferty Finance S.A. (“Raferty”). Raferty is controlled by Antonio Treminio, former CEO of the Company. Pursuant to this agreement the Company agreed to issue 5,000,000 shares of Company common stock; a Common Stock Purchase Warrant to purchase up to 10,000,000 shares of Company common stock at an exercise price of $.25 per share at any time before the 5-year anniversary of the warrant; a $50,000 payment upon execution of the agreement; monthly fees of $5,400 to commence upon the Company’s completion of a financing in the minimum amount of $1,000,000. Fees will increase to $13,500 per month upon the Company’s completion of a financing in the minimum amount of $5,000,000. This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000. Common shares under this contract were issued on July 19, 2017 and cash payment was made on June 30, 2017. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (SEE NOTE 7) if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 4.99% of the amount of the shares of Company common stock issued by the Company outside “Excepted issuances”.

On July 8, 2017, the Company entered into a consulting agreement with Imagic, LLC (“Imagic”). Imagic, is wholly owned by Ben Chang, son of Director Richard L. Chang and Chief Executive Officer of Rich Pharmaceuticals, Inc. Upon the commencement of this engagement, the consultant or it’s designees were issued shares of the Company in the amount of 12,000,000 common shares. Imagic was also issued a warrant to acquire 10,000,000 shares of the Company at an exercise price of $0.25. At all times during the term of this agreement prior to the $5,000,000 financing date, except with respect to the “Excepted Issuances” (SEE NOTE 7), if the Company issues any shares of Company common stock, the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company outside “Excepted issuances”.

On September 14, 2017, the Company issued a promissory note in the amount of $6,000 to Imagic LLC. Imagic, is wholly owned by Ben Chang, son of Director Richard L. Chang and Chief Executive Officer of Rich Pharmaceuticals, Inc. The note matures on September 14, 2018 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $213.

On November 3, 2017, the Company issued a promissory note in the amount of $5,000 to one of its directors, Richard L. Chang Holdings. The note matures on November 3, 2018 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $143.

On January 11, 2018, the Company issued a promissory note in the amount of $5,000 to Imagic. The note matures on January 11, 2019 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $96.

On February 14, 2018, the Company issued a promissory note in the amount of $3,000 to Imagic. The note matures on February 14, 2019 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $44.

On March 6, 2018, the Company issued a promissory note in the amount of $2,375 to Imagic, a related party. The note matures on March 16, 2019 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $28.

On March 12, 2018, the Company issued a promissory note in the amount of $250 to Imagic, a related party. The note matures on March 12, 2019 and bears 5% interest. Accrued interest on this note at May 31, 2018 is $3.

From time to time certain operational expenses of the Company are paid for by Ben Chang, a senior management consultant to the Company. These items are funded by Mr. Ben Chang or by its 100% owned entity Imagic. At June 30, 2018, the Company owed $4,814 and $8,191 to Mr. Ben Chang and Imagic, respectively.

As of June 30, 2018, the Company had three employment agreements. Under these agreements the Company accrued $170,250. Total annual compensation under these agreements is $233,000. As a stipulation to these agreements, the employees are to be compensated until such time that the board approves them as full-time employees. Prior to board approval the employees will be compensated for actual hours worked.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1

SUBSEQUENT EVENTS
12 Months Ended

May 31, 2018

Subsequent Events [Abstract]

SUBSEQUENT EVENTS
On June 1, 2018, the Company entered into a two-year consulting agreement with Richard L. Chang, Holdings LLC, a related party, an entity controlled by director, Richard L. Chang. Under the terms of the agreement the Company will compensate the consultant at the rate of $20,000 per monthly for services provided assisting in the area clinical operations, managing their patents and other intellectual property as well as assisting the Company in scientific and technical matters concerning manufacturing the drug, research and development.

On June 25, 2018, the Company issued a promissory note in the amount of $4,000 to Imagic, a related party. The note matures on June 25, 2019 and bears 5% interest.

On July 5, 2018, the Company entered into a Termination and Share Cancellation Agreement with Rafferty Finances, S.A. (“Rafferty”) pursuant to which the Company and Rafferty agreed to (i) the rescission and termination of the Consulting Agreement and Common Stock Purchase Warrant dated June 28, 2017 between the Company and Rafferty; (ii) the cancellation of 5,000,000 shares of Company common stock previously issued to Rafferty; (iii) Rafferty’s assistance to the Company to complete the cancellation of an additional 469,500 shares of Company common stock; and (iv) the issuance of 500,000 shares of Company common stock to Rafferty. The foregoing is only a brief description of the material terms of the Termination and Share Cancellation Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreement which is filed as an exhibit to this Current Report. The issuance of the shares of common stock was made in reliance on the exemption provided by Section 4(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company’s reliance upon Section 4(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the securities was an accredited investor.

On July 5, 2018, the Company entered into a Termination and Share Cancellation Agreement with Brighton Capital Ltd. (“Brighton”) pursuant to which the Company and Brighton agreed to (i) the rescission and termination of the Consulting Agreement and Common Stock Purchase Warrant dated June 28, 2017 between the Company and Brighton; and (ii) the cancellation of 5,500,000 shares of Company common stock from the 6,000,000 shares of Company common stock previously issued to Brighton. The foregoing is only a brief description of the material terms of the Termination and Share Cancellation Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder.

On July 9, 2018, the Company entered into a Cancellation Agreement with certain shareholders of the Company pursuant to which the Company and the shareholders agreed to the cancellation of a total of 74,999,998 shares. In consideration of the share cancellations and provided that the Company raises a minimum of $1,000,000 in equity financing on or before June 28, 2019, Richard L. Chang Holding’s, LLC agreed to waive its right of reversion of the patent assets contributed to the Company pursuant to the Asset Assignment Agreement dated June 28, 2017. The foregoing is only a brief description of the material terms of the Cancellation Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder.

On July 9, 2018, the Company entered into a Warrant Amendment Agreement with certain warrant holders of the Company pursuant to which the Company and the warrant holders agreed to amend warrants previously issued to them to reduce the number of warrants in the total amount of 10,000,000. In consideration of the amendment and provided that the Company raises a minimum of $1,000,000 in equity financing on or before June 28, 2019, Richard L. Chang Holding’s, LLC agreed to waive its right of reversion of the patent assets contributed to the Company pursuant to the Asset Assignment Agreement dated June 28, 2017. The foregoing is only a brief description of the material terms of the Warrant Amendment Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder.

On October 1, 2018, Imagic, LLC granted the Company a two-year extension to a 5%, one-year, promissory note dated September 14, 2017, having a principal amount of $6,000. Imagic, LLC, is wholly owned by Ben Chang, son of Director Richard L. Chang and Chief Executive Officer of Rich Pharmaceuticals, Inc.

On October 1, 2018, Richard L. Chang Holdings granted a two-year extension to a 5%, one-year, promissory note dated November 3, 2017, having a principal amount of $5,000. Richard L. Chang Holdings is controlled by director Richard L. Chang. The note matures on November 3, 2018 and bears 5% interest.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1

SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended

May 31, 2018

Accounting Policies [Abstract]

Use of Estimates and Assumptions

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. At May 31, 2018 and 2017, the Company had no cash equivalents.

Property and Equipment and Depreciation

Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.

Intangible Assets

Intangible assets consisted of a licensing fee under an asset assignment agreement for a patent which was granted November 10, 2016. At the time of the assignment on June 28, 2017, the patent had a remaining life of 19 years and 135 days, which the Company had determined to be the remaining useful life of the patent whereby total investment was to be amortized on a straight-line basis over this period. In exchange for the rights to the intellectual property the Company paid $100,000 in cash, issued 2,000,000 preferred shares and 75,000,000 commons shares. The total investment was valued at $177,000.

During the year ended May 31, 2018, the Company analyzed its intangible asset for the purposes of impairment testing. Although management believes that the asset has real economic value, the expense of an independent valuation is not something the Company is interested in doing, whereby the cost of this analysis could exceed the value of the asset. Conversely, the Company’s asset analysis is not objectively able to prove with any degree of certainty that it will ever see positive cashflow from its efforts. This industry is very complicated, risky and unpredictable as it relates to ultimate drug approval or even the sale of the asset. Due to a cost prohibitive asset valuation, uncertainty that the product can be brought to market or be sold and the fact that the that acquisition was from a related party the Company feels that is should fully impair the asset at this time.

Impairment of Long-Lived Assets

Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.

Net Loss Per Common Share

The Company computes per share amounts in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 260 Earnings per Share (“EPS”) which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to Common Stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of Common Stock and Common Stock equivalents outstanding during the periods; however, potential common shares are excluded for period in which the Company incurs losses, as their effect is anti-dilutive. For the years ended May 31, 2018 and 2017 the basic and fully diluted earnings per share were the same as the Company had a loss in each of these periods. At May 31, 2018, the Company had potentially dilutive instruments in the form of 60,000,000 common stock warrants with a cashless exercise provision outstanding as well as 1,965,954 common shares issuable upon the conversion of outstanding principal and interest on convertible notes.

Stock-Based Compensation

The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted on the grant date as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in stockholders’ equity/(deficit) over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.

The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value on the grant date of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services over the term of the related services.

Fair Value of Financial Instruments

ASC 825, “Disclosures about Fair Value of Financial Instruments”, requires disclosure of fair value information about financial instruments in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value hierarchy to classify the inputs used in measuring fair value as follows:

· Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

· Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

· Level 3-Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2018.

The respective carrying values of certain on-balance-sheet financial instruments approximate their fair values. These financial instruments include cash, accrued liabilities and notes payable. Fair values were assumed to approximate carrying values for these financial instruments since they are short term in nature and their carrying amounts approximate fair value. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet date.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current period presentation. The reclassifications had no effect on the net loss or cash flows of the Company.

Revenue Recognition

The Company recognizes revenues in accordance with FASB ASC Topic 605, “Revenue Recognition”, and with the guidelines of the Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104 “Revenue Recognition”.

Under SAB 104, four conditions must be met before revenue can be recognized: (i) there is persuasive evidence that an arrangement exists, (ii) delivery has occurred or service has been rendered, (iii) the price is fixed or determinable, and (iv) collection is reasonably assured.

Customers of our discontinued operation paid for their product at the time we are advised by the manufacturer/distributor that the product is ready for shipment or pick-up. The Company recognizes revenue when the pre-paid product has been delivered to, or picked up by, the customer. In the event there is a significant delay between the date the customer pre-pays for the product and the delivery or pick-up of the product, revenue would be deferred until the customer accepts delivery of the product. Under our current operations we do not expect to recognize revenue until we receive FDA approval to sell our Parkinson’s disease drug commercially.

Research and Development

The Company expenses research and development costs as incurred. Research and development costs were $0 for the years ended May 31, 2018 and 2017. The expense in the prior year is reflected in discontinued operations. The Company anticipates substantial expense as it conducts phase II trials and tries to move its product to market along with the development of its other products. The Company will also evaluate products and technologies in the medical products space, with its main focus on Parkinson’s Disease. As the Company continues to develop its products and relationships in these areas’ resultant expenses for trademark filings, license agreements, product development and design materials will be expensed as research and development. Some costs may be accumulated for subsidiaries prior to formation of entities.

Income Taxes

We will use the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for the reporting period presented.

The Company did not record any income tax accrual for the period from inception to May 31, 2018. We expect to incur significant expenses in future periods which will offset any net profit.

Recent Accounting Pronouncements

In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” which addresses accounting for issuance of all share-based payments on the same accounting model. Previously, accounting for share-based payments to employees was covered by ASC Topic 718 while accounting for such payments to non-employees was covered by ASC Subtopic 505-50. As it considered recently issued updates to ASC 718, the FASB, as part of its simplification initiatives, decided to replace ASC Subtopic 505-50 with Topic 718 as the guidance for non-employee share-based awards. Under this new guidance, both sets of awards, for employees and non-employees, will essentially follow the same model, with small variations related to determining the term assumption when valuing a non-employee award as well as a different expense attribution model for non-employee awards as opposed to employee awards. The ASU is effective for public business entities beginning in 2019 calendar years and one year later for non-public business entities.

In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815),” which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The Company is currently in the process of assessing the impact the adoption of this guidance will have on the Company’s financial statements.

Subsequent Events

In accordance with ASC 855 “Subsequent Events” the Company evaluated subsequent events after the balance sheet date through the date of issuance.

X

- References
No definition available.
+ Details

Name: HPGN_ReclassificationsPolicyTextBlock

Namespace Prefix: HPGN_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13279-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 50
-Section 25
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 40
-Section 30
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6389767&loc=d3e17916-109280

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.15)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reporting subsequent events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_SubsequentEventsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1

DISCONTINUED OPERATIONS (Tables)
12 Months Ended

May 31, 2018

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

HYPGEN INC
STATEMENTS OF DISCONTINUED OPERATIONS

For the years ended May 31,

2018 2017

Discontinued Operations:

Revenue $ — $ 73,171

Cost of Goods Sold:

Product Purchases — 53,197

Gross Profit — 19,974

Operating Expenses:

General and administrative — 3,000

Product development — —

Depreciation 76 910

Impairment loss on assets from discontinued operations 11,681 —

Total operating expense 11,757 3,910

Net income (loss) from discontinued operations $ (11,757 ) $ 16,064

May 31, 2018 May 31, 2017

Assets of discontinued operations $ — $ 11,757

Liabilities of discontinued operations — —

X

- References
No definition available.
+ Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760
+ Details

Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1

FIXED ASSETS (Tables)
12 Months Ended

May 31, 2018

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

May 31, 2018 May 31, 2017 Estimated Life

Computers, office furniture and equipment $ 1,939 $ — 3 years

Less: accumulated depreciation $ (458 ) $ —

Net $ 1,481 $ —

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1

INTANGIBLE ASSETS (Tables)
12 Months Ended

May 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of License Value Net of Amortization

May 31, 2018 Estimated Life

Investment in license $ 177,000 19.4 years

Less amortization $ (8,456 )

Less impairment loss (168,544 )

License fee net amortization $ —

X

- References
No definition available.
+ Details

Name: HPGN_ScheduleOfLicenseValueNetOfAmortizationTableTextBlock

Namespace Prefix: HPGN_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1

STOCK HOLDERS' EQUITY (Tables)
12 Months Ended

May 31, 2018

Stock Holders Equity

Schedule of Warrant Activity

Weighted

Weighted Average

Average Remaining Aggregate

Exercise Contractual Intrinsic

Shares Price Term Value

Outstanding at May 31, 2017 — $ — $ —

Granted 60,000,000 $ 0.25 5.00 $ —

Expired — — — —

Exercised — — — —

Canceled — — — —

Outstanding at May 31, 2018 60,000,000 $ 0.25 4.32 —

X

- References
No definition available.
+ Details

Name: HPGN_ScheduleOfWarrantActivityTableTextBlock

Namespace Prefix: HPGN_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_StockHoldersEquityTablesAbstract

Namespace Prefix: HPGN_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1

INCOME TAXES (Tables)
12 Months Ended

May 31, 2018

Income Taxes Tables Abstract

Schedule of Federal Income Tax

May 31, 2018 May 31, 2017

Net operating losses $ 267,900 $ 80,500

Effect of TCJA recalculation (79,100 ) (30,800 )

Change in valuation allowance (188,800 ) (49,700 )

Provision for income taxes $ — $ —

X

- References
No definition available.
+ Details

Name: HPGN_IncomeTaxesTablesAbstract

Namespace Prefix: HPGN_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the federal tax basis of investment holdings. This item captures the aggregate cost of securities, aggregate gross unrealized appreciation for all securities in which there is an excess of value over tax cost, aggregate gross unrealized depreciation for all securities in which there is an excess of tax cost over value, net unrealized appreciation (depreciation), and an explanation of the differences between tax and book.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-12C)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010
+ Details

Name: us-gaap_FederalIncomeTaxNoteTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1

ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) - USD ($)
12 Months Ended

May 31, 2018

May 31, 2017

State of incorporation State of Nevada

Date of incorporation Mar. 26, 2015

Net Income (loss) $ (892,248) $ (205,287)

Common stock, shares issued 135,800,000 5,000,000

Preferred stock, shares issued 2,000,000 0

Emerging growth company, description We will continue to be an emerging growth company until: (i) the last day of our fiscal year during which we had total annual gross revenues of $1,000,000,000 or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (iii) the date on which we have, during the previous 3-year period, issued more than $1,000,000,000 in non-convertible debt; or (iv) the date on which we are deemed to be a large accelerated filer, as defined in Section 12b-2 of the Exchange Act.

First Legacy Management LLC

Date of Agreement Jan. 18, 2017

Acquired common stock shares 4,000,000

Ownership percentage 80.00%

Cash paid $ 350,000

Asset Assignment Agreement | Richard L. Chang Holdings LLC

Date of Agreement Jun. 28, 2017

Common stock, shares issued 60,000,000

Preferred stock, shares issued 2,000,000

Common stock, voting right 1000 to 1 voting rights over shares of the Company’s common stock

Equity financing, minimum raise $ 1,000,000

Asset Assignment Agreement | RCHA

Common stock, shares issued 15,000,000

X

- References
No definition available.
+ Details

Name: HPGN_AcquiredCommonStockShares

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: HPGN_CashPaid

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: HPGN_DateOfAgreement

Namespace Prefix: HPGN_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_EmergingGrowthCompanyDescription

Namespace Prefix: HPGN_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_MinimumCapitalRaiseRequired

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Date when an entity was incorporated
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationDateOfIncorporation

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
State or Country Name where an entity is incorporated
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_CommonStockVotingRights

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=HPGN_FirstLegacyManagementLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=HPGN_AssetAssignmentAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_RichardLChangHoldingsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_RichPharmaceuticalsIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended

May 31, 2018

May 31, 2017

Cash Equivalents $ 0 $ 0

Estimated Useful Life 3 years

Preferred stock, shares issued 2,000,000 0

Common stock, shares issued 135,800,000 5,000,000

Research and development expenses $ 0 $ 0

Warrants Issued

Potentially Dilutive Instruments

Stock Issuable Upon Conversion 1,965,954

Warrants Issued 60,000,000

Patent

Date of Agreement Nov. 10, 2016

Estimated Useful Life 19 years 135 days

Cash paid $ 100,000

Preferred stock, shares issued 2,000,000

Common stock, shares issued 75,000,000

Noncash Investment $ 77,000

Investment in license $ 177,700

X

- References
No definition available.
+ Details

Name: HPGN_CashPaid

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: HPGN_DateOfAgreement

Namespace Prefix: HPGN_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_IssuedWarrants

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_StockIssuableUponConversion

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IndefiniteLivedLicenseAgreements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586
+ Details

Name: us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ShareholdersEquityClassAxis=HPGN_PotentiallyDilutiveInstrumentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1

DISCONTINUED OPERATIONS - Schedule of Discontinued Operations (Details) - USD ($)
12 Months Ended

May 31, 2018

May 31, 2017

Operating Expenses:

Impairment loss on assets from discontinued operations $ (11,681)

Assets of discontinued operations 11,757

Liabilities of discontinued operations

Statements Of Discontinued Operations

Discontinued Operations:

Revenue 73,171

Cost of Goods Sold:

Product Purchases 53,197

Gross Profit 19,974

Operating Expenses:

General and administrative 3,000

Product development

Depreciation 76 910

Impairment loss on assets from discontinued operations 11,681

Total operating expense 11,757 3,910

Loss from discontinued operations $ (11,757) $ 16,064

X

- References
No definition available.
+ Details

Name: HPGN_DisposalGroupIncludingDiscontinuedOperationProductDevelopmentExpenses

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230
+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CostOfGoodsAndServicesSoldAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 220
-Section 45
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114873921&loc=SL114875236-224282

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228
+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisposalGroupClassificationAxis=HPGN_StatementsOfDiscontinuedOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1

DISCONTINUED OPERATIONS (Details Narrative) - USD ($)
12 Months Ended

May 31, 2018

May 31, 2017

Statements Of Discontinued Operations

Depreciation $ 76 $ 910

Discontinued Operations, Held-for-sale

Date of Agreement May 25, 2015

Purchase Price $ 13,653

X

- References
No definition available.
+ Details

Name: HPGN_DateOfAgreement

Namespace Prefix: HPGN_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_DisposalGroupClassificationAxis=HPGN_StatementsOfDiscontinuedOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1

FIXED ASSETS - Schedule of Property and Equipment (Details) - USD ($)
12 Months Ended

May 31, 2018

May 31, 2017

Fixed Assets - Schedule Of Property And Equipment

Computers, office furniture and equipment $ 1,939

Less: accumulated depreciation (458)

Property and equipment, net $ 1,481

Estimated Useful Life 3 years

X

- References
No definition available.
+ Details

Name: HPGN_ScheduleOfPropertyAndEquipmentDetailsAbstract

Namespace Prefix: HPGN_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 45 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1

FIXED ASSETS (Details Narrative) - USD ($)
12 Months Ended

May 31, 2018

May 31, 2017

Property, Plant and Equipment [Abstract]

Depreciation expense $ 458 $ 0

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1

INTANGIBLE ASSETS - Schedule of License Value Net of Amortization (Details) - USD ($)
12 Months Ended

May 31, 2018

May 31, 2017

Amortization expense $ 8,456

License asset agreement, net of amortization

Estimated Useful Life 3 years

Patent

Investment in license $ 177,700

Amortization expense (8,456)

License asset agreement, net of amortization $ (168,544)

Estimated Useful Life 19 years 135 days

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedLicenseAgreementsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IndefiniteLivedLicenseAgreements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1

INTANGIBLE ASSETS (Details Narrative) - USD ($)
12 Months Ended

May 31, 2018

May 31, 2017

Common stock, shares issued 135,800,000 5,000,000

Preferred stock, shares issued 2,000,000 0

Amortization expense $ 8,456

Patent

Date of Agreement Nov. 10, 2016

Common stock, shares issued 75,000,000

Preferred stock, shares issued 2,000,000

Cash paid $ 100,000

Noncash Investment 77,000

Investment in license 177,700

Amortization expense $ (8,456)

Asset Assignment Agreement | Richard L. Chang Holdings LLC

Date of Agreement Jun. 28, 2017

Common stock, shares issued 60,000,000

Preferred stock, shares issued 2,000,000

Common stock, voting right 1000 to 1 voting rights over shares of the Company’s common stock

Equity financing, minimum raise $ 1,000,000

Asset Assignment Agreement | RCHA

Common stock, shares issued 15,000,000

X

- References
No definition available.
+ Details

Name: HPGN_CashPaid

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: HPGN_DateOfAgreement

Namespace Prefix: HPGN_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_MinimumCapitalRaiseRequired

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_CommonStockVotingRights

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IndefiniteLivedLicenseAgreements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586
+ Details

Name: us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=HPGN_AssetAssignmentAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_RichardLChangHoldingsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_RichPharmaceuticalsIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1

CONVERTIBLE NOTES PAYABLE (Details Narrative)
12 Months Ended

May 31, 2018

USD ($)

d

$ / shares

shares

May 31, 2017

USD ($)

Convertible Notes Payable $ 45,000

Interest expense and financing cost, net $ 73,170 $ 3,844

GHS

Date of Agreement Nov. 15, 2017

Term of Note 24 months

Due Date Aug. 14, 2018

Convertible Notes Payable $ 22,500

Interest rate 10.00%

Accrued interest $ 277

Description of conversion price The amounts under the Note may be converted by GHS at any time after the maturity date or upon any event of default into shares of Company common stock at a conversion price equal to 80% of the average closing bid price during the 5-day period prior to conversion, subject to a floor price of $0.00005 per share.

Equity Registration Rights, Shares to be Registered | shares 7,000,000

Interest expense and financing cost, net $ 10,922

Conv Note #1

Date of Debt Instrument Jan. 27, 2017

Term of Note 1 year

Convertible Notes Payable $ 100,000

Interest rate 8.00%

Accrued interest $ 4,244

Debt instrument, convertible, conversion price | $ / shares $ 0.25

Description of conversion price The holder of the note was entitled to a conversion price equal to seventy percent of the average trading price computed based on the previous 7 trading days prior to notice of conversion.

Conv Note #2

Date of Debt Instrument Apr. 07, 2017

Term of Note 1 year

Convertible Notes Payable $ 100,000

Interest rate 8.00%

Accrued interest $ 2,800

Debt instrument, convertible, conversion price | $ / shares $ 0.25

Debt instrument, convertible, trading days | d 7

Description of conversion price The holder of the note was entitled to a conversion price equal to seventy percent of the average trading price computed based on the previous 7 trading days prior to notice of conversion.

Conv Note #3

Date of Debt Instrument Jun. 28, 2017

Due Date Jun. 28, 2019

Convertible Notes Payable $ 400,000

Interest rate 10.00%

Accrued interest $ 38,889

Debt instrument, convertible, conversion price | $ / shares $ 0.50

Description of conversion price may be converted at any time by the holder into shares of Company common stock at a conversion price of $.50 per share; and automatically converts into shares of Company common stock at a conversion price of $.50 per share upon the Company’s completion of a financing in the minimum amount of $5,000,000

Conv Note #1&2

Accrued interest $ 7,044

Debt instrument, convertible, conversion price | $ / shares $ 0.25

Date of Issuance Aug. 11, 2017

Stock Issued, Shares | shares 800,000

Stock Issued, Value $ 200,000

Conv Note #4

Date of Debt Instrument Nov. 17, 2017

Due Date Aug. 19, 2018

Convertible Notes Payable $ 22,500

Interest rate 10.00%

Accrued interest $ 277

Description of conversion price Upon any event of default, the note holder may convert the note in its entirety into shares of Company common stock at a conversion price equal to 80% of the average closing bid price during the 5-day period prior to conversion, subject to a floor price of $0.00005 per share

X

- References
No definition available.
+ Details

Name: HPGN_DateOfAgreement

Namespace Prefix: HPGN_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_SharesToBeRegistered

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_TermOfConvertibleNote

Namespace Prefix: HPGN_

Data Type: us-types:durationStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=29642582&loc=d3e27881-108397

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 25
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=29642582&loc=d3e27862-108397

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399
+ Details

Name: us-gaap_AccountsPayableInterestBearingInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_ConversionOfStockAmountIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
No definition available.
+ Details

Name: us-gaap_DebtConversionDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentConvertibleThresholdTradingDays

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Date the debt instrument was issued, in CCYY-MM-DD format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentIssuanceDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The net amount of operating interest income (expense).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.10)
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Date the targeted stock was issued, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: us-gaap_TargetedOrTrackingStockIssuanceDates

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OtherCommitmentsAxis=us-gaap_EquityUnitPurchaseAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=HPGN_ConvertibleNote1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=HPGN_ConvertibleNote2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=HPGN_ConvertibleNote3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=HPGN_ConvertibleNote1And2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=HPGN_ConvertibleNote4Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended

May 31, 2018

May 31, 2018

May 31, 2017

Convertible Notes Payable $ 45,000 $ 45,000

Common stock, shares issued 135,800,000 135,800,000 5,000,000

Conv Note #3

Date of Debt Instrument Jun. 28, 2017

Due Date Jun. 28, 2019

Convertible Notes Payable $ 400,000 $ 400,000

Interest rate 10.00% 10.00%

Debt instrument, convertible, conversion price $ 0.50 $ 0.50

Minimum

Monthly Consultant Fees $ 5,400

Maximum

Monthly Consultant Fees 13,500

Apica Investments Ltd

PPM, minimum raise 1,000,000

PPM, maximum raise $ 5,000,000

Date of Agreement Jun. 28, 2017

Stock to be Issued 15,000,000

Warrants to be Issued 10,000,000

Warrants, exercise price $ 0.25 $ 0.25

Warrant, term 5 years

Contract Expiration Description This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000.

Additional Share Grant, Description
the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company

Apica Investments Ltd | Minimum

Monthly Consultant Fees $ 1,800

Apica Investments Ltd | Maximum

Monthly Consultant Fees $ 4,500

Brighton Capital Ltd

Date of Agreement Jul. 05, 2018 Jun. 28, 2017

Stock to be Issued 6,000,000

Warrants to be Issued 10,000,000

Warrants, exercise price $ 0.25 $ 0.25

Warrant, term 5 years

Cash Paid $ 50,000 $ 50,000

Contract Expiration Description This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000.

Additional Share Grant, Description
the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company

Brighton Capital Ltd | Minimum

Monthly Consultant Fees $ 1,800

Brighton Capital Ltd | Maximum

Monthly Consultant Fees 4,500

Rafferty Finance S.A.

PPM, minimum raise 1,000,000

PPM, maximum raise $ 5,000,000

Date of Agreement Jul. 05, 2018 Jun. 28, 2017

Date of Issuance Jul. 19, 2017

Stock to be Issued 500,000 5,000,000

Warrants to be Issued 10,000,000

Warrants, exercise price $ 0.25 $ 0.25

Warrant, term 5 years

Cash Paid $ 50,000 $ 50,000

Contract Expiration Description This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000.

Common stock, shares issued 5,000,000 5,000,000

Additional Share Grant, Description
the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company

Imagic, LLC

Date of Agreement Jul. 08, 2017

Warrants to be Issued 10,000,000

Warrants, exercise price $ 0.25 $ 0.25

Common stock, shares issued 12,000,000 12,000,000

Additional Share Grant, Description
the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company

Employment Agmt

Date of Agreement Jul. 08, 2017

Common stock, shares issued 8,000,000 8,000,000

Asset Assignment Agreement | Richard L. Chang Holdings LLC

PPM, minimum raise $ 1,000,000

Financing Due Date Jun. 28, 2018

Proceeds from PPM, current $ 0

PPM, maximum raise $ 5,000,000

Date of Agreement Jun. 28, 2017

Common stock, shares issued 60,000,000 60,000,000

X

- References
No definition available.
+ Details

Name: HPGN_AdditionalGrantOfSharesDescription

Namespace Prefix: HPGN_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_CashPaid

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: HPGN_ContractExpirationDescription

Namespace Prefix: HPGN_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_ContractualTermOfWarrant

Namespace Prefix: HPGN_

Data Type: us-types:durationStringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_DateOfAgreement

Namespace Prefix: HPGN_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_FinancingDueDate

Namespace Prefix: HPGN_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_MaximumCapitalRaise

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_MinimumCapitalRaiseRequired

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_StockToBeIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_WarrantsToBeIssued

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=29642582&loc=d3e27881-108397

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 25
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=29642582&loc=d3e27862-108397

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399
+ Details

Name: us-gaap_AccountsPayableInterestBearingInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Date the debt instrument was issued, in CCYY-MM-DD format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentIssuanceDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.
+ References
No definition available.
+ Details

Name: us-gaap_ProfessionalAndContractServicesExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Date the targeted stock was issued, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: us-gaap_TargetedOrTrackingStockIssuanceDates

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=HPGN_ConvertibleNote3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=HPGN_ConsultingAgreement1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=HPGN_ConsultingAgreement2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=HPGN_ConsultingAgreement3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=HPGN_ConsultingAgreement4Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=us-gaap_EmploymentContractsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=HPGN_AssetAssignmentAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_RichardLChangHoldingsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1

STOCK HOLDERS' EQUITY - Schedule of Warrant Activity (Details) - $ / shares
12 Months Ended

May 31, 2018

May 31, 2017

Stock Holders Equity - Schedule Of Warrant Activity

Beginning Balance, Issued Warrants 60,000,000

Beginning Balance, Average Exercise Price $ 0.25

Issued, Warrants

Issued, Average Exercise Price

Weighted Average, Term 4 years 6 months

Aggregate Intrinsic Value

Expired Warrants

Expired Average Exercise Price

Exercised, Warrants

Exercised, Average Exercise Price

Cancelled, Warrants

Cancelled, Average Exercise Price

Ending Balance, Issued Warrants 60,000,000 60,000,000

Ending Balance, Average Exercise Price $ 0.25 $ 0.25

X

- References
No definition available.
+ Details

Name: HPGN_CancelledAverageExercisePrice

Namespace Prefix: HPGN_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_CancelledWarrants

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_ExercisedWarrants

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_IssuedWarrants

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_ScheduleOfWarrantActivityDetailsAbstract

Namespace Prefix: HPGN_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_WarrantsExercisedAverageExercisePrice

Namespace Prefix: HPGN_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_WarrantsExpiredCancelledAverageExercisePrice

Namespace Prefix: HPGN_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_WarrantsExpiredCancelledWarrants

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_WarrantsIssuedAverageExercisePrice

Namespace Prefix: HPGN_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_WarrantsOutstanding

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: HPGN_WarrantsOutstandingAverageExercisePrice

Namespace Prefix: HPGN_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: HPGN_WeightedAverageRemainingContractualTerm

Namespace Prefix: HPGN_

Data Type: us-types:durationStringItemType

Balance Type: na

Period Type: duration

X

- Definition
The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 51 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1

STOCK HOLDERS' EQUITY (Details Narrative) - USD ($)
12 Months Ended

May 31, 2018

May 31, 2017

Jan. 26, 2017

Common Stock, Par Value $ 0.001 $ 0.001

Common Stock, Shares Authorized 1,000,000,000 1,000,000,000 75,000,000

Preferred Stock, Par Value $ 0.001 $ 0.001

Preferred Stock, Shares Authorized 2,000,000 0

Preferred stock, shares issued 2,000,000 0

Common stock, shares issued 135,800,000 5,000,000

Warrants Issued

Convertible Notes Payable $ 45,000

GHS

Date of Agreement Nov. 15, 2017

Due Date Aug. 14, 2018

Convertible Notes Payable $ 22,500

Interest rate 10.00%

Term of Note 24 months

Equity Registration Rights, Shares to be Registered 7,000,000

Asset Assignment Agreement | Richard L. Chang Holdings LLC

Date of Agreement Jun. 28, 2017

Preferred stock, shares issued 2,000,000

Common stock, shares issued 60,000,000

Patent

Date of Agreement Nov. 10, 2016

Preferred stock, shares issued 2,000,000

Common stock, shares issued 75,000,000

Investment in license $ 177,700

Conv Note #1&2

Date of Issuance Aug. 11, 2017

Stock Issued, Shares 800,000

Stock Issued, Value $ 200,000

Debt instrument, convertible, conversion price $ 0.25

SPA

Date of Agreement Jan. 18, 2017

Stock Issued, Shares 4,000,000

Payment for Stock $ 350,000

Equity Interest 80.00%

Consulting Agmts

Warrants Issued 50,000,000

Stock Issued for Services, Shares 44,725,000

Employees

Warrants Issued 10,000,000

Stock Issued, Employee Compensation 10,275,000

X

- References
No definition available.
+ Details

Name: HPGN_DateOfAgreement

Namespace Prefix: HPGN_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_IssuedWarrants

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_SharesToBeRegistered

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_TermOfConvertibleNote

Namespace Prefix: HPGN_

Data Type: us-types:durationStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=29642582&loc=d3e27881-108397

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 25
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=29642582&loc=d3e27862-108397

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399
+ Details

Name: us-gaap_AccountsPayableInterestBearingInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_ConversionOfStockAmountIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IndefiniteLivedLicenseAgreements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The level of ownership or equity interest acquired in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586
+ Details

Name: us-gaap_NoncashOrPartNoncashAcquisitionInterestAcquired1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares of stock issued during the period pursuant to acquisitions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Date the targeted stock was issued, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: us-gaap_TargetedOrTrackingStockIssuanceDates

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OtherCommitmentsAxis=us-gaap_EquityUnitPurchaseAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=HPGN_AssetAssignmentAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_RichardLChangHoldingsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=HPGN_ConvertibleNote1And2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareholdersEquityClassAxis=HPGN_StockPurchaseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareholdersEquityClassAxis=HPGN_ConsultantingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareholdersEquityClassAxis=HPGN_EmployeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1

Income Taxes - Schedule of Federal Income Tax (Details) - USD ($)
12 Months Ended

May 31, 2018

May 31, 2017

Federal income tax benefit attributable to:

Net operating losses $ 267,900 $ 80,500

Effect of TCJA recalculation (79,100) (30,800)

Change in valuation allowance (188,800) (49,700)

Provision for income taxes

X

- References
No definition available.
+ Details

Name: HPGN_EffectOfTCJARecalculation

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentFederalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_DeferredFederalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319
+ Details

Name: us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1

INCOME TAXES (Details Narrative) - USD ($)
12 Months Ended

May 31, 2018

May 31, 2017

Income Tax Disclosure [Abstract]

Effective Income Tax Rate, Federal 21.00%

Effective Income Tax Rate, State

Net Operating Loss Carry-Forwards $ 1,114,329 $ 236,905

Change in valuation allowance (188,800) (49,700)

Deferred tax assets $ 188,800 $ 49,700

X

- Definition
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_DeferredFederalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 54 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended

May 31, 2018

May 31, 2018

May 31, 2017

Related Party Loan $ 29,816

Convertible Notes Payable $ 45,000 $ 45,000

Common stock, shares issued 135,800,000 135,800,000 5,000,000

Accrued salary, wages and taxes $ 185,152 $ 185,152

Proceeds from related party 4,814

Apica Investments Ltd

PPM, minimum raise 1,000,000

PPM, maximum raise $ 5,000,000

Date of Agreement Jun. 28, 2017

Stock to be Issued 15,000,000

Warrants to be Issued 10,000,000

Warrants, exercise price $ 0.25 $ 0.25

Warrant, term 5 years

Contract Expiration Description This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000.

Additional Share Grant, Description
the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company

Rafferty Finance S.A.

PPM, minimum raise $ 1,000,000

PPM, maximum raise $ 5,000,000

Date of Agreement Jul. 05, 2018 Jun. 28, 2017

Stock to be Issued 500,000 5,000,000

Warrants to be Issued 10,000,000

Warrants, exercise price $ 0.25 $ 0.25

Warrant, term 5 years

Contract Expiration Description This contract is in effect until two years after the anniversary date of the Company’s completion of raising $1,000,000.

Additional Share Grant, Description
the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company

Common stock, shares issued 5,000,000 5,000,000

Imagic, LLC

Date of Agreement Jul. 08, 2017

Warrants to be Issued 10,000,000

Warrants, exercise price $ 0.25 $ 0.25

Additional Share Grant, Description
the consultant shall be granted additional shares of the Company’s common stock in an amount equal to 10.6% of the amount of the shares of Company common stock issued by the Company

Common stock, shares issued 12,000,000 12,000,000

Conv Note #1

Date of Debt Instrument Jan. 27, 2017

Convertible Notes Payable $ 100,000 $ 100,000

Term of Note 1 year

Interest rate 8.00% 8.00%

Accrued interest $ 4,244 $ 4,244

Interest rate 8.00% 8.00%

Debt instrument, convertible, conversion price $ 0.25 $ 0.25

Description of conversion price The holder of the note was entitled to a conversion price equal to seventy percent of the average trading price computed based on the previous 7 trading days prior to notice of conversion.

Conv Note #3

Date of Debt Instrument Jun. 28, 2017

Convertible Notes Payable $ 400,000 $ 400,000

Due Date Jun. 28, 2019

Accrued interest $ 38,889 $ 38,889

Interest rate 10.00% 10.00%

Debt instrument, convertible, conversion price $ 0.50 $ 0.50

Description of conversion price may be converted at any time by the holder into shares of Company common stock at a conversion price of $.50 per share; and automatically converts into shares of Company common stock at a conversion price of $.50 per share upon the Company’s completion of a financing in the minimum amount of $5,000,000

Richard L. Chang, Director

Related Party Loan $ 750

Audit fees by related party 650

Related party bank deposit 100

Consultant

Related Party Loan $ 100

Prom Note #1

Date of Debt Instrument Sep. 14, 2017

Interest rate 5.00% 5.00%

Debt Instrument $ 6,000 $ 6,000

Due Date Sep. 14, 2018

Accrued interest $ 213 $ 213

Prom Note #2

Date of Debt Instrument Nov. 03, 2017

Interest rate 5.00% 5.00%

Debt Instrument $ 5,000 $ 5,000

Due Date Nov. 03, 2018

Accrued interest $ 143 $ 143

Prom Note #3

Date of Debt Instrument Jan. 11, 2018

Interest rate 5.00% 5.00%

Debt Instrument $ 5,000 $ 5,000

Due Date Jan. 11, 2019

Accrued interest $ 96 $ 96

Prom Note #4

Date of Debt Instrument Feb. 14, 2018

Interest rate 5.00% 5.00%

Debt Instrument $ 5,000 $ 5,000

Due Date Feb. 14, 2019

Accrued interest $ 4 $ 4

Prom Note #5

Date of Debt Instrument Mar. 12, 2018

Interest rate 5.00% 5.00%

Debt Instrument $ 250 $ 250

Due Date Mar. 12, 2019

Accrued interest $ 3 $ 3

Prom Note #6

Date of Debt Instrument Mar. 06, 2018

Interest rate 5.00% 5.00%

Debt Instrument $ 2,375 $ 2,375

Due Date Mar. 16, 2019

Accrued interest 28 $ 28

Employment Agmts

Accrued salary, wages and taxes 170,250 170,250

Annual Compensation $ 233,000 233,000

Senior Consultant

Proceeds from related party 4,814

Senior Consultant Entity

Proceeds from related party $ 8,191

X

- References
No definition available.
+ Details

Name: HPGN_AdditionalGrantOfSharesDescription

Namespace Prefix: HPGN_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_ContractExpirationDescription

Namespace Prefix: HPGN_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_ContractualTermOfWarrant

Namespace Prefix: HPGN_

Data Type: us-types:durationStringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_DateOfAgreement

Namespace Prefix: HPGN_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_MaximumCapitalRaise

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_MinimumCapitalRaiseRequired

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_StockToBeIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_TermOfConvertibleNote

Namespace Prefix: HPGN_

Data Type: us-types:durationStringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_WarrantsToBeIssued

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=29642582&loc=d3e27881-108397

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 25
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=29642582&loc=d3e27862-108397

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399
+ Details

Name: us-gaap_AccountsPayableInterestBearingInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedSalariesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
No definition available.
+ Details

Name: us-gaap_DebtConversionDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Date the debt instrument was issued, in CCYY-MM-DD format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentIssuanceDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Amounts due to employees, not to include stockholders or officers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToEmployeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDueToRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of transactions with related party during the financial reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864
+ Details

Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI http://asc.fasb.org/extlink&oid=114873854&loc=SL114874292-224272

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_RevenueFromRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherCommitmentsAxis=HPGN_ConsultingAgreement1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=HPGN_ConsultingAgreement3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=HPGN_ConsultingAgreement4Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=HPGN_ConvertibleNote1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=HPGN_ConvertibleNote3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=us-gaap_DirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_ConsultantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_PromissoryNote1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_PromissoryNote2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_PromissoryNote3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_PromissoryNote4Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_PromissoryNote5Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_PromissoryNote6Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_EmploymentAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_SeniorConsultantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_SeniorConsultantEntityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1

SUBSEQUENT EVENTS (Details Narrative)
3 Months Ended 12 Months Ended

May 31, 2018

USD ($)

shares

May 31, 2018

USD ($)

shares

Rafferty Finance S.A.

Date of Agreement Jul. 05, 2018 Jun. 28, 2017

Common stock, shares cancelled (5,496,500)

Stock to be Issued 500,000 5,000,000

Warrants to be Issued 10,000,000

PPM, minimum raise | $ $ 1,000,000

Brighton Capital Ltd

Date of Agreement Jul. 05, 2018 Jun. 28, 2017

Common stock, shares cancelled (5,500,000)

Stock to be Issued 6,000,000

Warrants to be Issued 10,000,000

Cancellation Agmt

Date of Agreement Jul. 09, 2018

Common stock, shares cancelled (74,999,998)

PPM, minimum raise | $ $ 1,000,000

Financing Due Date Jun. 28, 2019

Agreement Description
In consideration of the share cancellations and provided that the Company raises a minimum of $1,000,000 in equity financing on or before June 28, 2019, Richard L. Chang Holding’s, LLC agreed to waive its right of reversion of the patent assets contributed to the Company pursuant to the Asset Assignment Agreement dated June 28, 2017.

Warrant Amdt Agmt

Date of Agreement Jul. 09, 2018

Warrants to be Issued (10,000,000)

PPM, minimum raise | $ $ 1,000,000

Financing Due Date Jun. 28, 2019

Agreement Description
In consideration of the amendment and provided that the Company raises a minimum of $1,000,000 in equity financing on or before June 28, 2019, Richard L. Chang Holding’s, LLC agreed to waive its right of reversion of the patent assets contributed to the Company pursuant to the Asset Assignment Agreement dated June 28, 2017.

Brighton Capital Ltd

Date of Agreement Jun. 01, 2018

Monthly Salary | $ $ 20,000

Prom Note #7

Date of Debt Instrument Jun. 25, 2018

Interest rate 5.00% 5.00%

Debt Instrument | $ $ 4,000 $ 4,000

Due Date Jun. 25, 2019

X

- References
No definition available.
+ Details

Name: HPGN_AgreementDescription

Namespace Prefix: HPGN_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_CommonStockSharesCancelled

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_DateOfAgreement

Namespace Prefix: HPGN_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_FinancingDueDate

Namespace Prefix: HPGN_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_MinimumCapitalRaiseRequired

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_MonthlySalary

Namespace Prefix: HPGN_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_StockToBeIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: HPGN_WarrantsToBeIssued

Namespace Prefix: HPGN_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Date the debt instrument was issued, in CCYY-MM-DD format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentIssuanceDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OtherCommitmentsAxis=HPGN_ConsultingAgreement3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=HPGN_ConsultingAgreement2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=HPGN_CancellationAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_OtherCommitmentsAxis=HPGN_WarrantAmendmentAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_ConsultingAgreement2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=HPGN_PromissoryNote7Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R9999.htm IDEA: XBRL DOCUMENT v3.10.0.1

Label Element Value

Preferred Stock

Asset Assignment Agreement, Shares us-gaap_StockIssuedDuringPeriodSharesOther

Common Shares issued for, Amount us-gaap_StockIssuedDuringPeriodValueNewIssues

Stock Issued for Debt Conversion, Amount us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments

Stock Issued for Debt Conversion, Shares us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Stock Issued for Services, Shares us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Stock Issued for Services, Amount us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Common Shares issued for, Shares us-gaap_StockIssuedDuringPeriodSharesNewIssues

Asset Assignment Agreement, Amount us-gaap_StockIssuedDuringPeriodValueOther

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

RENDERED XBRL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end RENDERED XBRL 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} RENDERED XBRL 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 93 217 1 false 43 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://HPGN/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://HPGN/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://HPGN/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://HPGN/role/StatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Statements of Changes in Shareholders Deficit Sheet http://HPGN/role/StatementsOfChangesInShareholdersDeficit Statements of Changes in Shareholders Deficit Statements 5 false false R6.htm 00000006 - Statement - Statements of Cash Flows Sheet http://HPGN/role/StatementsOfCashFlows Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION Sheet http://HPGN/role/OrganizationAndBasisOfPresentation ORGANIZATION AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://HPGN/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - DISCONTINUED OPERATIONS Sheet http://HPGN/role/DiscontinuedOperations DISCONTINUED OPERATIONS Notes 9 false false R10.htm 00000010 - Disclosure - FIXED ASSETS Sheet http://HPGN/role/FixedAssets FIXED ASSETS Notes 10 false false R11.htm 00000011 - Disclosure - INTANGIBLE ASSETS Sheet http://HPGN/role/IntangibleAssets INTANGIBLE ASSETS Notes 11 false false R12.htm 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://HPGN/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE Notes 12 false false R13.htm 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://HPGN/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 00000014 - Disclosure - STOCK HOLDERS' EQUITY Sheet http://HPGN/role/StockHoldersEquity STOCK HOLDERS' EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - INCOME TAXES Sheet http://HPGN/role/IncomeTaxes INCOME TAXES Notes 15 false false R16.htm 00000016 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://HPGN/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://HPGN/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://HPGN/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - DISCONTINUED OPERATIONS (Tables) Sheet http://HPGN/role/DiscontinuedOperationsTables DISCONTINUED OPERATIONS (Tables) Tables http://HPGN/role/DiscontinuedOperations 19 false false R20.htm 00000020 - Disclosure - FIXED ASSETS (Tables) Sheet http://HPGN/role/FixedAssetsTables FIXED ASSETS (Tables) Tables http://HPGN/role/FixedAssets 20 false false R21.htm 00000021 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://HPGN/role/IntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://HPGN/role/IntangibleAssets 21 false false R22.htm 00000022 - Disclosure - STOCK HOLDERS' EQUITY (Tables) Sheet http://HPGN/role/StockHoldersEquityTables STOCK HOLDERS' EQUITY (Tables) Tables http://HPGN/role/StockHoldersEquity 22 false false R23.htm 00000023 - Disclosure - INCOME TAXES (Tables) Sheet http://HPGN/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://HPGN/role/IncomeTaxes 23 false false R24.htm 00000024 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) Sheet http://HPGN/role/OrganizationAndBasisOfPresentationDetailsNarrative ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) Details http://HPGN/role/OrganizationAndBasisOfPresentation 24 false false R25.htm 00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://HPGN/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://HPGN/role/SignificantAccountingPoliciesPolicies 25 false false R26.htm 00000026 - Disclosure - DISCONTINUED OPERATIONS - Schedule of Discontinued Operations (Details) Sheet http://HPGN/role/DiscontinuedOperations-ScheduleOfDiscontinuedOperationsDetails DISCONTINUED OPERATIONS - Schedule of Discontinued Operations (Details) Details 26 false false R27.htm 00000027 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative) Sheet http://HPGN/role/DiscontinuedOperationsDetailsNarrative DISCONTINUED OPERATIONS (Details Narrative) Details http://HPGN/role/DiscontinuedOperationsTables 27 false false R28.htm 00000028 - Disclosure - FIXED ASSETS - Schedule of Property and Equipment (Details) Sheet http://HPGN/role/FixedAssets-ScheduleOfPropertyAndEquipmentDetails FIXED ASSETS - Schedule of Property and Equipment (Details) Details 28 false false R29.htm 00000029 - Disclosure - FIXED ASSETS (Details Narrative) Sheet http://HPGN/role/FixedAssetsDetailsNarrative FIXED ASSETS (Details Narrative) Details http://HPGN/role/FixedAssetsTables 29 false false R30.htm 00000030 - Disclosure - INTANGIBLE ASSETS - Schedule of License Value Net of Amortization (Details) Sheet http://HPGN/role/IntangibleAssets-ScheduleOfLicenseValueNetOfAmortizationDetails INTANGIBLE ASSETS - Schedule of License Value Net of Amortization (Details) Details 30 false false R31.htm 00000031 - Disclosure - INTANGIBLE ASSETS (Details Narrative) Sheet http://HPGN/role/IntangibleAssetsDetailsNarrative INTANGIBLE ASSETS (Details Narrative) Details http://HPGN/role/IntangibleAssetsTables 31 false false R32.htm 00000032 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://HPGN/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://HPGN/role/ConvertibleNotesPayable 32 false false R33.htm 00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://HPGN/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://HPGN/role/CommitmentsAndContingencies 33 false false R34.htm 00000034 - Disclosure - STOCK HOLDERS' EQUITY - Schedule of Warrant Activity (Details) Sheet http://HPGN/role/StockHoldersEquity-ScheduleOfWarrantActivityDetails STOCK HOLDERS' EQUITY - Schedule of Warrant Activity (Details) Details 34 false false R35.htm 00000035 - Disclosure - STOCK HOLDERS' EQUITY (Details Narrative) Sheet http://HPGN/role/StockHoldersEquityDetailsNarrative STOCK HOLDERS' EQUITY (Details Narrative) Details http://HPGN/role/StockHoldersEquityTables 35 false false R36.htm 00000036 - Disclosure - Income Taxes - Schedule of Federal Income Tax (Details) Sheet http://HPGN/role/IncomeTaxes-ScheduleOfFederalIncomeTaxDetails Income Taxes - Schedule of Federal Income Tax (Details) Details 36 false false R37.htm 00000037 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://HPGN/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://HPGN/role/IncomeTaxesTables 37 false false R38.htm 00000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://HPGN/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://HPGN/role/RelatedPartyTransactions 38 false false R39.htm 00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://HPGN/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://HPGN/role/SubsequentEvents 39 false false R9999.htm Uncategorized Items - hpgn-20180531.xml Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - hpgn-20180531.xml Cover 40 false false All Reports Book All Reports hpgn-20180531.xml hpgn-20180531.xsd hpgn-20180531_cal.xml hpgn-20180531_def.xml hpgn-20180531_lab.xml hpgn-20180531_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true RENDERED XBRL 63 0001662252-18-000094-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001662252-18-000094-xbrl.zip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end

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	May 31, 2018	Oct. 01, 2018	Nov. 30, 2017
Document And Entity Information
Entity Registrant Name	HypGen Inc
Entity Central Index Key	0001653629
Document Type	10-K
Document Period End Date	May 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--05-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		50,000,502
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Shell Company	false
Entity Small Business	true
Emerging Growth Company	true
Entity Ex Transition Period	false

Balance Sheets - USD ($)	May 31, 2018	May 31, 2017
CURRENT ASSETS
Cash		$ 8,415
Prepaid Expenses		2,000
License asset agreement, net
Assets from discontinued operations		11,757
Total current assets		22,172
Property and equipment, net	1,481
TOTAL ASSETS	1,481	22,172
Current Liabilities:
Accrued expenses and payables	31,044	11,233
Loan payable - related party	34,630
Bank overdraft	228
Accrued salary, wages and taxes	185,152
Liabilities from discontinued operations
Accrued interest including related party	47,014	3,844
Convertible Note Payable related party, current portion		200,000
Convertible Notes Payable, net of discounts	45,000
Total Current Liabilities	343,067	215,077
Other Liabilities
Convertible Note Payable related party, net of current portion	400,000
Total Liabilities	743,067	215,077
Commitments and contingencies
STOCKHOLDERS DEFICIT
Preferred stock: authorized 2,000,000; $0.001 par value; shares issued and outstanding at May 31, 2018 and no shares issued or authorized as of May 31, 2017	2,000
Common stock: authorized 1,000,000,000; $0.001 par value; 135,800,000 and 5,000,000 shares issued and outstanding at May 31, 2018 and May 31, 2017	135,800	5,000
Additional Paid in Capital	249,767	39,000
Accumulated deficit	(1,129,153)	(236,905)
Total Stockholders Deficit	(741,586)	(192,905)
TOTAL LIABILITIES AND STOCKHOLDER DEFICIT	$ 1,481	$ 22,172

Balance Sheets (Parenthetical) - $ / shares	May 31, 2018	May 31, 2017	Jan. 26, 2017
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000	75,000,000
Common Stock, Issued	135,800,000	5,000,000
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	2,000,000	0
Preferred Stock, Issued	2,000,000	0

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	May 31, 2018	May 31, 2017
Continuing Operations:
Revenue
Cost of Goods Sold:
Product Purchases
Gross Profit
Operating Expenses:
Depreciation and amortization	8,914	910
Salary and payroll expense	204,269
Professional fees	111,444	56,000
Consulting fees	270,338	54,000
General and administrative	43,812	107,347
Total operating expense	638,777	218,257
Net income (loss) from operations	(638,777)	(218,257)
OTHER (INCOME) EXPENSE
Interest expense and financing cost, net	73,170	3,844
Loss on impairment	168,544
Forgiveness of related party debt		(750)
Total other (income) expense	241,714	3,094
Discontinued Operations:
Net income (loss) from discontinued operations	(76)	16,064
Impairment loss on assets from discontinued operations	(11,681)
Total Income (loss) from discontinued operations	(11,757)	16,064
Net income before income tax provision	(892,248)	(205,287)
Provision for income tax
Net Loss	$ (892,248)	$ (205,287)
Basic and diluted net loss per share of common stock:
Continuing operations	$ (0.008)	$ (0.044)
Discontinued Operations	(0.000)	0.003
Basic and diluted	$ (0.008)	$ (0.041)
Weighted average number of shares outstanding:
Basic and diluted	117,603,288	5,000,000

Statements of Changes in Shareholders Deficit - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Gain (Loss)	Total
Beginning Balance, Shares at May. 31, 2016		5,000,000
Beginning Balance, Amount at May. 31, 2016		$ 5,000	$ 39,000	$ (31,618)	$ 12,382
Net gain (loss)				(205,287)	(205,287)
Ending Balance, Shares at May. 31, 2017		5,000,000
Ending Balance, Amount at May. 31, 2017		$ 5,000	3,900	(236,905)	(192,905)
Stock Issued for Services, Shares		55,000,000
Stock Issued for Services, Amount		$ 55,000			55,000
Asset Assignment Agreement, Shares	2,000,000	75,000,000
Asset Assignment Agreement, Amount	$ 2,000	$ 75,000			77,000
Stock Issued for Debt Conversion, Shares		800,000
Stock Issued for Debt Conversion, Amount		$ 800	199,200		200,000
Warrants issued to consultants			11,567		11,567
Net gain (loss)				(892,248)	(892,248)
Ending Balance, Shares at May. 31, 2018		135,800,000
Ending Balance, Amount at May. 31, 2018	$ 2,000	$ 135,800	$ 249,767	$ (1,129,153)	$ (741,586)

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	May 31, 2018	May 31, 2017
Operating activities:
Net loss from continuing operations	$ (880,491)	$ (221,351)
Net income (loss) from discontinuing operations	(11,757)	16,064
Net Loss	(892,248)	(205,287)
Adjustment to reconcile net loss to net cash provided by operations:
Amortization and depreciation	8,990	910
Loss on impairment	168,544
Loss on impairment on assets held in discontinued operations	11,681
Non-cash interest charges - commitment fees	30,000	3,844
Forgiveness of related party debt		(750)
Warrants and Shares issued to consultants for services	66,567
Changes in assets and liabilities:
Decrease (Increase) in prepaid and deposits	2,000	(2,000)
Increase in accrued interest and finance charges	43,170
Increase in accrued expenses and payables	204,962	11,233
Net cash used in operating activities	(356,334)	(192,050)
Investing activities:
Cash paid for property and equipment	(1,939)
Cash paid for license fee	(100,000)
Net cash used in investing activities	(101,939)
Financing activities:
Proceeds from Convertible note payable - related party	400,000	200,000
Bank overdraft	228
Proceeds from convertible notes	15,000
Proceeds from related party	4,814
Proceeds from loans - related party	29,816
Net cash provided by financing activities	449,858	200,000
Net increase (decrease) in cash	(8,415)	7,950
Cash, beginning of period	8,415	465
Cash, end of period		8,415
Supplemental disclosure of cash flow information:
Cash paid during the period Taxes
Cash paid during the period Interest Paid
Non-cash activity:
Common and Preferred shares issued to acquired license	77,000
Convertible notes redeemed for common stock	$ 200,000

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Policies)	May 31, 2018
Accounting Policies [Abstract]
Use of Estimates and Assumptions	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
Cash and Cash Equivalents	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. At May 31, 2018 and 2017, the Company had no cash equivalents.
Property and Equipment and Depreciation	Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.
Intangible Assets	Intangible assets consisted of a licensing fee under an asset assignment agreement for a patent which was granted November 10, 2016. At the time of the assignment on June 28, 2017, the patent had a remaining life of 19 years and 135 days, which the Company had determined to be the remaining useful life of the patent whereby total investment was to be amortized on a straight-line basis over this period. In exchange for the rights to the intellectual property the Company paid $100,000 in cash, issued 2,000,000 preferred shares and 75,000,000 commons shares. The total investment was valued at $177,000. During the year ended May 31, 2018, the Company analyzed its intangible asset for the purposes of impairment testing. Although management believes that the asset has real economic value, the expense of an independent valuation is not something the Company is interested in doing, whereby the cost of this analysis could exceed the value of the asset. Conversely, the Company’s asset analysis is not objectively able to prove with any degree of certainty that it will ever see positive cashflow from its efforts. This industry is very complicated, risky and unpredictable as it relates to ultimate drug approval or even the sale of the asset. Due to a cost prohibitive asset valuation, uncertainty that the product can be brought to market or be sold and the fact that the that acquisition was from a related party the Company feels that is should fully impair the asset at this time.
Impairment of Long-Lived Assets	Long-lived assets, primarily fixed assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. The Company will perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company would recognize an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and estimated fair value.
Net Loss Per Common Share	The Company computes per share amounts in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 260 Earnings per Share (“EPS”) which requires presentation of basic and diluted EPS. Basic EPS is computed by dividing the income (loss) available to Common Stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is based on the weighted-average number of shares of Common Stock and Common Stock equivalents outstanding during the periods; however, potential common shares are excluded for period in which the Company incurs losses, as their effect is anti-dilutive. For the years ended May 31, 2018 and 2017 the basic and fully diluted earnings per share were the same as the Company had a loss in each of these periods. At May 31, 2018, the Company had potentially dilutive instruments in the form of 60,000,000 common stock warrants with a cashless exercise provision outstanding as well as 1,965,954 common shares issuable upon the conversion of outstanding principal and interest on convertible notes.
Stock-Based Compensation	The Company accounts for Stock-Based Compensation under ASC 718 “Compensation-Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 requires measurement of cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized. The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted on the grant date as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and an offset to additional paid-in capital in stockholders’ equity/(deficit) over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period. The Company issues stock to consultants for various services. The costs for these transactions are measured at the fair value on the grant date of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company recognized consulting expense and a corresponding increase to additional paid-in-capital related to stock issued for services over the term of the related services.
Fair Value of Financial Instruments	ASC 825, “Disclosures about Fair Value of Financial Instruments”, requires disclosure of fair value information about financial instruments in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value hierarchy to classify the inputs used in measuring fair value as follows: · Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. · Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. · Level 3-Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of May 31, 2018. The respective carrying values of certain on-balance-sheet financial instruments approximate their fair values. These financial instruments include cash, accrued liabilities and notes payable. Fair values were assumed to approximate carrying values for these financial instruments since they are short term in nature and their carrying amounts approximate fair value. Due to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the balance sheet date.
Reclassifications	Certain prior year amounts have been reclassified to conform to the current period presentation. The reclassifications had no effect on the net loss or cash flows of the Company.
Revenue Recognition	The Company recognizes revenues in accordance with FASB ASC Topic 605, “Revenue Recognition”, and with the guidelines of the Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104 “Revenue Recognition”. Under SAB 104, four conditions must be met before revenue can be recognized: (i) there is persuasive evidence that an arrangement exists, (ii) delivery has occurred or service has been rendered, (iii) the price is fixed or determinable, and (iv) collection is reasonably assured. Customers of our discontinued operation paid for their product at the time we are advised by the manufacturer/distributor that the product is ready for shipment or pick-up. The Company recognizes revenue when the pre-paid product has been delivered to, or picked up by, the customer. In the event there is a significant delay between the date the customer pre-pays for the product and the delivery or pick-up of the product, revenue would be deferred until the customer accepts delivery of the product. Under our current operations we do not expect to recognize revenue until we receive FDA approval to sell our Parkinson’s disease drug commercially.
Research and Development	The Company expenses research and development costs as incurred. Research and development costs were $0 for the years ended May 31, 2018 and 2017. The expense in the prior year is reflected in discontinued operations. The Company anticipates substantial expense as it conducts phase II trials and tries to move its product to market along with the development of its other products. The Company will also evaluate products and technologies in the medical products space, with its main focus on Parkinson’s Disease. As the Company continues to develop its products and relationships in these areas’ resultant expenses for trademark filings, license agreements, product development and design materials will be expensed as research and development. Some costs may be accumulated for subsidiaries prior to formation of entities.
Income Taxes	We will use the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized. ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for the reporting period presented. The Company did not record any income tax accrual for the period from inception to May 31, 2018. We expect to incur significant expenses in future periods which will offset any net profit.
Recent Accounting Pronouncements	In June 2018, the FASB issued ASU No. 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” which addresses accounting for issuance of all share-based payments on the same accounting model. Previously, accounting for share-based payments to employees was covered by ASC Topic 718 while accounting for such payments to non-employees was covered by ASC Subtopic 505-50. As it considered recently issued updates to ASC 718, the FASB, as part of its simplification initiatives, decided to replace ASC Subtopic 505-50 with Topic 718 as the guidance for non-employee share-based awards. Under this new guidance, both sets of awards, for employees and non-employees, will essentially follow the same model, with small variations related to determining the term assumption when valuing a non-employee award as well as a different expense attribution model for non-employee awards as opposed to employee awards. The ASU is effective for public business entities beginning in 2019 calendar years and one year later for non-public business entities. In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815),” which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The Company is currently in the process of assessing the impact the adoption of this guidance will have on the Company’s financial statements.
Subsequent Events	In accordance with ASC 855 “Subsequent Events” the Company evaluated subsequent events after the balance sheet date through the date of issuance.

ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) - USD ($)	12 Months Ended
	May 31, 2018	May 31, 2017
State of incorporation	State of Nevada
Date of incorporation	Mar. 26, 2015
Net Income (loss)	$ (892,248)	$ (205,287)
Common stock, shares issued	135,800,000	5,000,000
Preferred stock, shares issued	2,000,000	0
Emerging growth company, description	<p style="margin: 0pt"><font style="font: normal 10pt Times New Roman, Times, Serif; text-transform: none; letter-spacing: normal; word-spacing: 0px">We will continue to be an emerging growth company until: (i) the last day of our fiscal year during which we had total annual gross revenues of $1,000,000,000 or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (iii) the date on which we have, during the previous 3-year period, issued more than $1,000,000,000 in non-convertible debt; or (iv) the date on which we are deemed to be a large accelerated filer, as defined in Section 12b-2 of the Exchange Act.</font></p>
First Legacy Management LLC
Date of Agreement	Jan. 18, 2017
Acquired common stock shares	4,000,000
Ownership percentage	80.00%
Cash paid	$ 350,000
Asset Assignment Agreement \| Richard L. Chang Holdings LLC
Date of Agreement	Jun. 28, 2017
Common stock, shares issued	60,000,000
Preferred stock, shares issued	2,000,000
Common stock, voting right	<p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">1000 to 1 voting rights over shares of the Company’s common stock</font></p>
Equity financing, minimum raise	$ 1,000,000
Asset Assignment Agreement \| RCHA
Common stock, shares issued	15,000,000

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	May 31, 2018	May 31, 2017
Cash Equivalents	$ 0	$ 0
Estimated Useful Life	3 years
Preferred stock, shares issued	2,000,000	0
Common stock, shares issued	135,800,000	5,000,000
Research and development expenses	$ 0	$ 0
Warrants Issued
Potentially Dilutive Instruments
Stock Issuable Upon Conversion	1,965,954
Warrants Issued	60,000,000
Patent
Date of Agreement	Nov. 10, 2016
Estimated Useful Life	19 years 135 days
Cash paid	$ 100,000
Preferred stock, shares issued	2,000,000
Common stock, shares issued	75,000,000
Noncash Investment	$ 77,000
Investment in license	$ 177,700

DISCONTINUED OPERATIONS (Details Narrative) - USD ($)	12 Months Ended
DISCONTINUED OPERATIONS (Details Narrative) - USD ($)	May 31, 2018	May 31, 2017
Statements Of Discontinued Operations
Depreciation	$ 76	$ 910
Discontinued Operations, Held-for-sale
Date of Agreement	May 25, 2015
Purchase Price	$ 13,653

FIXED ASSETS - Schedule of Property and Equipment (Details) - USD ($)	12 Months Ended
	May 31, 2018	May 31, 2017
Fixed Assets - Schedule Of Property And Equipment
Computers, office furniture and equipment	$ 1,939
Less: accumulated depreciation	(458)
Property and equipment, net	$ 1,481
Estimated Useful Life	3 years

FIXED ASSETS (Details Narrative) - USD ($)	12 Months Ended
FIXED ASSETS (Details Narrative) - USD ($)	May 31, 2018	May 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 458	$ 0

INTANGIBLE ASSETS - Schedule of License Value Net of Amortization (Details) - USD ($)	12 Months Ended
	May 31, 2018	May 31, 2017
Amortization expense	$ 8,456
License asset agreement, net of amortization
Estimated Useful Life	3 years
Patent
Investment in license	$ 177,700
Amortization expense	(8,456)
License asset agreement, net of amortization	$ (168,544)
Estimated Useful Life	19 years 135 days

INTANGIBLE ASSETS (Details Narrative) - USD ($)	12 Months Ended
INTANGIBLE ASSETS (Details Narrative) - USD ($)	May 31, 2018	May 31, 2017
Common stock, shares issued	135,800,000	5,000,000
Preferred stock, shares issued	2,000,000	0
Amortization expense	$ 8,456
Patent
Date of Agreement	Nov. 10, 2016
Common stock, shares issued	75,000,000
Preferred stock, shares issued	2,000,000
Cash paid	$ 100,000
Noncash Investment	77,000
Investment in license	177,700
Amortization expense	$ (8,456)
Asset Assignment Agreement \| Richard L. Chang Holdings LLC
Date of Agreement	Jun. 28, 2017
Common stock, shares issued	60,000,000
Preferred stock, shares issued	2,000,000
Common stock, voting right	<p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">1000 to 1 voting rights over shares of the Company’s common stock</font></p>
Equity financing, minimum raise	$ 1,000,000
Asset Assignment Agreement \| RCHA
Common stock, shares issued	15,000,000

CONVERTIBLE NOTES PAYABLE (Details Narrative)	12 Months Ended
CONVERTIBLE NOTES PAYABLE (Details Narrative)	May 31, 2018 USD ($) d $ / shares shares	May 31, 2017 USD ($)
Convertible Notes Payable	$ 45,000
Interest expense and financing cost, net	$ 73,170	$ 3,844
GHS
Date of Agreement	Nov. 15, 2017
Term of Note	24 months
Due Date	Aug. 14, 2018
Convertible Notes Payable	$ 22,500
Interest rate	10.00%
Accrued interest	$ 277
Description of conversion price	<p style="margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">The amounts under the Note may be converted by GHS at any time after the maturity date or upon any event of default into shares of Company common stock at a conversion price equal to 80% of the average closing bid price during the 5-day period prior to conversion, subject to a floor price of $0.00005 per share.</font></p>
Equity Registration Rights, Shares to be Registered \| shares	7,000,000
Interest expense and financing cost, net	$ 10,922
Conv Note #1
Date of Debt Instrument	Jan. 27, 2017
Term of Note	1 year
Convertible Notes Payable	$ 100,000
Interest rate	8.00%
Accrued interest	$ 4,244
Debt instrument, convertible, conversion price \| $ / shares	$ 0.25
Description of conversion price	<p style="font: 13.33px " color: rgb(0, 0, 0)"><font style="font: normal 10pt Times New Roman, Times, Serif; text-transform: none; letter-spacing: normal; word-spacing: 0px">The holder of the note was entitled to a conversion price equal to seventy percent of the average trading price computed based on the previous 7 trading days prior to notice of conversion.</font></p>
Conv Note #2
Date of Debt Instrument	Apr. 07, 2017
Term of Note	1 year
Convertible Notes Payable	$ 100,000
Interest rate	8.00%
Accrued interest	$ 2,800
Debt instrument, convertible, conversion price \| $ / shares	$ 0.25
Debt instrument, convertible, trading days \| d	7
Description of conversion price	<p style="font: 13.33px " color: rgb(0, 0, 0)"><font style="font: normal 10pt Times New Roman, Times, Serif; text-transform: none; letter-spacing: normal; word-spacing: 0px">The holder of the note was entitled to a conversion price equal to seventy percent of the average trading price computed based on the previous 7 trading days prior to notice of conversion.</font></p>
Conv Note #3
Date of Debt Instrument	Jun. 28, 2017
Due Date	Jun. 28, 2019
Convertible Notes Payable	$ 400,000
Interest rate	10.00%
Accrued interest	$ 38,889
Debt instrument, convertible, conversion price \| $ / shares	$ 0.50
Description of conversion price	<p style="font: 13.33px " color: rgb(0, 0, 0)"><font style="font: normal 10pt Times New Roman, Times, Serif; text-transform: none; letter-spacing: normal; word-spacing: 0px">may be converted at any time by the holder into shares of Company common stock at a conversion price of $.50 per share; and automatically converts into shares of Company common stock at a conversion price of $.50 per share upon the Company’s completion of a financing in the minimum amount of $5,000,000</font></p>
Conv Note #1&2
Accrued interest	$ 7,044
Debt instrument, convertible, conversion price \| $ / shares	$ 0.25
Date of Issuance	Aug. 11, 2017
Stock Issued, Shares \| shares	800,000
Stock Issued, Value	$ 200,000
Conv Note #4
Date of Debt Instrument	Nov. 17, 2017
Due Date	Aug. 19, 2018
Convertible Notes Payable	$ 22,500
Interest rate	10.00%
Accrued interest	$ 277
Description of conversion price	<p style="margin: 0pt"><font style="font: 10pt Times New Roman, Times, Serif">Upon any event of default, the note holder may convert the note in its entirety into shares of Company common stock at a conversion price equal to 80% of the average closing bid price during the 5-day period prior to conversion, subject to a floor price of $0.00005 per share</font></p>

STOCK HOLDERS' EQUITY - Schedule of Warrant Activity (Details) - $ / shares	12 Months Ended
	May 31, 2018	May 31, 2017
Stock Holders Equity - Schedule Of Warrant Activity
Beginning Balance, Issued Warrants	60,000,000
Beginning Balance, Average Exercise Price	$ 0.25
Issued, Warrants
Issued, Average Exercise Price
Weighted Average, Term	4 years 6 months
Aggregate Intrinsic Value
Expired Warrants
Expired Average Exercise Price
Exercised, Warrants
Exercised, Average Exercise Price
Cancelled, Warrants
Cancelled, Average Exercise Price
Ending Balance, Issued Warrants	60,000,000	60,000,000
Ending Balance, Average Exercise Price	$ 0.25	$ 0.25

STOCK HOLDERS' EQUITY (Details Narrative) - USD ($)	12 Months Ended
STOCK HOLDERS' EQUITY (Details Narrative) - USD ($)	May 31, 2018	May 31, 2017	Jan. 26, 2017
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000	75,000,000
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	2,000,000	0
Preferred stock, shares issued	2,000,000	0
Common stock, shares issued	135,800,000	5,000,000
Warrants Issued
Convertible Notes Payable	$ 45,000
GHS
Date of Agreement	Nov. 15, 2017
Due Date	Aug. 14, 2018
Convertible Notes Payable	$ 22,500
Interest rate	10.00%
Term of Note	24 months
Equity Registration Rights, Shares to be Registered	7,000,000
Asset Assignment Agreement \| Richard L. Chang Holdings LLC
Date of Agreement	Jun. 28, 2017
Preferred stock, shares issued	2,000,000
Common stock, shares issued	60,000,000
Patent
Date of Agreement	Nov. 10, 2016
Preferred stock, shares issued	2,000,000
Common stock, shares issued	75,000,000
Investment in license	$ 177,700
Conv Note #1&2
Date of Issuance	Aug. 11, 2017
Stock Issued, Shares	800,000
Stock Issued, Value	$ 200,000
Debt instrument, convertible, conversion price	$ 0.25
SPA
Date of Agreement	Jan. 18, 2017
Stock Issued, Shares	4,000,000
Payment for Stock	$ 350,000
Equity Interest	80.00%
Consulting Agmts
Warrants Issued	50,000,000
Stock Issued for Services, Shares	44,725,000
Employees
Warrants Issued	10,000,000
Stock Issued, Employee Compensation	10,275,000

Income Taxes - Schedule of Federal Income Tax (Details) - USD ($)	12 Months Ended
	May 31, 2018	May 31, 2017
Federal income tax benefit attributable to:
Net operating losses	$ 267,900	$ 80,500
Effect of TCJA recalculation	(79,100)	(30,800)
Change in valuation allowance	(188,800)	(49,700)
Provision for income taxes

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
INCOME TAXES (Details Narrative) - USD ($)	May 31, 2018	May 31, 2017
Income Tax Disclosure [Abstract]
Effective Income Tax Rate, Federal	21.00%
Effective Income Tax Rate, State
Net Operating Loss Carry-Forwards	$ 1,114,329	$ 236,905
Change in valuation allowance	(188,800)	(49,700)
Deferred tax assets	$ 188,800	$ 49,700

SUBSEQUENT EVENTS (Details Narrative)	3 Months Ended	12 Months Ended
SUBSEQUENT EVENTS (Details Narrative)	May 31, 2018 USD ($) shares	May 31, 2018 USD ($) shares
Rafferty Finance S.A.
Date of Agreement	Jul. 05, 2018	Jun. 28, 2017
Common stock, shares cancelled	(5,496,500)
Stock to be Issued	500,000	5,000,000
Warrants to be Issued		10,000,000
PPM, minimum raise \| $		$ 1,000,000
Brighton Capital Ltd
Date of Agreement	Jul. 05, 2018	Jun. 28, 2017
Common stock, shares cancelled	(5,500,000)
Stock to be Issued		6,000,000
Warrants to be Issued		10,000,000
Cancellation Agmt
Date of Agreement	Jul. 09, 2018
Common stock, shares cancelled	(74,999,998)
PPM, minimum raise \| $	$ 1,000,000
Financing Due Date	Jun. 28, 2019
Agreement Description	In consideration of the share cancellations and provided that the Company raises a minimum of $1,000,000 in equity financing on or before June 28, 2019, Richard L. Chang Holding’s, LLC agreed to waive its right of reversion of the patent assets contributed to the Company pursuant to the Asset Assignment Agreement dated June 28, 2017.
Warrant Amdt Agmt
Date of Agreement	Jul. 09, 2018
Warrants to be Issued	(10,000,000)
PPM, minimum raise \| $	$ 1,000,000
Financing Due Date	Jun. 28, 2019
Agreement Description	In consideration of the amendment and provided that the Company raises a minimum of $1,000,000 in equity financing on or before June 28, 2019, Richard L. Chang Holding’s, LLC agreed to waive its right of reversion of the patent assets contributed to the Company pursuant to the Asset Assignment Agreement dated June 28, 2017.
Brighton Capital Ltd
Date of Agreement		Jun. 01, 2018
Monthly Salary \| $		$ 20,000
Prom Note #7
Date of Debt Instrument	Jun. 25, 2018
Interest rate	5.00%	5.00%
Debt Instrument \| $	$ 4,000	$ 4,000
Due Date	Jun. 25, 2019

Label	Element	Value
Preferred Stock
Asset Assignment Agreement, Shares	us-gaap_StockIssuedDuringPeriodSharesOther
Common Shares issued for, Amount	us-gaap_StockIssuedDuringPeriodValueNewIssues
Stock Issued for Debt Conversion, Amount	us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
Stock Issued for Debt Conversion, Shares	us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
Stock Issued for Services, Shares	us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Stock Issued for Services, Amount	us-gaap_StockIssuedDuringPeriodValueIssuedForServices
Common Shares issued for, Shares	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Asset Assignment Agreement, Amount	us-gaap_StockIssuedDuringPeriodValueOther